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Abstract 
Primary keratinocytes form 3 types of colony with different morphologies 
termed holoclones, meroclones and paraclones, thought to be derived from 
stem, early and late stage precursor cells respectively (Barrandon and 
Green, 1987b, Rochat et al., 1994). Cancer cell lines produce colonies with 
morphologies analogous to those of holoclones, meroclones and paraclones, 
and consequently holoclone morphology is used as a surrogate marker for 
stem cell colonies. The aim of this study was to elucidate the relationship 
between clonogenicity, colony morphology and stem cells.  
Colonies formed by primary prostate epithelial cells and prostate cancer cell 
lines (DU145, PC3, LNCaP) were characterised. The proportions of colonies 
were not altered significantly by modification of culture conditions.  In contrast 
to cancer cells, primary prostate epithelial cells form only two types of colony, 
termed types 1 and 2, which are analogous to holoclones and paraclones. 
Only type 1 colonies were highly proliferative, able to self-renew and express 
putative stem cell markers.   
Paradoxically, cells from DU145 meroclones formed holoclones and had self-
renewal capacity (by serial cloning and xenografting). It is concluded that the 
major difference between holoclone and meroclone colonies from the cancer 
cell line DU145 is the proportion of stem cells within each colony, not the 
presence or absence of stem cells.  Phage display was used to look for 
targets on the surface of cells in Type 1 colonies. Various experimental 
protocols were tested, but no targets were identified. 
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1 Introduction 
1.1 The Prostate and it’s Diseases 
1.1.1 Prostate Anatomy 
The prostate is an exocrine gland of the male reproductive system located 
inferior to the bladder, which surrounds the initial part of the urethra and 
some of the ejaculatory duct. The function of the prostate is to secrete an 
alkaline fluid into the semen to help neutralise the acidity of the female 
vaginal tract, and prostate-specific antigen (PSA) which liquefies the semen 
(Kirby, 2003).  
The prostate gland is a pyramid-shaped organ with its apex adjacent to the 
urethra and directed downward and its bases adjacent to the bladder and 
directed upward. It lies below the urinary bladder and is located in front of the 
rectum and the seminal vesicles are located at its base. The prostate weighs 
about 20 g by early adulthood and is made up of several glandular and non-
glandular components with no obvious capsular morphology (McNeal, 1988). 
The prostate can be divided into 5 lobes: an anterior, two lateral, a median 
and a posterior lobe (Kirby, 2003). However, this idea is disputed and 
alternatively 3 distinct zones of the prostate can be identified: the central 
zone (CZ), peripheral zone (PZ), and transition zone (TZ) (McNeal, 1981, 
McNeal, 1988) (Figure 1). These zones differ both physiologically and 
biologically and a zonal description of prostate morphology is central to 
present understanding of prostatic diseases, particularly prostate cancer. 
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Figure 1. Anatomy the normal prostate gland. 
Cartoon showing peripheral, central and transitional zones (Potter et al., 
2005).  
 
The peripheral zone comprises about 70% of the glandular prostate in young 
men and is predominantly mesodermal in origin (Argani et al., 1998). Its 
ducts exit from the posteriolateral recess of the urethral wall and extend 
mainly laterally in the coronal plane, branching both anteriorly and posteriorly 
(McNeal, 1988). The central zone is a cone shaped region that surrounds the 
ejaculatory ducts and makes up approximately 25% of the glandular prostate 
mass in young adults. The transition zone accounts for only 5% of the 
glandular prostate tissue and surrounds the proximal urethra. The non-
glandular prostate tissue comprises of the preprostatic sphincter, striated 
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sphincter, anterior fibromuscular stroma and the prostatic capsule (McNeal, 
1988).  
There are three diseases of the prostate: prostatitis (inflammation), benign 
prostatic hyperplasia (BPH) and prostate cancer (PCa), which affect the 
different zones of the prostate. BPH develops predominantly in the transition 
zone and PCa in the peripheral zone.  
1.1.1 Prostate Histology 
The human prostate gland comprises of two distinct epithelial cell types: 
basal and secretory luminal cells which along with rarer neuroendocrine cells 
to form a complex branching ductal structure embedded in a muscular 
stroma containing smooth muscle cells and fibroblasts (Kirby, 2003). Basal 
cells form a layer along the basement membrane and luminal cells sit above 
the basal cells and secrete prostatic proteins into the lumen (Figure 2). The 
primary role of luminal epithelial cells is to secrete PSA, a single-chain 
glycoprotein consisting of 237 acids.  
The two layers of epithelial cells are distinguished by their protein marker 
expression and secretions, as shown in Figure 2. Luminal cells express 
prostate specific antigen (PSA), prostatic acid phosphatase (PAP), androgen 
receptor (AR), CD57, 15-lipoxygenase (15-LOX2) and low molecular weight 
cytokeratins K8 and K18. Basal cells express high molecular weight 
cytokeratins K5 and K14, CD44, p63, telomerase and bcl-2 (Hudson, 2004, 
Bagley R.G. , 2009).  
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Figure 2. Structure of the human prostatic gland.  
Cartoon of the structure and marker expression of the prostatic ducts, which 
comprise a basal and a luminal epithelial layer with distinct protein 
expression (Honorio 2009). 
 
1.1.2 Benign Prostatic Hyperplasia  
BPH occurs mainly in the transition zone, and is caused by hyperplasia of the 
prostatic stromal and epithelial cells (McNeal, 2006). Large fibromuscular 
nodules form in the periurethral region of the prostate, which can compress 
the urethral canal and cause obstruction of the urethra and interfere with the 
flow of urine. Symptoms include urinary hesitancy, dysuria (painful urination), 
nocturia, increased risk of urinary tract infections, and urinary retention. 
Although age is the major risk factor for BPH, androgens influence the 
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disease etiology as men castrated before puberty do not develop the disease 
(Wilson and Roehrborn, 1999). 
Diagnosis is usually by digital rectal examination (DRE) and biopsy to rule 
out PCa. Treatments include 5α-reductase inhibitors that reduce conversion 
of testosterone to DHT and alpha-adrenergic blockers to relax smooth 
muscle in the prostate and the bladder neck, thereby increasing urine flow 
(Timms and Hofkamp, 2011). Both 5α-reductase and alpha-adrenoceptor 
blockade are well tolerated and effective treatments (Tammela, 1997).  A 
surgical alternative is transurethral resection of the prostate (TURP), thus 
removing the urethral blockage. However, TURP can result in considerable 
side effects (Tammela, 1997). Other alternatives are transurethral needle 
ablation (TUNA) and transurethral microwave thermotherapy and although 
these have lower associated risks, are not as effective as TURP (Schatzl et 
al., 2000).  
1.1.3 Prostate Cancer 
Prostate cancer is an adenocarcinoma most frequently found in the 
peripheral zone of the prostate. Initially, small clumps of cancer cells are 
confined to otherwise normal prostate glands, a condition known as prostatic 
intraepithelial neoplasia (PIN), which can develop into invasive cancers. 
Prostate cancer most commonly metastasizes to the bone via the lymph 
nodes, and also can invade rectum, bladder and lower ureters after local 
progression (Kirby, 2003).  
PCa diagnosis is confirmed by a combination of PSA screening, DRE, 
Magnetic Resonance Imaging (MRI) and prostate biopsy.  PSA is a protein 
produced by normal epithelial cells as well as PCa, and can be elevated in 
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prostatic disorders. Biopsy samples of PCa are classified according to their 
Gleason score based the morphology of the cancer (Epstein et al., 2005). 
Cytological features may include hyperchromatic, enlarged nuclei with 
prominent nucleoli and abundant cytoplasm (Kirby and Madhavan, 2010).  
Clinically, localized disease is treated by surgery (prostatectomy) or radiation 
therapy (external beam or brachytherapy), which have high success rates. 
An alternative is active surveillance which involves monitoring PSA levels 
(Bannuru et al., 2011). The use of surgery to treat localized disease can be 
controversial and some studies have shown no survival advantages when 
compared to active surveillance in men with low grade disease (Wilt et al., 
2012).  
Treatment of advanced disease is less successful.  First line treatment 
depends on the androgen sensitivity of PCa, using androgen ablation or 
blockade of androgen action through the androgen receptor (Miyamoto et al., 
2004). Although this treatment initially leads to tumour regression in the 
majority of patients, the cancer recurs in a median period of 18-24 months, 
leading to castrate resistance (Miyamoto et al., 2004). Recently two new 
treatments, Abiraterone and Enzalutamide have been developed to target 
castrate resistant disease. Abiraterone is an inhibitor of CYP17 activity which 
significantly decreases testosterone levels (Barrie et al., 1994). In Phase III 
trials, it extended median survival to 14.8 months versus 10.9 months. Phase 
III trials of the androgen receptor antagonist Enzalutamide increased survival  
to 18.4 months compared to 13.6 months in the control group (Scher et al., 
2012). Both drugs have now received FDA approval and offer promising new 
therapy regimes. Development of alternative treatments is required to treat 
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metastatic disease and further improve the long term prognosis of men with 
advanced disease (Wolff and Mason, 2012).  
1.2 Adult Stem Cells 
Organs are composed of differentiated cells that perform discrete functions 
(Miller et al., 2005) and comprise the bulk the cells (Ichim and Wells, 2006). 
The continuous replacement of differentiated, functional cells by more 
primitive cells is a normal homeostatic process driven by multi-potential stem 
cells (SCs). These cells are also known as somatic or adult stem cells and 
have been identified in most tissues. They replenish dying cells and maintain 
organ health and functionality. Adult stem cells have features in common, 
including a large nuclear-to-cytoplasmic ratio, few organelles and they are 
structurally unspecialised or undifferentiated (Miller et al., 2005).  
1.2.1 The Adult Stem Cell Hierarchy 
An adult stem cell has two properties which allow it to maintain organ 
function: Potency and self-renewal. The potential the cell has to differentiate 
to form all the functional cell types within a tissue is called potency.  The SC 
is at the apex of the hierarchy and is the initiating cell in the cell division and 
differentiation process producing a large family of differentiated descendants 
known as clonal expansion. To replenish the stem cell compartment lost 
during differentiation, the SC can undergo symmetrical division to produce 
two identical stem cell daughters, a process termed self-renewal (Mackillop 
et al., 1983).  
In addition to self-renewing stem cells, the hierarchy model predicts two other 
types of cell: proliferating, non-self-renewing cells (transit amplifying) (TA) 
and non-proliferating, differentiated end cells (DC). The hierarchy in Figure 3 
31 
 
illustrates how the potential for division and differentiation changes as a cell 
moves down the hierarchy. Following division, the stem cell can give rise to a 
transit amplifying cell that will undergo further proliferation. The cells 
progressively differentiate and irreversibly commit to one of the  lineages 
specific to the tissue (Miller et al., 2005). As cells move down the hierarchy 
acquiring the differentiated features associated with tissue function, the 
proportion of differentiated cells increases.  
Somatic SCs reside in confined tissue compartments, referred to as niches 
(Loeffler and Roeder, 2002), where the microenvironment suppresses SC 
proliferation, resulting in a quiescent SC population. The SCs may be 
triggered to proliferate and differentiate in response to injury to repair 
damaged tissue (Ghotra et al., 2009). In this way the stem cell has the ability 
to maintain the organ over its lifetime (Miller et al., 2005). 
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Figure 3. Adult Stem Cell Hierarchy.  
The stem cell can self-renew or divide to produce proliferative transitional 
cells expand clonally. As cells differentiate they lose their proliferative 
potential and become more abundant. 
 
1.2.2 Stem Cells in the Haematopoietic System 
The first evidence for the existence of SCs in adult animals was generated by  
Till and McCulloch, who showed that mouse bone marrow (BM) cells injected 
into irradiated recipient mice developed visible spleen colonies derived from 
grafted cells. (Till and McCulloch, 1961, McCulloch and Till, 1962) The 
number of donor cells was directly proportional to the number of colonies that 
developed within the spleen. This result suggested that the transplanted BM 
cells were capable of self-renewal and it was hypothesised that these cells 
were stem cells. In addition, the radiation survival curve of cells that form 
colonies closely resembled the in vitro cell survival curves of clonogenic cells 
developed by Puck and Marcus (1956). The clonal origin of spleen colonies 
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was confirmed by transplantation of sub lethally irradiated bone marrow into 
heavily irradiated recipient mice. Some donor bone marrow cells containing 
genetic abnormalities caused by the irradiation cells, retained the ability to 
proliferate and produce clones containing the abnormality, demonstrating 
their clonal origin (Becker et al., 1963).  
If the capacity to form colonies is to be considered as a criterion to identify 
stem cells, the cell must lose this capacity upon undergoing differentiation. 
The differentiation and subsequent loss of colony forming capacity was 
confirmed by applying hypoxia as a differentiating pressure which resulted in 
a reduction in colony formation in the spleens of hypoxic mice (Bruce and 
McCulloch, 1964). This result was thought to be due erythropoiesis which 
stimulates erythropoietin stimulated by hypoxia. The data suggested that an 
increased demand for differentiated cells reduced the number of stem cells, 
resulting in a reduction of colony forming ability. This confirmed the property 
of these stem cells as able to undergo both self-renewal and differentiation.  
This data inspired further work studying stem cells, particularly within the 
haematopoietic system, leading to the discovery that BM contains at least 3 
different stem cell populations: haematopoetic stem cells (HSCs), 
mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs) 
(Alison and Islam, 2009). Single unselected BM cells can also form colonies 
in non-lympho-haematopoietic tissue, such as hepatocytes (Petersen et al., 
1999), muscle fibre (Ferrari et al., 1998), microglia and astroglia (Eglitis and 
Mezey, 1997) and neuronal tissue (Brazelton et al., 2000, Mezey et al., 
2000). The morphology and marker expression of these colonies are similar 
to the native cells.  
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1.2.3 Adult Stem Cell Identification 
Morphology, proliferative/ cycling rates, location and marker expression are 
all used to identify and characterise stem cells in adult tissues. Advances in 
the identification and characterisation of adult stem cells have been aided by 
the development of techniques to label cells based on surface marker 
expression. Stem cells are identified by staining cell surface markers with 
monoclonal antibodies (mAb), exclusion of fluorescent dyes such as Hoechst 
33342 or long term labelling with tritiated thymidine (Mittal et al., 2009). mAb 
technology and flow-cytometery based sorting  (FACS) and analysis have 
been the main driving force in recent SC developments to enrich SC 
populations. 
The identification of SCs is confirmed by the ability of the selected cells to 
recapitulate the organ of origin. The haematopoietic system and tissues with 
high cell turnover rates, such as the cells of the digestive tracts and skin, 
have been extensively studied, although SC in almost all organs have been 
identified and enriched for based on cell surface marker expression (Alison 
and Islam 2009). Table 1 lists markers for the identification and selection of 
adult stem cells in both blood and solid tissues. Of note is CD133 (Prominin 
1), a marker which is a potential stem cell marker in several tissues, although 
its function in this context remains unclear. 
The putative SC markers are also compared by clonogenicity, growth in non-
adherent culture, the ability to reconstitute the organ when transplanted 
orthotopically in vivo and lineage tracing studies. Potential molecular markers 
for stem cells have also been identified in embryonic stem cells. These 
markers include the transcription factors Oct4, Sox2 and Nanog which are 
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known to control self-renewal and differentiation. These markers can 
identified in situ by immunocytochemistry and are used in combination to 
identify the location of the stem cell niche. Reverse transcription polymerase 
chain reaction (RT-PCR) analysis of cells retrieved from the mouse stomach 
stem cell niche by laser capture micro-dissection revealed a gene expression 
profile closely matching that of HSCs (Mills et al., 2002).  
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Table 1.  Prospective Adult Stem Cell Markers. 
Tissue/ stem 
cells 
Markers Used to Enrich for SCs 
Brain CD133 (Lee et al., 2005) 
CD184+ CD271− CD44− CD24+ (Yuan et al., 2011) 
Bone marrow 
(HSC) 
CD34+  CD133+ CD45+ and c-kit+ (Bhatia, 2001) 
 
Bone marrow/ 
(MSC) 
CD105+/CD73+/CD90+/CD34-/ CD45-, (Dominici et al., 
2006) 
Breast α6integrin + CK19+ ESA+ MUC1− CALLA− (Clarke et al., 
2005) 
Cardiac Lin− c-kit+ (Beltrami et al., 2003) 
Intestinal Lgr5+ (Barker et al., 2007) 
Kidney CD133+ CD73+ CD29+  and CD44+ (Bussolati et al., 
2005) 
Liver CD29+ CD73+ CD44+ and CD90+ (Herrera et al., 2006) 
Skin CK19+ (Michel et al., 1996) 
CD34+ and CK15+ (Blanpain et al., 2004) 
Lgr6+ (Snippert et al., 2010) 
Potential cell surface markers for the identification of adult stem cells in 
the respective tissues.  
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1.3 Prostate Stem Cells 
The earliest evidence for the existence of stem cells in the adult prostate 
came from androgen-ablation studies, where it was observed that adult 
rodent prostate can undergo multiple rounds of castration-induced regression 
and testosterone-induced regeneration (Isaacs and Coffey, 1989). Following 
castration there is a rapid reduction in prostate volume due to apoptosis. The 
remaining epithelial cell population can survive long periods and regenerate 
the prostate following androgen replacement (English et al., 1987, Evans and 
Chandler, 1987). This suggests that a small population of SCs possess the 
ability to self-renew and differentiate to regenerate the prostate, whilst the 
bulk of the prostate cells which are androgen dependent lack this function.  
The castration studies suggest that SCs reside within the basal epithelial 
compartment of the prostate, as the majority of cells that survive castration 
have a basal rather than a luminal phenotype. (Kirby, 2003). Expression of 
proliferation and survival markers such as telomerase, p63 and Bcl-2 are 
localised in the basal compartment, which further supports this theory 
(Kasper, 2008).  During regeneration SCs differentiate to produce androgen-
independent TA cells that give rise to androgen-dependent fully differentiated 
secretory luminal cells providing evidence for a cellular hierarchy within the 
adult human prostate (English et al., 1987).  
1.3.1 Prostate Stem Cell Identification 
Several candidate prostate SC populations have been isolated based on 
marker expression observed only in the basal layer of the epithelium. 
Potential markers include K5/K18 double positive cells (Hudson et al., 2000) 
and CD44+ α2β1hi CD133+ cells (Richardson et al., 2004). α2β1 integrin 
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selects for cells which have a higher colony forming efficiency, are positive 
for the basal markers K5 and K14  and form prostate-like glands in vivo 
(Collins et al., 2001). Other potential markers for enrichment of  prostate SCs 
include CD44, CD49f (Yamamoto et al., 2012), CD117 (c-kit) and CD133 
(Collins et al., 2001), alone and in combination . Cells expressing these 
markers demonstrate increased colony forming efficiency (CFE) and can 
generate glandular structures when implanted under the renal capsule when 
recombined with rat urogenital mesenchyme (rUGM) (Leong et al., 2008). 
SCs from the prostate also appear to be enriched in side population (SP) 
cells. SP cells express the ATP-binding cassette membrane transporter 
ABCG2 transporter, which actively effluxes Hoechst 33342 from the cell 
which allows enrichment by FACS (Brown et al., 2007).    
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1.4 Cancer Stem Cells 
1.4.1 Models of Tumour Heterogeneity 
Like normal tissue, cancers are composed of a heterogeneous mixture of 
cells with range of capacity to differentiate, proliferate and form tumours 
(Pierce and Speers, 1988). Studies in vivo have demonstrated that, within a 
cancer population, only a small percentage of cells are able to initiate tumour 
development (Bonnet and Dick, 1997, Al-Hajj et al., 2003, Singh et al., 2004). 
Two models have been proposed to explain phenotypic and functional 
tumour heterogeneity: the stochastic and hierarchical, which are described in 
Figure 4. 
 Stochastic Model of Stem Cells  1.4.1.1
The stochastic model predicts that all tumour cells have similar proliferative 
capacity, but their behaviour is influenced by extrinsic factors (e.g. host 
factors, immune response, and microenvironment) or intrinsic (e.g. signalling 
pathways, levels of transcription factors). The randomness and 
unpredictability of these variables results in heterogeneity in marker 
expression, proliferation and tumour initiation capacity (Dick, 2008).  
For the stochastic model to be correct, tumour cells cannot be permanently 
affected by these factors and all cells must have equal capacity to act as 
stem cells (Wang and Dick, 2005). The stochastic models predicts  a growth 
fraction of less than 100% due to cell loss and the result of the constraints of 
the micro-environment (Miller et al., 2005). In this model tumour initiating 
activity cannot be enriched or selected for, because no markers are 
available.  
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 CSC Hierarchy Model of Stem Cells 1.4.1.2
The second model is the cancer stem cells (CSC) hierarchy model which 
predicts that the tumour is a ‘caricature of normal tissue development (Pierce 
and Speers, 1988). Like normal tissue, tumours are hierarchically organised, 
with the CSCs at the apex, driving tumour growth and regeneration. Like 
normal SCs, CSCs maintain the hierarchy by self-renewal or they generate 
transit amplifying cells which divide to produce differentiated offspring which 
form the bulk of the tumour and lack stem cell properties. The CSCs are 
thought to be a relatively small population of cells essential for tumour 
initiation (Frank et al., Reya et al., 2001). As in normal tissue only a small 
percentage of the tumour population maintain the capacity for long term 
proliferation, while most cells proceed down the differentiation pathway 
resulting in terminal differentiation (Miller et al., 2005). Due to differences in 
their characteristics, including proliferative capacity and marker expression, 
CSCs can be selected for.  
Current cancer treatments may eradicate the tumour bulk but spare the 
populations of stem cells which are able to regenerate the cancer (Wang et 
al., 2012). This process may explain why tumour regression does not 
translate to improved patient survival in many clinical trials. It is still not clear 
whether CSCs are originally somatic SCs which have undergone oncogenic 
changes, or TA or DCs which have gained genetic changes which result in 
SC behaviour. The evidence for the hierarchical model which underlies the 
CSC theory comes from clonogenic and tumourigenic assays, which will be 
discussed further. 
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 Clonal Evolution 1.4.1.3
A parallel and popular idea is the clonal evolution model of cancer in which 
cancer is a stepwise evolutionary process of Darwinian natural selection 
(Greaves and Maley, 2012). Intrinsic differences can be caused by stochastic 
genetic (Nowell, 1986) or epigenetic changes (Baylin and Jones, 2011). This 
model complements both the CSC and the stochastic model (Shackleton et 
al., 2009). It proposes that most neoplasms arise from a single cell of origin, 
and tumour progression results from acquired stepwise genetic changes. The 
newly acquired genetic changes  within the original clone allow the sequential 
selection of more aggressive sub-lines (Nowell, 1976). 
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Figure 4 Stochastic and Hierarchical Models of Cancer Stem Cells. 
The hierarchical model predicts that tumours are composed of functionally distinct cells, including cancer stem cells, which have 
different functional properties. The stochastic model predicts that all cells are functionally equal and that cell heterogeneity is due to 
intrinsic and extrinsic influences which affect cell behaviour. Adapted from Dick, 2008.
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1.4.2 Cancer Stem Cell Definition 
The CSC is defined as “A cell within a tumour that possesses the capacity to 
self-renew and to cause the heterogeneous lineages of cancer cells that 
comprise the tumour. CSCs can thus only be defined experimentally by their 
ability to recapitulate the generation of a continuously growing tumour” 
(Clarke et al., 2006). Therefore CSCs express the stem cell properties of self-
renewal and potency. Self-renewal is the ability to undergo cell division while 
maintaining stem cell capacity. Potency is the ability of cells to differentiate 
into the cells that comprise the tumour of origin (Mittal et al., 2009). 
Experimentally, the ‘gold standard’ for CSC identification is the ability to 
serially xenograft (Clarke et al., 2006).  
1.4.3 Identification of Cancer Stem Cells 
The first evidence for the existence of CSCs came from cell proliferation 
studies. Radiolabelling of cells and the use of autoradiography enabled 
measurements of proliferation, hierarchical relationships and lifespan in 
normal and neoplastic tissues (Belanger and Leblond, 1946, Dick, 2008). 
From these studies came the proposal that tumours are caricatures of normal 
development and contain stem cells (Pierce and Speers, 1988). 
 Haematopoietic CSCs 1.4.3.1
Like somatic stem cells, much of the early work on CSCs relied on cancers of 
the haematopoietic system. In the 1970s, cytokinetic studies of cell lines, 
murine models of acute leukaemias and in vivo examination of leukaemia 
blast proliferation kinetics in human AML (Acute Myeloid Leukaemia) and 
ALL (Acute Lymphoblastic Leukaemia) patients demonstrated functional 
heterogeneity (Clarkson et al., 1970, Dick, 2008). The majority of leukaemic 
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blasts were post mitotic the population was replenished from a relatively 
small fraction of proliferative cells. Only a small number of leukemic blast 
cells were cycling in vivo and two proliferative fractions were observed: a 
larger, fast cycling subset with a 24 hour cell cycle time and a smaller, slow 
cycling subset with a dormancy of weeks to months. It was proposed that the 
slow cycling fraction generates the fast cycling fraction. These kinetic 
properties were similar to normal haematopoietic stem cells (Cheshier et al., 
1999) and this observation indicates that cancers also exhibit functional 
heterogeneity in terms of proliferative potential.  
The inability of conventional therapies to kill slow cycling leukemic stem cells 
(LSCs) is predicted to be the cause of relapse and failure of chemotherapy 
(Cronkite, 1970). LSCs respond to the depletion of the leukemic cell mass 
following chemotherapy by entering the cell cycle to regenerate the cancer 
(Clarkson et al., 1975). It has been suggested that the way to eliminate 
dormant LSCs was to find the time frame in which they are cycling, but the 
eradication of dormant LSCs by chemotherapeutic agents has, so far, not 
been fully achieved (Dick, 2008). The inability to identify and assay potential 
LSCs was a major stumbling block to these studies, and characterising LSCs 
was impossible due to an inability to identify markers. Therefore attention 
was focused on the clonogenic assay which was adapted by several groups 
to study AML. By using the clonogenic assay, these groups managed to 
identify the phenotype of AML cultures in vitro with differing proliferative 
potential, providing further proof for hierarchy in AML (McCulloch et al., 1981, 
McCulloch, 1983, Griffin and Lowenberg, 1986). 
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1.4.4 Identification of CSCs: In Vivo Tumourigenicity  
Advances in the types of immunocompromised animal models makes in vivo 
serial xeno-transplantation assay the gold standard of CSC identification 
(Clarke et al., 2006). A CSC enriched cell fraction must display significantly 
increased tumourigenic capacity to validate the cell surface markers upon 
which it was selected.  
The serial xeno-transplantation model is shown diagrammatically in Figure 5.  
Cells from the original tumour are dissociated, usually by enzymatic or 
mechanical means. The CSCs population is enriched for based on molecular 
marker expression with mAbs. The cells are then injected either 
subcutaneously or orthotopically into immunocompromised mice and form a 
xenograft. The xenografted tumour is in turn harvested, digested and 
transplanted into the same site into further mice. In vivo limiting dilution 
assays must be performed with both the target and depleted cell fractions to 
confirm enhanced tumourigenicity in the positive fraction.  
The CSC containing fraction must re-establish the phenotypic characteristics 
of the original tumour. The non CSC fraction is also injected as a control 
which, if selection is successful, fails to form a tumour (Visvader and 
Lindeman, 2008). Clonogenicity in vitro can also be used to estimate CSC 
frequency and results often correlate with tumourigenicity (O'Brien et al., 
2010). 
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Figure 5.  In Vivo Serial Xeno-transplantation Assay.  
Human CSCs from human tumours are enriched for by marker selection and 
injected subcutaneously or orthotopically into immunodeficient mice. The 
resulting tumour is removed, digested and either reselected or transferred 
directly into secondary mice. Adapted from (O'Brien et al., 2010). 
 
The xenotransplantation assay was first used to show that human 
leukaemias contain a small population (≤1%) of cells, with a CD34+, CD38- 
phenotype, which give rise to differentiated  leukaemia cells and recapitulate 
the heterogeneous phenotype of the bulk tumour cancer in NOD/SCID mice 
(Bonnet and Dick, 1997). This finding was a crucial first step in demonstrating 
that subsets of cancer cells with enhanced tumourigenicity can be isolated 
based on molecular markers. The phenotypically more mature cells failed to 
engraft in mice, suggesting the presence of an identifiable tumour cell 
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hierarchy. This experiment also demonstrated the hierarchical organisation of 
human AML.   
 CSCs in Solid Tissues 1.4.4.1
Fractions of serially tumourigenic cells have been identified in solid tumours, 
such as breast (CD44+ CD24-/low) and brain (CD133+) (Singh et al., 2004). 
In these experiments small numbers of selected cells produced tumours in 
recipient mice. CD44 and CD133, which are markers frequently used to 
isolate somatic SC populations, are often used to isolate CSCs. A list of 
potential CSC markers shown to enrich for tumourigenicity in mice are shown 
in Table 2. Other CSC markers have been suggested, but although they 
increased CFE, they have so far failed to enhance tumourigenicity of primary 
human tumour samples in mice. Most of the currently used markers 
recognise molecules on the cell surface and not functional stem cell activity. 
Interestingly, there is a noticeable similarity between markers used to enrich 
normal adult SCs and CSCs, suggesting that they share some phenotypic 
traits. However, in some cases it has proven difficult to confirm markers that 
originally appeared to distinguish tumorigenic from non-tumourigenic cells. 
Following the initial discovery of some markers, conflicting results have been 
published and the suitability of several markers refuted (Magee et al., 2012). 
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Table 2. Putative Cancer Stem Cell Markers.  
Cancer Marker Used to Enrich for CSCs 
Haematopoietic 
(AML) 
CD34+, CD38-  (Lapidot et al., 1994, Bonnet 
and Dick, 1997)  
Brain CD133+ (Singh et al., 2004)  
Breast  CD44+ CD24-/low (Al-Hajj et al., 2003) 
Colon CD133+ (O'Brien et al., 2007, Ricci-Vitiani et 
al., 2007) 
Pancreas CD133+ (Hermann et al., 2007) 
ESA+CD44+ CD24+ (Li et al., 2007) 
Melanoma ABC5+ (Schatton et al., 2008) 
CD20+ CD166+ Nestin+ (Klein et al., 2007) 
Phenotypic populations which enrich for tumour initiating cells when serially 
transplanted immunocompromised mice. 
 
Studying CSCs in solid tumours has proved more challenging than those in 
the haematopoietic system and the frequency of CSCs in solid tumours 
identified by current methods is highly variable (Visvader and Lindeman 
2008). Evidence for the existence of cancer stem cells in solid tumours has 
been more difficult to obtain than in the haematopoietic system for several 
reasons:  
1) The cells within the tumour are less accessible and tissue has to undergo 
mechanical or enzymatic digestion to obtain a single cell suspension which 
can be analysed;  
2) There is a lack of functional assays suitable for detecting and quantifying 
non-cancerous stem cells from many organs;  
3) Only a few cell surface stem cell markers have been identified and 
characterised. The identified markers are often used in combination as for 
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most tumour types and no single marker can select for a 100% pure stem cell 
population.  
Improvements to the NOD/SCID murine model by engineering mice to be 
deficient in natural killer and macrophage activity has increased the reliability 
of these assays. These improvements have also raised questions about the 
frequency of CSCs observed in tumours. The number of CSCs estimated in 
cancer tissue may be affected by the xeno-transplantation model used and 
the extent to which the host immune system is suppressed may account for 
some of the variation between studies (Brehm et al., 2010).  A study into the 
frequency of cancer stem cells in melanoma has suggested that the number 
of stem cells within a tumour can be much higher than previously thought. 
Using NOD/SCID interleukin-2 receptor gamma chain null (Il2rg2/2) mice, 
25% of unsorted primary and metastatic melanoma cells were tumourigenic. 
Enrichment using markers had no effect on the tumourigenicity of the cells 
(Quintana et al., 2008).  
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1.5 Prostate Cancer Stem Cells 
Like other cancers, there is evidence for CSCs in the progression of prostate 
cancer, much of which comes from clonogenic assays. Small percentages of 
cells can establish serially passagable clones or spheres, which are enriched 
in putative stem cell markers (Tang et al., 2007, Li et al., 2008). However, the 
majority of these studies involve cancer cell lines rather than primary tumour 
samples. A combination of markers from primary human cancers which can 
reconstitute the tumour in immune-compromised mice has not yet been 
identified.  
1.5.1 Cellular Origin of Prostate Cancer  
The cell of origin of prostate cancer is still unknown, although recent studies 
suggest that it may originate in the basal epithelial compartment (Goldstein et 
al., 2010). The majority of cells in prostate cancer have a luminal phenotype, 
expressing K8, K18, AR and PSA, which has to suggestions that prostate 
cancer may arise by the malignant transformation of a luminal cell (Okada et 
al., 1992). Emerging evidence suggests, however, that this theory may be 
incorrect and that the ‘cell of origin’ lies within the basal epithelial cell layer of 
the prostate which is more susceptible to malignant transformation (Goldstein 
et al., 2010). This theory is  supported by the fact that most prostate cancers 
contain a minor fraction of basal-like cells which express markers such as 
CD44, p63, ABGG2 and CD133. Surprisingly, one study has shown that the 
CD133 negative population (the non-stem cell population) of BPH-1(SV-40 
transformed normal prostate epithelial) is more susceptible to malignant 
transformation than CD133 positive cells  (Taylor et al., 2012).  
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1.5.2 Prostate Cancer Stem Cell Identification 
Like other cancers, putative populations of prostate CSCs have been sorted 
and enriched for based on their cell surface marker expression. In both 
primary human prostate cancers and cell lines, CD44+/α2β1hi/CD133+ 
populations isolated by FACS demonstrate increased CFE and SFE (Collins 
et al., 2005, Gu et al., 2007, Patrawala et al., 2007). Increased serial 
tumourigenicity is also observed in CD44+ PC-3  cells and CD44+CD24- 
LNCaP prostate cells, where as few as 100 cells form tumours in mice 
(Patrawala et al., 2006). These CD44+ CSCs express embryonic stem cell 
genes such as Oct4, Bmi-1, β-catenin and Smo which are more invasive 
suggesting a role in metastases (Klarmann et al., 2009).  TRA-1-60, CD151 
and CD166 triple positive cells from the prostate xenograft model CWR22 
have enhanced tumourigenicity and  also demonstrate enhanced nuclear 
factor-κB activity (Rajasekhar et al., 2011).  
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1.6 Clonogenicity  
1.6.1 The Clonogenic Assay 
In 1956 Puck and Marcus published a paper describing a cell culture 
technique for assessment of colony forming ability of single mammalian cells 
(Puck, Marcus et al. 1956). Plated in culture dishes with a suitable medium, 
human cervical carcinoma cells (HeLa) were supplemented with a large 
number of irradiated feeder cells and the number of colonies formed was 
counted. This technique is a simple rapid method for growing single 
mammalian cells into macroscopic colonies with a colony forming efficiency 
of 80-100%. The assay was developed further to enable quantification of the 
effects of x-rays on cell populations in vitro, to produce the first in vitro 
radiation cell survival curves (Puck and Marcus 1955; Cieciura, Marcus et al. 
1956; Puck, Marcus et al. 1956).  
The colony forming assay demonstrates heterogeneity in vitro. A clone is 
defined as a group of cells derived from a single ancestor cell and 
clonogenicity is the ability of a given cell population, when plated as single 
cells, to produce one or more clones. The clonogenic potential of a cell 
population can be measured by clonogenic assay, which quantifies the 
proportion of colony forming cells, as a percentage of the plated cell number, 
referred to as colony forming efficiency (CFE). It is believed that colony-
forming cells are able to both self-renew and differentiate (Bruce and 
McCulloch, 1964).  Therefore, the ability to measure the capacity of cells to 
form clones is a useful tool and much of the evidence for the hierarchy model 
of tumour heterogeneity derives from clonogenic assays.  
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Several adaptations to the original method have been made. Immobilising 
cells in a top layer of 0.3% agar avoids formation of tumour cell aggregates 
by random movement, which can be confused with colony growth (Bizzari 
and Mackillop 1985). Agar can be replaced by agarose, which is easier to 
handle or methylcellulose which allows better recovery of the colony for 
replating (Bizzari and Mackillop 1985). Other groups have simplified the 
culture medium and omitted feeder cells, although this is dependent on cell 
type (Franken et al., 2006). 
The clonogenic assay has been used for a wide variety of studies, with many 
cell types, using a range of culture conditions, and for the testing of many 
potential chemotherapeutic agents. It has played a crucial role in the 
identification and characterisation of CSCs. Secondary cloning has allowed 
study of self-renewal and longer term proliferation of CSCs and has the 
advantage of being able to identify cells that undergo a large number of cell 
divisions, a fundamental property of SCs (Bizzari and Mackillop 1985). This 
technique involves selecting specific colonies to determine their proliferative 
potential over a number of passages.  
The role of CSCs in multiple myeloma has been studied using an anchorage 
independent growth clonogenic assay (Hamburger and Salmon, 1977), 
Anchorage independence growth is thought to be a characteristic of stem 
cells (Mori et al., 2009). Bone marrow samples from patients with multiple 
myeloma and normal volunteers cultured in the presence of an agar feeder 
layer prepared by either human type O+ washed erythrocytes or adherent 
spleen cells of BALB/c mice, have a linear relationship between colony 
formation and the number of nucleated bone marrow cells. Multiple myeloma 
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patient samples have a higher CFE compared to normal volunteers and, 
crucially, the number of colonies is proportional to the number of cells 
seeded, suggesting a single cell origin (Hamburger and Salmon, 1977). 
The study of stem cell capacity using clonogenic assays demonstrated the 
presence of a cellular hierarchy in many human cancers, lending support to 
the stem cell model of tumour growth (Mackillop et al., 1983). A few cells in 
each tumour are able to give rise to colonies in culture. Some colonies 
contain transit amplifying cells capable of undergoing a limited number of 
further divisions (Dick, 2008). Studies of serial CFE and colony size of human 
tumours has demonstrated the proliferative heterogeneity of a wide range of 
tumour types including neoplastic human urothelium  (Mackillop et al., 1985), 
melanoma (Asano and Riglar, 1981, Meyskens et al., 1985) and squamous 
carcinoma (Grenman et al., 1989).  
1.6.2 The Human Tumour Stem Cell Assay (HTSCA) 
The success of Hamburger and Salmon in showing a relationship between 
multiple myeloma and colony forming efficiency led to the human tumour 
stem cell assay (HTSCA) as an in vitro method to test sensitivity of individual 
tumours to anticancer drugs (Friedman and Glaubiger, 1982, Panasci et al., 
1985).  Semi-solid agar enriched with medium supports colony growth from 
cell suspensions from a variety of malignant human tumours (Hamburger and 
Salmon, 1977). The aim of the HTSCA was to tailor chemotherapeutic 
regimes to the individual patient and test the effectiveness of new cytotoxic 
agents (Kirkels et al., 1983) including sensitivity of both leukaemias (Santini 
et al., 1989) and solid tumours (Von Hoff et al., 1983, Kuczek and Axelrod, 
1987).  
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Although the development of the HTSCA looked promising the results were 
controversial and it was invalidated (Daniels et al., 1997). Part of the failure is 
attributed to the relatively small proportion of patient tumour samples that 
produce sufficient colonies for in vitro testing. Also, only a small proportion of 
tumours exhibited detectable in vitro sensitivity (Selby et al., 1983).  
The response of clonogenic cells to drugs in vitro should correlate with the 
response of the tumour to the same drug in the patient (Dick, 2008). The 
stem cell model of human cancer suggests that cure or duration of remission 
after clinical treatment should correlate with killing of CSCs. Assessment of 
treatment effects on an unselected cell population (e.g. on the basis of 
morphological criteria) could be misleading since the effects on a small 
population of stem cells will be masked by those on the large population of 
stem cells (Selby et al., 1983).  
Some studies directly compared the response in vitro with the subsequent 
clinical response and showed poor correlation. There have been a wide 
range of predictive value positives reported for the human clonogenic tumour 
cell assay when applied to a patient population with an expected clinical 
response rate of 15-49% (Hug et al., 1984). This value could be misleading 
and in practice may only be workable for cytotoxicity testing for only one third 
of specimens tested.  
Other problems with the use and interpretation of human tumour clonogenic 
assays include technical issue such as difficulty in preparing single cell 
suspensions, production of only small quantities of data, and problems 
defining drug sensitivity and response criteria (Selby et al., 1983, Hug et al., 
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1984). These problems lead to the failure of the HTSCA to become a routine 
tool for analysis and treatment of cancers.  
1.6.3 Non-adherent Colonies 
Culture of single cells in non-adherent conditions is a clonogenic assay which 
is used to measure the number of self-renewing cells, by the formation of 
spheres. Prior to the early 1990s, it was believed that the brain was 
incapable of regeneration due to an absence of SCs. However, the 
propagation of neurospheres in a non-adherent system has demonstrated 
the brain does contain SCs capable of self-renewal and differentiation 
(Reynolds and Weiss, 1992). In a non-adherent culture system containing 
growth factors which select for primitive cells, more committed progenitors 
and mature cells die, positively selecting for proliferating neural stem cells 
(Galli et al., 2003).   
In the sphere forming assay, either freshly digested or previously adherent 
cells are dissociated and cultured as single cells in non-adherent conditions, 
either on low attachment tissue culture plates or in a basement membrane 
matrix suspension (Pastrana et al., 2011). The resultant spheres are 
dissociated and re-plated under identical growth conditions. Differentiated 
cells within the original sphere die rapidly, while the neural SCs continue to 
proliferate exponentially to give rise to secondary spheres. This technique 
has led to the generation of stable neural SC lines (Galli et al., 2003). The 
selection of self-renewing cells in non-adherent culture  is also possible in 
mammary cells, which have been shown to form floating structures known as 
mammospheres, (Dontu et al., 2003a, Dontu et al., 2003b, Dontu and Wicha, 
2005)  and prostate (prostapheres) (Garraway et al., 2010) which are 
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similarly enriched in stem cells. Putative SC markers have been observed 
and identified in these systems, although formation of spheres alone is not 
enough to define a SC (Pastrana et al., 2011).  
1.6.4 Barrandon and Green: Holoclones, Meroclones and Paraclones 
In a seminal paper, Barrandon and Green (1987b) showed that freshly 
isolated clonogenic human epidermal cells form colonies with distinct 
morphologies, which are linked to their proliferative potential.  Inoculation of 
single keratinocyte cells into dishes and transfer of the subsequent colonies 
into indicator dishes for further growth demonstrated that the founding cells 
were heterogeneous in their capacity for sustained growth. This provided the 
first evidence of a relationship between stem cells and colony morphology.  
The founding single cells were classified as holoclones, meroclones and 
paraclones, based on the frequency of terminal colonies produced when the 
clone was transferred to indicator dishes, shown in Table 3. When 100% of 
colonies were terminal  the cell was classified as paraclone; when more than 
5% but less than 100% of the colonies were terminal, the clone was 
classified as meroclone; when 0-5% of colonies were terminal the clone was 
classified as a holoclone. A link between proliferative capacity and colony 
morphology was also observed with holoclones tending to form large 
colonies with a smooth outline and consisting of small cells (Figure 6). 
Meroclones tended to form smaller colonies with a wrinkled outline and 
heterogeneity of cell size and morphology within the colony. Paraclones 
tended to form small colonies with irregular edges and terminally 
differentiated cells, which were generally incapable of further division.  
 
58 
 
Table 3. Barrandon and Green Colonies.  
Typically 
formed by 
Colony Morphology Colony 
Area 
Cell Size Proliferative 
Capacity 
Holoclone Large nearly circular 
with smooth perimeter. 
10-30mm2 Small  <5% cells 
terminal 
Meroclone Wrinkled colony that is 
in between holoclone 
and paraclones in size. 
5-10mm2 Mixture 5-95% cells 
terminal 
Paraclone Small, highly irregular 
perimeter 
<5mm2 Large 
and 
flattened 
>95% 
terminal 
Colony morphology and proliferative heterogeneity of keratinocyte clones in 
vitro. (Barrandon and Green, 1987b) 
 
 
 
Figure 6. Barrandon and Green Colonies. 
Morphologies of colonies derived from holoclone (left), meroclone (middle) 
and paraclone (right) keratinocyte cells (Barrandon and Green, 1987b). 
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The terms holoclone, meroclone and paraclone are now synonymous with 
stem cells, early and late transit amplifying cells respectively (Barrandon and 
Green, 1987b, Barrandon and Green, 1987a, Rochat et al., 1994). Further 
analysis in murine keratinocytes has shown that only holoclones can form 
secondary holoclones and be serially passaged long term (Tudor et al., 2004, 
Tudor et al., 2007). This has led to the holoclone forming assay being 
adopted as a surrogate assay to identify adult SCs, particularly in the skin 
(Mavilio et al., 2006, Murayama et al., 2007, Szabo et al., 2013) , follicular 
(Rochat et al., 1994) and limbal (Pellegrini et al., 2001, Shortt et al., 2007) 
tissues. Holoclones also demonstrate expression of survival genes such as 
p63 (Pellegrini et al., 2001), activation of β-catenin and Akt pathways 
(Murayama et al., 2007) and increased expression of self-renewal genes 
such as Bmi1 (Claudinot et al., 2005).   
 
1.6.5 Cancer Colony Morphology 
Cell lines derived from cancer are a useful tool for studying CSCs. The three 
colony types including holoclone have been observed in cancer cell lines 
including head and neck, breast (Locke et al., 2005), prostate  (Locke et al., 
2005, Wei et al., 2007, Li et al., 2008, Pfeiffer and Schalken, 2010) and 
pancreas  (Li et al., 2007, Wang et al., 2013). These cell lines are 
heterogeneous in terms of CFE, secondary plating efficiency, tumourigenicity 
and marker expression. There is further evidence to indicate the presence of  
stem cells, including dye-exclusion (Hirschmann-Jax et al., 2004, Setoguchi 
et al., 2004, Locke et al., 2005, Patrawala et al., 2006), and sphere formation  
in non-adherent culture conditions (Reynolds, 1992).  A fraction of cells within 
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the cell lines also demonstrate increased serial tumourigenicity and chemo-
resistance (Reynolds and Putnam, 1992).   
Prostate cancer cell lines form colonies with three different morphologies 
when cultured at clonal density (Locke et al., 2005, Wei et al., 2007, Li et al., 
2008, Pfeiffer and Schalken, 2010, Zhang and Waxman, 2010, Beaver, 
2012). Their morphologies are similar to the Barrandon and Green definitions 
of holoclone, meroclone and paraclone. This suggests the presence of a 
cellular hierarchy similar to normal epithelial cell populations containing stem 
cells, transit amplifying cells and differentiating cells (Locke et al., 2005).  
Previous studies have shown that holoclones can be passaged long term, 
(Pfeiffer and Schalken, 2010) are serially transplantable in immune-
compromised mice, and show increased expression of stem cell markers 
such as CD44, α2β1 integrin and β-catenin in PC-3 (Li et al., 2008) and 
DU145 clones (Locke et al., 2005) and aldehyde dehydrogenase 1 (ALDH1) 
activity (Doherty et al., 2011). In contrast meroclones and paraclones can 
only be passaged for a limited period and are non-tumourigenic. Cells sorted 
based on CD44+, integrin α2β1+, CD133+ expression have a higher CFE and 
form more  holoclones than CD44+ integrin α2β1low CD133low  sorted DU145 
cells. (Wei et al., 2007).  However, the meroclone fraction has been studied 
in depth only in PC-3 cells, whilst other studies on other cell lines have 
concentrated on the differences between holoclones and  paraclones and 
ignored meroclones.  
The holoclone forming assay has been extensively utilised in cancer stem 
cell research, particularly within prostate cancer, as a surrogate stem cell 
assay. As well as confirming SC enrichment by cell surface expression 
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(Patrawala et al., 2006, Gao et al., 2009, Marian et al., 2010), dye exclusion 
(Marian et al., 2010) and  reduced PSA expression (Qin et al., 2012)  the 
holoclone assay has given insight into how CSCs are controlled and how this 
may affect metastasis and disease progression. In conjunction with 
tumourigenicity, an increase in the number of holoclones formed by 
overexpression of Nanog has demonstrated a functional role for the stem cell 
gene Nanog in prostate cancer, which supports stem cell model (Jeter et al., 
2009, Jeter et al., 2011). The holoclones assay has also demonstrates role 
for miR-34a in the control of prostate cancer stem cells and metastases (Liu 
et al., 2011). Despite their frequent use, only the PC-3 cell line colonies have 
been rigorously characterised.  
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1.7 Drug Discovery by Phage Display 
Phage display is a technology that can identify a wide range of biological 
targets, varying from small molecules to organ specific ligands. Developed by 
George Smith in 1985, phage display is essentially an affinity selection of 
random peptides displayed on the surface of a bacteriophage that binds 
strongly to the target (Smith, 1985).  
Bacteriophages are viruses that infect bacterial cells, and a key property is 
that they can incorporate DNA and translate the sequence to be expressed 
as peptides on their surface (Smith and Petrenko, 1997). This ability is 
utilised in the phage display technique, where phage are manipulated to 
display a potentially infinite range of random peptides. The technique then 
relies on the ability to rapidly identify ligands with the desired target property 
from a large population of phage clones (called a library library) displaying 
diverse surface peptides (Vodnik et al., 2011). Phage display systems that 
display antibody fragments have also been developed (Clackson et al., 1991) 
which display either scFv or Fab fragments (Carmen and Jermutus, 2002). 
Both peptide and antibody phage display libraries have been used in in vivo 
selection and panning experiments, primarily in mice (Rajotte et al., 1998, Li 
et al., 2006, Newton et al., 2006, Du et al., 2010). The phage library is 
injected and the phage homes to and binds to organs.  Following sacrifice 
harvested tissues can then analysed to recover clones binding to them. 
1.7.1 Bacteriophages 
Bacteriophages have a simple structure which consists of a protein capsid 
enclosing genetic material. A wide range of bacteriophages with differing 
protein coats and modes of infectivity exist, although most published phage 
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display work uses filamentous phage strains M13, fd, or f1 as the vector. 
Filamentous phage are shaped like flexible rods approximately 1 µm long 
and 6 nm in diameter composed mainly of a tube of helically arranged 
molecules of the 50-residue major coat protein pVIII, shown in  
Figure 7. Inside the tube is single stranded viral DNA (ssDNA) consisting of 
6407 bases coding for 11 genes, five of which are coat proteins. At one tip of 
the protein tube are five copies of each of the minor coat proteins pIII and pVI 
and at the other tip are minor coat proteins pVII and pIX. 2700 copies of the 
major coat protein pVIII encapsulate the phage encoded by gene 8 (Griffiths 
et al., 1994).  
 
 
Figure 7. Filamentous Bacteriophage. 
Structure of a filamentous bacteriophage showing the protein coats and their 
locations. pVIII coats the entire phage with pIX and pVII at one end and pIII 
and pVI at the other. pIII (or P3) coat protein is present in 5 copies and is 
frequently the site used to display the peptide library (Sidhu, 2001).  
 
1.7.2 Bacteriophage Infection of an E.coli Host 
Bacteriophages used in phage display can only infect an E.coli cell that 
displays the thread like appendage F pilus. They are non-lytic, meaning that 
they leave the host cell intact. The pIII protein has two N-terminal domains 
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(N1 and N2) and a C-terminal domain connected by glycine-rich linkers G1 
and G2 (Figure 8). Infection is initiated when the N-terminal domain of pIII 
attaches to the tip of the host pilus and the particle enters the cell by 
dissolving coat proteins on the surface of the cell envelope and the uncoated 
ssDNA enters the cytoplasm. A complementary DNA strand is synthesised 
by the host, resulting in the double stranded replicative form (RF). The RF 
replicates to make progeny RFs and acts as the template for transcription of 
phage genes and synthesis of progeny ssDNAs. The new progeny ssDNAs 
are extruded through the cell envelope, acquiring new coat proteins from the 
membrane, emerging as complete virons which are excreted continuously 
from the host cell without killing it (Smith and Petrenko, 1997).  
 
 
 
Figure 8. Phage coat protein pIII. 
The modular structure of phage coat protein pIII which is essential for phage 
activity has two N-terminal domains (N1 and N2) and a C-terminal domain 
connected with glycine rich linkers (G1 and G2). It can be modified to display 
a peptide library between N2 and CT or at the N terminus (Carmen and 
Jermutus, 2002).  
 
1.7.3 Peptide phage display 
For phage display, foreign peptides have been fused to the coat proteins pIII, 
pVIII and pVI, although the most commonly used is pIII. The foreign random 
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DNA sequence is inserted between the amino-terminal half and the carboxyl-
terminal half of pIII, which minimally disrupts its function, particularly its 
infectivity (Smith, 1985). A phage display library contains phage clones 
carrying a wide range of different, random gene inserts and when the phage 
replicates its foreign peptides are also replicated, producing identical progeny 
when infecting a new bacterial host (Smith and Petrenko, 1997).  
A peptide display library contains a large number of clones,  typically 109- 
1010 , although there can be up to 1012, and each clone expresses multiple 
copies of the unique peptide sequence on its surface (Lunder et al., 2005). 
The library is used for affinity selection assays, where the peptide library 
vectors are incubated with an immobilised target, a process called panning. 
Phages that do not bind to the target are washed away, whilst bound phage 
are eluted and then amplified in the E.coli host.  
Amplified phage are again incubated with the immobilised target and panning 
is repeated 3-4 times. Too many rounds of panning can result in phage with 
replicative advantage being selected for. The final round eluate should 
contain phage which are enriched for peptides which bind to the target.  
Various targets can be panned for in vitro, from simple proteins to whole live 
cells, either in solution or adherent. Clones displaying peptides with high 
affinity for the target bind strongly whilst others are washed away. Selected 
clones are isolated and DNA coding the displayed peptide can be 
sequenced. Usually, peptide-encoding DNA libraries are based on partially 
randomised oligonucleotides (Lindner et al., 2012). Commercially available 
phage display libraries include Filamentous phage M13 Ph.D-7, Ph.D-12 and 
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Ph.D-C7C (New England Biolabs) and Spherical T7 phage called T7 Select 
(Merck).  
1.7.4 Targeting Tumours by Phage Display 
Phage display has been used for a wide range of targets. Although initially 
phage display was used for relatively simple targets, the system is also 
utilised for both in vitro whole cell phage display and in vivo panning. Peptide 
phage display has generally yielded peptide sequences which bind to 
previously known cellular targets. Studies have screened peptide phage 
libraries against proteins of interest in cancers such as PSA (Ferrieu-
Weisbuch et al., 2006, Shanmugam et al., 2011) , prostate-specific 
membrane antigen (PSMA) (Lupold and Rodriguez, 2004), ErbB-2 
(Karasseva et al., 2002) and isolated putative cancer stem cell protein 
markers such as CD44 (Park et al., 2011). Of particular interest commercially 
have been peptides targeting growth factor activity, such as the motif CVRAC 
which binds to epidermal growth factor receptor (EGFR) (Cardo-Vila et al., 
2010) and peptides which inhibit Vascular endothelial growth factor (VEGF) 
mediated angiogenesis in vitro (Yayon et al., 1993).  
Peptides have been screened against whole tumour cells, cancer cell lines 
and putative stem cell populations. In this way peptides influencing cell 
attachment and invasion (Romanov et al., 2001, Fukuchi et al., 2010) and 
targeting specific receptors such as urokinase receptor have been identified 
(Goodson et al., 1994, Fong et al., 2002).  
Using cancer cells in vitro for selection has yielded some interesting potential 
targets for cancer such as peptide VHLGYAT (Zhang et al., 2007), and  
HEWSYLAPYPWF (Rasmussen et al., 2002) for colon and breast carcinoma 
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and CPLDIDFYC, believed to be a  α4β1 integrin receptor for AML (Jager et 
al., 2007). Potential ligands have been identified panning against prostate 
cells using either several cancer cell lines and normal prostate epithelial cells 
as a negative selection step. Panning against PC-3 cells has yielded 
DTDSHVNL, DTPYDLTG and DVVYALSDD as potential ligands, and these 
have proved to be useful for in vivo imaging applications (Jayanna et al., 
2010). Screening of the National Cancer Institute panel of human cancer cell 
lines (NCI-60) identified tri-peptide motifs which were recurrently selected 
across the panel, although much heterogeneity was observed (Kolonin et al., 
2006). This study identified motifs that were similar to domains of human 
tumour ligands. Antibody phage display has identified antibody fragments 
which bind to prostate cancer cells but not normal prostate epithelium 
(Popkov et al., 2004) and single chain antibodies (scFv) which target a 
putative breast cancer stem cell population (Jakobsen et al., 2007, Gur et al., 
2009) but not normal breast tissue.  
Phage display has been used to target normal cells such as keratinocytes 
(Jensen et al., 2003), rat pancreatic islet-cells (Ueberberg and Schneider, 
2010) and the luminal surface of polarised endothelium of human umbilical 
veins (Maruta et al., 2003). Some of these phage ligands have been shown 
to resemble binding proteins of bacterial and viral pathogens (Writer et al., 
2004).  
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1.8 Experimental Aims  
Clonogenic assays are widely used as a surrogate assay to identify highly 
proliferative cells in normal and neoplastic tissue. Prostate cancer cells are 
known to form three types of colony similar to the Barrandon and Green 
holoclones, meroclone and paraclones. The use of holoclones formation as a 
surrogate stem cell assay has become popular in the study of prostate 
cancer stem cells. However, the heterogeneity and characteristics of these 
colonies has not been fully studied and previously meroclones have been 
ignored.  
The aim of this study was to elucidate relationship between clonogenicity, 
colony morphology and stem cells in normal and cancer cell populations. To 
do this the stem cell traits (proliferative capacity, self-renewal and 
differentiation) of each type of colony were compared. Full characterisation of 
the clonogenic cells will validate of this assay for the identification stem cells. 
Once validated, the clonogenic assay was used to identify potential 
therapeutic targets against cell surface molecules.   
1.8.1 Hypothesis 
The clonogenic assay can be used as a surrogate assay for stem cell 
identification. The number of stem cells in the cell population is directly 
proportional to the number of holoclones formed in both normal and 
cancerous cells. The formation of proliferative colonies can be used to 
identify peptides which target highly proliferative stem cells, by peptide phage 
display.  
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1.8.2 Objectives 
The following objectives test the hypothesis: 
 Identify the types of colonies formed by single cells from prostate 
cancer derived cell lines and primary prostate epithelial cells from 
patients undergoing TURP for BPH.  
 Test the stability of the number of stem cell colonies under different 
conditions. Is the number of stem cell colonies inherent to the cell line 
or can it be significantly altered? 
 Characterise colonies in terms of proliferative capacity, tumourigenicity 
and marker expression. Are all colonies equal? Is there a difference 
between colonies formed by cell lines and primary cells? 
 Identify potential therapeutic targets by peptide phage display.  
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2 Materials and Methods 
2.1 Prostate Cancer Cell Lines 
The cell lines used in this study were derived from metastatic prostate 
cancers from men with castrate-resistant disease. DU145 was derived from a 
brain metastasis (Stone et al., 1978). PC-3 cells were derived from advanced 
androgen independent bone metastasis of prostate cancer (Kaighn et al., 
1979). LNCaP cells were derived from a supraclavicular lymph node 
metastasis (Horoszewicz et al., 1983). All cell lines were obtained from their 
originators (Stone et al., 1978, Kaighn et al., 1979, Horoszewicz et al., 1983) 
and their identification confirmed by STR profiling.  
The cells were maintained in 25cm2 tissue culture flasks (Nunc) in RMPI-
1640 (Invitrogen, UK) supplemented with 10% foetal bovine serum (FBS) 
(PAA, UK #A10409-1608) and 2 mM L-Glutamine (Invitrogen). A medium 
change was performed every 3-4 days or with sub-culturing when confluent. 
Cells were passaged by removing medium by aspiration. The remaining FBS, 
which inhibits trypsinisation, was removed by washing with Phosphate 
Buffered Saline (PBS) (Invitrogen). 1ml of 0.25% trypsin (Invitrogen) was 
added to each culture flask, the cells coated and incubated for approximately 
5 minutes at 37°C in 5% CO2 until cells rounded up and detached from the 
bottom of the flask. Standard culture medium containing serum was added to 
stop the trypsinisation process and cells diluted 1:10 and introduced into 
fresh culture flasks. Cells were used for a maximum of 10 passages before 
retrieving further cells from the liquid nitrogen cell bank.  
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2.2 Primary Human Prostate Epithelial Cells 
2.2.1 Tissue Collection 
Tissue was obtained from Guy’s Hospital with ethical approval and in 
accordance with the Human Tissue Act 2006 regulations. Samples were 
collected from patients between the ages of 59-81 years undergoing 
treatment for benign prostatic hyperplasia. All patients underwent TURP or 
Holmium Laser Enucleation of the Prostate (HoLEP) which removed between 
10 – 100 g tissue. A maximum of 10% of the tissue was placed in in 25ml of 
transport medium made up of Lebovitz L15 medium  supplemented with 5% 
FBS, 1 % Penicillin/Streptomycin and 1% Ampicillin (all Invitrogen) and 
transported from theatre on ice to the laboratory within 1 h. Lebovitz medium 
is buffered with air, so a stable pH is maintained during transportation.  
2.2.2 Tissue Digestion 
Protocols for tissue digestion and clonogenic assays followed previously 
published protocols (Hudson et al., 2000, Hudson, 2004). The tissue was 
transferred to a sterile 10cm Petri dish and washed with fresh transport 
medium. Clumps of blood and charred tissue were removed with a sterile 
scalpel and forceps and the tissue minced finely using sterile, curved 
scissors. Tissue pieces were transferred to a 50ml centrifuge tube (BD 
Biosciences) and washed by the addition of 20ml PBS. Tissue pieces were 
allowed to sink to the bottom of the tube and the PBS was carefully removed 
by aspiration. The wash step was repeated until the sample was clear of 
blood. It was then digested in transport medium containing 200U/ml 
Collagenase IV (Worthington, New Jersey, USA) for 18-20 h at 37°C with 
gentle shaking.  After digestion any remaining pieces were broken up by 
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gently pipetting up and down with a 5ml pipette. The cell suspension was 
centrifuged at 170 x g for 5 min to pellet the cells and the supernatant 
removed. 20 ml of PBS was added and centrifugation step was repeated.  
2.2.3 Single Cell Suspension 
To produce a single cell suspension, the cell pellet was resuspended in 2 ml 
of 0.25% trypsin and incubated for 2 minutes at 37°C with gentle shaking. 
Trypsinisation was stopped by the addition of 2 ml of 1mg/ml soybean trypsin 
inhibitor (Sigma-Aldrich) in PBS. To remove large cell aggregates and 
produce a single cell suspension, the cell suspension was made up to 10ml 
with PBS and passed through a 100 µm cell sieve (BD-Biosciences, UK). 
The cells were washed twice with PBS, centrifuged, as previously described, 
and re-suspended in 2 ml Prostate Epithelial Basal Medium (PrEBM) (Lonza, 
UK) supplemented with prostate epithelial growth medium (PrEGM) bullet kit 
(Lonza) and 1% Penicillin/Streptomycin and 1% Ampicillin.  
2.3 Clonogenic Assays 
2.3.1 Cell Lines 
The cell line clonogenic assay was adapted from previously published 
methods (Franken et al., 2006). Growth medium was aspirated from a cell 
monolayer at approximately 70% confluence and the cells were washed with 
PBS. 1 ml of 0.25% trypsin was added to the flask and incubated at 37°C for 
5 minutes until the cells became rounded and detached from the culture 
flask. Nine ml of growth medium was added to stop the trypsinisation 
process. The cell suspension was gently pipetted up and down several times 
to break up clumps and produce a single cell suspension. 50µl of cell 
suspension was diluted 1:1 (v/v) with trypan blue (Sigma-Aldrich, UK) and 
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about 10µl was added to each side of a Neubauer haemocytometer 
chamber.  
The number of viable cells was counted in 8 separate squares of the 
haemocytometer. Viable cells are phase bright and dark cells which took up 
trypan blue as a result of a permeable cell membrane were deemed to be 
non-viable. On the basis that each of the large squares is equivalent is 0.1µl, 
the number of cells per ml can calculated from the number of cells per grid x 
104 ml. The average number of live cells per grid was determined and was 
multiplied by the dilution factor by 104 to give the viable cell count per ml. Cell 
suspensions which contained fewer than 95% single, viable cells were 
rejected.  
Cells were seeded into 60mm petri-dishes at a density of 200 (DU145 and 
PC-3) or 500 (LNCaP) cells per dish in 5ml growth medium in triplicate. The 
dishes were gently shaken side to side and front to back to evenly distribute 
the cells and incubated for either two weeks (DU145 and PC-3) or three 
weeks (LNCaP) at 37°C in 5% CO2. The medium was changed every 7 days.   
2.3.2 Primary Prostate Epithelial Cells 
Cells isolated from TURP or HoLEP tissue (described in section 2.2.3) were 
counted using trypan blue exclusion and the number of single cells 
determined. Only samples containing >90% single cells were used for 
clonogenic assays. 1000 or 10,000 single cells were seeded into collagen 
coated petri dishes supported by a feeder layer of Swiss 3T3 fibroblasts with 
5ml PrEGM in triplicate. Cells were incubated at 37°C at 5% CO2 for 12 days. 
Following 4 days incubation, the cells were removed from the incubator and 
washed gently by removing PrEGM and adding 5ml PBS. The liquid was 
74 
 
aspirated and fresh PrEGM added gently, so as not to disturb adherent 
colonies.   
 Preparation of Collagen Coated Dishes 2.3.2.1
Sixty mm diameter petri dishes were coated with 2µg / cm2 of Type I 
Collagen from rat tail (Sigma-Aldrich) by diluting 15 µl of the 4 mg / ml stock 
in 1ml dH2O and swirling to coat the bottom of the dish. The dishes were 
incubated at 37 °C for 2 hours and then washed with dH2O, allowed to dry, 
sealed with laboratory film and stored at 4°C for up to 1 month. 
 Preparation of Feeder Layer 2.3.2.2
Murine Swiss 3T3 cells (ATCC) were maintained in RPMI-1640 
supplemented with 2 mM L-Glutamine and 10 % new born calf serum (NBS) 
(Sigma-Aldrich). When the cells were approximately 70 % confluent they 
were treated with 4 µg/ml Mitomycin C in culture medium (Sigma-Aldrich) for 
2 hours at 37 °C. The cells were washed with 5ml PBS and harvested by 
incubation with 3 ml of 0.25 % trypsin for 5 minutes, counted by trypan Blue 
exclusion and frozen at – 80 °C in 10 % dimethylsulfoxide (DMSO) in 
complete culture medium. To check mitotic inhibition, 2 x 105 treated cells 
were cultured in a 75 cm2 flask for 7 days. Only treated cells which did not 
proliferate within the 7 days were used to provide a supportive feeder layer 
for primary prostate epithelial growth. 24 hours prior to clonogenic assay, 3T3 
cells were defrosted rapidly at 37 °C and seeded into 60 mm petri dishes at a 
density of 1 x 105 cells and incubated overnight at 37 ° C, 5 % CO2. 
2.3.3 Analysis 
Following incubation, cells were fixed by the addition of 3 ml of 70% industrial 
methylated spirit (IMS) in dH2O for 30 minutes. The IMS was removed and 
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the cells stained by with  0.1 % Crystal Violet (CV) (Sigma-Aldrich) dissolved 
in 20 % IMS in dH20 for 30 min. The CV was removed and the dishes were 
washed gently with tap water so as not to disturb the colonies, and allowed to 
air dry for 24 hours. 
The colonies which contain >32 cells were scored and counted under a 
dissection microscope. Colonies were colour coded by pen for easy 
identification and measurement. The total number of colonies and the 
number of each colony type were determined and the CFE calculated as a 
percentage of the number of input cells.  
Mean colony size, cell size and number of cells per colony were determined 
by measuring the colony size and counting the number of cells across the 
diameter. Twenty colonies of each type were measured using a graticule and 
calibrated eye piece across the x and y axis. 
From these measurements the area (a) of each colony was calculated  based 
on the following equation: 
           
The number (n) of cells across the y axis of each colony was counted and the 
average cell diameter (d) was calculated by diving it by the length of the y 
axis:   
 
 
 
The colony diameter was then used to estimate the area (A) taken up by 
each of each cell:      (     )  (     ) 
The number of cells per colony (N) was estimated by calculating the number 
of cells based on the equation:    
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In later experiments, the mean number of cells per mm2 from twenty colonies 
of each morphological type was used to estimate the number of cells in 
colonies, based on colony diameter, by multiplying the estimated colony area 
by the mean number of cells per mm2 (c): 
      
 
2.4 Effect of Culture Conditions on Clonogenicity 
Conditions that affect CFE were assessed by clonogenic assay. Firstly the 
optimum seeding densities for DU145, PC-3 and LNCaP cell lines were 
determined. Optimal cell numbers were then cultured with different 
concentrations of FBS, on different substrates and with different media. The 
same incubation times and parameters were applied for each condition, 
changing only the test condition each time. Finally, optimum conditions for 
each cell line were tested in combination.   
2.4.1 Seeding Density 
The following numbers of single cells were seeded in triplicate in 60mm petri-
dishes containing 5ml growth medium: 1000, 500, 200, 100, 50 and 20.  
Dishes were gently shaken side to side and front to back to evenly distribute 
the cells and incubated for either two weeks (DU145 and PC-3) or three 
weeks (LNCaP) at 37°C 5% CO2. The medium was changed every 7 days.   
2.4.2 FBS Concentration 
A clonogenic assay was used to analyse the effect of FBS concentration on 
the prostate cancer colonies.  To acclimatise cells to new conditions, one 
25cm2 flask of 70% confluent cells was spilt into 5 fresh flasks and cultured 
77 
 
with 50, 20, 10, 5 or 1% FBS in RPMI-1640. Following 7 days incubation, 
each flask was trypisinsed to produce a single cell suspension and cells 
counted by trypan Blue exclusion. 200 cells (DU145 and PC-3) or 500 cells 
(LNCaP) were seeded in triplicate in 60mm petri-dishes containing 5ml of  
the corresponding FBS containing medium.  
 Substrate 2.4.2.1
The effect of the substrates collagen, fibronectin, laminin, vitronectin and a 
feeder layer of mitomycin C treated Swiss 3t3 cells was tested by clonogenic 
assay. All substrates were prepared in 60mm petri-dishes according to 
manufacturer’s instructions and the final concentrations are shown in Table 
4. Petri dishes were coated with 2µg / cm2 Type I Collagen from rat tail 
(Sigma-Aldrich) by diluting 15 µl of the 4 mg / ml stock in 1ml dH2O and 
coating the bottom of the dish with 1ml. The dishes were incubated at 37 °C 
for 2 hours and  then washed with dH2O, allowed to dry, sealed and stored at 
4°C for up to 1 month. A 0.5 µg / ml fibronectin solution was made by diluting 
stock fibronectin (Invitrogen) in growth medium and 3ml was added per dish 
and incubated for 1 hour at 37 °C in 5 % CO2 prior to seeding cells. At 
seeding a further 2 ml of growth medium was also added. A working solution 
of 0.5 µg/ml of Laminin (Sigma-Aldrich) was prepared by diluting 50 µg in 
PBS.  3 ml of the working solution was added to each dish and incubated at 
37 °C for 2 hours and washed with PBS, sealed and stored at 4 °C for up to 1 
month. A working solution of vitronectin (Sigma-Aldrich) was prepared at a 
concentration of 0.5 µg / ml in dH2O and 3 ml added to each 60 mm petri 
dish, incubated at 37 °C for 2 hours and washed with PBS. Vitronectin dishes 
were prepared fresh for each assay. A feeder layer of 1x104  mitomycin C 
treated 3t3 cells per cm was prepared as in 2.3.2.2. Into each of the prepared 
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dishes, 200 (DU145 and PC-3) or 500 single cells (LNCaP) were seeded as 
described above. Again, the cells were incubated for 14 or 21 days and the 
medium changed every 7 days. 
 
Table 4. Substrates Tested By Clonogenic Assay 
Substrate Concentration Supplier 
Tissue Culture Plastic N/A Nunc (UK) 
Type I rat tail Collagen 2µg/cm2 Sigma-Aldrich (C3867-1VL) 
Fibronectin 50ng/cm2 Invitrogen (#33010-018) 
Laminin 50ng/cm2 Sigma-Aldrich (L4544) 
Vitronectin 50ng/cm2 Sigma-Aldrich (V8379) 
3T3 feeder cells 1x104 /cm N/A 
 
 
 Culture Medium  2.4.2.2
The commonly used cell culture media shown in Table 5 were tested for their 
ability to support colony forming cells. Each medium was supplemented with 
10% FBS. As with the FBS assay, 7 days prior to the assay, cells were 
introduced to the test culture medium to allow acclimatisation to new 
conditions. Again, following 7 days incubation, each flask was trypsinised to 
produce a single cell suspension and cells counted by trypan blue exclusion. 
200 cells (DU145 and PC-3) or 500 cells (LNCaP) were seeded in triplicate in 
60mm petri-dishes containing 5ml of each medium. 
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Table 5. Cell Culture Medium Tested by Clonogenic Assay.  
 
Medium Manufacturer 
RPMI-1640 Gibco #31870 
DMEM High Glucose Gibco #41966 
DMEM Low Glucose Gibco #31885 
Ham’s F12 Gibco #21765 
Hams’ F12/ DMEM High Glucose 1:1 mixture of  Gibco #21765 and #41966 
Advanced MEM Gibco #12492 
 
 Analysis 2.4.2.3
After the incubation period, the colonies were fixed and stained with crystal 
violet as previously described. All colonies were counted and scored based 
on previously determined parameters. Twenty colonies of each colony type 
for each condition for each experiment were measured using a graticule and 
eye piece. Colony size and cell number were determined based on mean cell 
number of measured colonies (see section 2.3.3).  An estimation of the 
number of cells in LNCaP colonies was not possible due to the three-
dimensional nature of the colonies.   
 Statistical Analysis 2.4.2.4
The total number of colonies, the  number of each colony type and colony 
size were analysed by MANOVA followed by Tukey’s honestly significant 
difference (HSD) post hoc pairwise comparison using the statistics package 
PAWS Statistics 18 (formerly SPSS). This post hoc test was chosen to 
compare all possible means based on Studentised Range Distribution. 
Tukey’s HSD allows comparison of each pair of conditions to see of their 
difference is significant. The Tukey test looks at the random variation that 
exists between the pair of means (the standard error of the differences 
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between pairs of means). The variation between the pairs of means is then 
compared to the standard error of the sample. To transform the colony size 
data to ensure that the data has a normal distribution essential for Tukey’s 
HSD, the log of each measurement was taken. Results with a p < 0.05 were 
deemed significant. 
 
2.5 Secondary Cloning 
Under a phase contrast light microscope well isolated colonies were 
selected, circled with a pen and numbered for identification. Colony diameter 
was measured using a calibrated eye piece and graticule to estimate cell 
number based on previous calculations (see section 2.3.3). 
Culture medium was removed from the petri-dish by aspiration and cells 
washed with 5ml of PBS. A sterile glass cloning ring coated with vacuum 
grease around the bottom edge was placed around each selected colony 
with sterile forceps and gently twisted to produce a seal. The colony was 
inspected under a light microscope to ensure the correct placement of the 
ring and to ensure vacuum grease did not touch the colony.  100µl of 0.25% 
trypsin was added to each ring and the cells incubated at 37°C in 5% CO2 for 
10 minutes until the cells rounded and detached.  
2.5.1 Cell Lines 
The contents of each cloning ring were transferred to a sterile universal tube 
and the ring washed with growth medium to collect any remaining cells. The 
cell suspension was diluted with growth medium to a concentration of 1000 
cells per ml, based on the estimation of the number of cells within each 
colony. 200 cells were seeded in triplicate into 60mm petri-dishes in 5ml 
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growth medium and cultured for a further 2 weeks. If the colony consisted of 
fewer than 200 cells, the entire colony was transferred directly to a fresh petri 
dish. Following 2 weeks incubation the colonies were analysed as in section 
2.3.3 and CFE determined as the percentage of colonies per number of input 
cells.  
2.5.2 Primary Prostate Epithelial Cells 
The contents of each cloning ring were transferred to a sterile universal tube 
and the ring washed with growth medium to collect any remaining cells. 
Trypsin activity was inhibited by the addition of 100µl of 1mg/ml soybean 
trypsin inhibitor and the tube centrifuged at 170 xg. The cell suspension was 
diluted with complete PrEGM to a concentration of 1000 cells per ml, based 
on the estimation of the number of cells within each colony. 1000 cells were 
seeded in triplicate into collagen coated 60mm petri-dishes supported by a 
feeder cells with 5ml PrEGM and cultured for a further 2 weeks. If the colony 
consisted of fewer than 1000 cells, the entire colony was transferred directly 
to a fresh petri dish.  
2.6 Serial Cloning  
DU145 colonies were serially cloned to compare the proliferative capacity of 
each of the colony types. Three colonies of each type generated by a 
standard clonogenic assay were ring cloned and seeded at clonal density to 
generate secondary colonies. Subsequent colonies of each lineage were 
then ring cloned and the process repeated until either no colonies were 
formed or until the end of the experiment (Figure 9). At each generation, 
remaining dishes not sued for further cloning were fixed with 70% IMS and 
stained with Crystal Violet to analyse CFE and colony morphology.  
82 
 
 
Figure 9. Long term serial cloning of prostate colonies. 
Type 1, 2 and 3 colonies were serially cloned until terminal or until the 200 
cell divisions were reached. Pure lineages were cloned e.g. secondary type 1 
colonies from primary type 1 colonies, secondary type 2 colonies from 
primary type 2 colonies. As secondary type 1 colonies were observed from a 
primary type 2 colony this lineage was also serially cloned. Type 3 colonies 
were terminal upon secondary plating.  
 
2.7 Serial Passage  
2.7.1 Cell Lines 
The long term growth potential of prostate cancer cells under normal cell line 
maintenance conditions were compared. Each colony was ring cloned and 
transferred to a T25cm2 flasks for long term culture. In three separate 
experiments, 5 colonies of each type were ring cloned, as previously 
described, resuspended in 5ml culture medium and transferred to a T25cm2 
flask. The cells were incubated at 37°C in 5% CO2 until 70-90% confluent. 
Flasks were monitored 2-3 times per week and once the cells reached 
confluence they were passaged using standard subculture techniques,  as 
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previously described in (section 2.1), and seeded at a 1:10 dilution. The cells 
were serially passaged when confluent until they reached 20 passages, at 
which point they were deemed immortal. Flasks that failed to reach 
confluence were monitored until the other flasks containing actively dividing 
cells reached 20 passages, a period of approximately 14 weeks.  
2.7.2 Prostate Epithelial Cells 
The long term growth potential of primary prostate epithelial cells was 
compared by serial passage. Each colony was ring cloned and transferred to 
a T25cm2 flasks for long term culture. Using 3 patient samples, 5 colonies of 
each type were ring cloned, as previously described, resuspended in 5ml 
culture medium and transferred to a collagen coated T25cm2 flask. The cells 
were incubated at 37°C in 5% CO2 until 70-90% confluent. Flasks were 
monitored daily and, once cells reached confluence, passaged using 
standard subculture techniques and seeded at a 1:6 dilution. Cells were 
serially passaged until no further growth was observed.  Colonies that failed 
to reach confluence were monitored until flasks containing actively dividing 
cells ceased to proliferate.   
 
2.8 Sphere Formation 
The sphere forming assay under non-adherent conditions is a measure of 
self-renewal (Reynolds and Weiss, 1992). Colonies were selected by ring 
cloning, cultured under non-adherent conditions (Hudson et al., 2000, Rybak 
et al., 2011) and the resulting number and size of spheres determined. 
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2.8.1 Cell Lines 
Colonies were prepared and ring cloned as previously described. The single 
cell suspension was diluted to a concentration of 1x104 cells/ ml in sphere 
forming medium (serum-free DMEM/F12 medium, 20 ng/ml basic FGF, 20 
ng/ml EGF 1x B27 (all Invitrogen) and 3 μg/ml insulin (Sigma)). 100µl of cell 
suspension (1000 cells) was placed into a 1.5 eppendorf tube and made up 
to 135µl with sphere forming medium. 135µl of MatrigelTM (BD Bioscience, 
Michigan, USA), which had been kept on ice to prevent setting, was added 
and pipetted up and down gently to mix. The 1:1 cell suspension:Matrigel 
mixture was transferred to one well of a 6 well plate and gently pipetted 
around the edges of the dish. Up to 3 wells were prepared for each colony, 
depending the number of cells it contained, and the dish was incubated at 
37°C until Matrigel had set. When the cell suspension had solidified, 3ml of 
sphere medium was added to the centre of the well to avoid dislodging the 
cells. The spheres were incubated for 2 weeks at 37°C in 5% CO2 with a 
medium change at 7 days. 
 Prostate Epithelial Cells 2.8.1.1
Primary prostate epithelial colonies from 5 patient samples were prepared 
and ring cloned as previously described. The single cell suspension was 
diluted to a concentration of 1x104 cells/ ml in PrEGM. 100µl of cell 
suspension (1000 cells) was transferred to a 1.5 eppendorf tube and made 
up to 135µl with sphere forming medium. 135µl of MatrigelTM was added to 
each one well of a 6 well plate and gently pipetted around the edges of the 
dish. Up to 3 wells were prepared for each colony, depending the number of 
cells, and the dish was incubated at 37°C until the Matrigel had set. When 
the cell suspension had solidified, 3ml of sphere medium was added to the 
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centre of the well to avoid dislodging the cells. The spheres were incubated 
for 2 weeks at 37°C in 5% CO2 with a medium change at 7 days. 
2.8.2 Analysis 
Following two weeks incubation the spheres were examined under phase 
contrast microscopy. The number of spheres in each well was counted and 
each sphere was measured using an eye piece and graticule to determine its 
diameter. The sphere forming efficiency (% SFE) was determined as the 
number of spheres formed as a percentage of the number of cells seeded.  
 
2.9 Tumourigenicity 
The ‘gold standard’ for confirming a cancer stem cell is the ability to form 
serially transplantable tumours in immuno-compromised mice (Clarke et al., 
2006). In this study, colonies of each morphological type were harvested and 
pooled. 10,000 or 1,000 cells were injected subcutaneously into the flanks of 
nude mice and the resultant tumour rate determined. Some of the primary 
tumours were digested, expanded in vitro and re-injected to form secondary 
tumours. The protocol is shown diagrammatically in Figure 10.  
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Figure 10. Assessment of Colony Tumourigencity In Vivo.  
Type 1 and 2 DU145 colonies were ring cloned and injected subcutaneously 
with MatrigelTM into the flanks of nude mice. After 12 weeks the tumours were 
removed and analysed. Tumours were and digested and cultured at clonal 
density to assess Clonogenicity and confirm formation of colony types. 
Tumours were also fixed, paraffin embedded, sectioned and stained for 
histology. Some tumour samples were digested and the cells re-injected into 
secondary mice to assess their ability to form secondary tumours.  
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2.9.1 Primary Tumourigenicity 
DU145 cells were cultured under standard clonogenic conditions for two 
weeks.  Colonies were scored and measured to determine the number of 
cells per colony (as previously described). Colonies were ring cloned and 
smaller colonies were pooled to produce enough cells for each injection and 
resuspended in 10 ml of culture medium. Cells were washed by centrifuging 
at 120xg for 5 minutes, the supernatant removed and the cell pellet 
resuspended at a density of 1x104 cells per ml. As a positive control DU145 
cells cultured in a monolayer were harvested by trypisinisation, counted and 
resuspended at a density of 1x104. Either 10,000 or 1,000 cells were 
transferred to individual 1.5ml microfuge tubes, made up to 1ml with culture 
medium and centrifuged again at 120xg.  The supernatant was removed and 
the cells resuspended in a mixture of 100µl 1:1 MatrigelTM: RPMI-1640 + 
10% FBS which had been kept on ice to prevent solidification. The tubes 
were kept on ice until injection to prevent MatrigelTM solidifying.  
Cell suspensions were injected into the flanks of 7 week old (19-20 g) male 
BALB/cOlaHsd-Foxn1nu Nu/nu (Nude) mice from Harlan, UK, with a 100-U 
insulin syringe with a 28 Gauge  ½ inch Micro-FineTM IV needle (BD 
Biosciences). Once injected MatrigelTM rapidly forms a gel at temperatures 
above 22˚C, retaining the cell suspension at the injection site. As a control 
100μl culture medium:MatrigelTM alone (vehicle control) was injected into 
mice. Three separate experiments were performed with 2-6 replicates for 
each condition, dependent on the number of colonies harvested.   
Tumour development was monitored weekly and tumour growth measured 
using 150mm digital callipers (World Precision Instruments, Hitchin, UK). 
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Tumour volume was calculated using the formula 0.5(ab2), where a is the 
longer and b the shorter of the two perpendicular diameters. Mice were killed 
by cervical dislocation after 12 weeks or earlier if the maximum tumour 
burden of 5% of body weight was reached. As the average body weight of 
the nude mouse is 20g this was calculated as 1g, which corresponds to a live 
volume of around 3500mm3.  
The mice were dissected, photographed, and the tumour removed using a 
fine sterile scalpel. Each tumour was weighed and placed in transport buffer 
consisting of PBS + 1% penicillin/ streptomycin, for transport to the 
laboratory. Each tumour was cut in to two. One piece was washed in PBS 
and fixed in 4% paraformaldehyde (PFA) and stored at 4°C. The other piece 
was either snap frozen in liquid nitrogen and stored at -80°C or digested and 
cultured (section 2.9.2). Samples fixed in 4% PFA were sent to the 
cryosectioning facility at the University of Dundee, paraffin embedded, cut 
into 10μm sections, mounted on microscope slides and stained with 
Haematoxylin and Eosin (H&E). Tumour sections were photographed 
analysed.  
2.9.2 Clonogenicity of Xenografts 
Xenografts were transferred to a 10cm petri dish and washed with transport 
buffer. The buffer was aspirated and replaced with 2ml PBS and the tissue 
was finely minced using curved 14.5cm scissors (World Precision 
Instruments). Tissue was transferred to a 15ml centrifuge tube and 10ml 
transport buffer added. The cells were centrifuged for 5 minutes at 120xg, the 
supernatant removed and the cells resuspended in 600U/ml filter-sterilised 
type 1 collagenase (Sigma-Aldrich) in 10ml RPMI-1640 (5% FBS + 1% 
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penicillin / streptomycin) and digested for 2 hours at 37°C with continuous 
shaking on a Luckham R100 orbital shaker on medium setting. The digested 
cell suspension was centrifuged at 120 xg for 5 minutes, the supernatant 
removed and the cells re-suspended in 5ml of RPMI-1640 supplemented with 
10% FBS. Viable cells were counted by trypan blue exclusion and either 200 
or 1000 viable cells were seeded into 60mm petri-dishes containing 5ml 
RPMI-1640 and cultured for 2 weeks in a clonogenic assay. Following 2 
weeks incubation the cells were fixed, stained and CFE and colony 
morphology was determined.  
2.9.3 Secondary Tumourigenicity 
Cells from digested tumour samples were used to assess the ability of clones 
to form secondary tumours. Digested cells were seeded into T25cm2 flasks 
and expanded for 2 weeks until confluent. Cells were washed, trypsinised, 
resuspended and counted using trypan blue exclusion. The cell samples for 
injection in the flanks of nude mice were prepared as described above for the 
DU145 monolayer at a cell number of 10,000 per injection and monitored 
over 12 week as previously described for the primary experiment.  Tumours 
were removed and analysed as previously described.   
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2.10 Immunocytochemistry 
The markers expressed by DU145 and prostate epithelial colonies were 
analysed by immunocytochemistry. Each type of colony was stained with a 
primary antibody against proliferation marker (Ki67), stem cell (CD44, α2β1, 
Oct4 and Bmi1) and differentiation (Cytokeratin 5 and 18) markers.  
2.10.1 Sample Preparation 
 DU145 Cells 2.10.1.1
DU145 cells grown in a T25cm2 flask were washed, trypsinised and counted. 
Ten cells were seeded with 1ml of culture medium in to each well of a 24-well 
plates and incubated for 2 weeks with a medium change after 7 days. After 2 
weeks, the medium was removed and the cells were washed with PBS. The 
PBS was aspirated and the cells were fixed with 200µl of 4% PFA (Sigma-
Aldrich) in PBS for 20 minutes at room temperature. The PFA was removed 
and PBS added, and the plates were sealed and stored at 4°C for up to 1 
month. 
 Prostate Epithelial Cells 2.10.1.2
Primary prostate epithelial cells derived from 3 patients were cultured in a 
clonogenic assay for 2 weeks supported by a feeder layer. After 2 weeks, the 
medium was removed and the cells were washed with PBS. The PBS was 
aspirated and the cells were fixed with 1ml of 4% PFA (Sigma-Aldrich) in 
PBS for 20 minutes at room temperature. The PFA was removed and PBS 
added, and the plates were sealed and stored at 4°C for up to 1 month. 
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 Positive Controls 2.10.1.3
PC-3 (Ki67, K18, K5) and GCT27 (α2β1, CD44, Oct4 and Bmi1) cells were 
used as positive controls for immunohistochemistry. Cells grown in a T25cm2 
flask were washed, trypsinised and counted. 1 x 104 cells were seeded with 
1ml of culture medium in to each well of a 24-well plates and incubated for 2 
days. The medium was removed and the cells were washed with PBS. The 
PBS was aspirated and the cells were fixed with 200µl of 4% PFA (Sigma-
Aldrich) in PBS for 20 minutes at room temperature. The PFA was removed 
and PBS added, and the plates were sealed and stored at 4°C for up to 1 
month. 
2.10.2 Staining 
The PBS was removed and the colonies which were to be stained for 
intracellular markers (Ki67, K5, K18, Bmi1 and Oct4) were permeabilised by 
adding 200µl 0.2% Triton X-100 (Sigma-Aldrich) in PBS for 10 minutes at 
room temperature. The permeabilisation buffer was removed and cells 
blocked with 10% normal goat serum (NGS) (PAA) in PBS for 30 minutes at 
room temperature to prevent non-specific binding. Primary antibody dilutions 
(Table 6) were prepared in 1% NGS in PBS and the blocking buffer was 
removed and replaced with the primary antibody and  incubated overnight at 
4°C in a humidity box, to prevent drying.  For negative control, antibody 
diluent containing no antibody was added to the target well. Following an 
overnight incubation, the primary antibody was removed and the wells were 
washed 4 times with PBS containing 1% NGS. Secondary antibody dilutions 
(Table 6) were prepared and added to the target wells for 1 hour at room 
temperature in the dark to prevent photo bleaching. The antibodies were 
removed and wells washed 4 times. The final wash buffer was aspirated and 
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the plates turned upside down on tissue paper to allow any excess liquid to 
drain. A drop of Vectashield® mounting medium with DAPI (Vector 
Laboratories Inc, Peterborough, U.K.) was added to each well and the cells 
were covered with a 13mm coverslip (VWR, Lutterworth, UK) using fine 
forceps. The plates were stored at 4°C in the dark. 
2.10.3 Two Colour Staining 
To determine cytokeratin expression of prostate cells, colonies were 
sequentially stained with antibodies against K5 and K18 antibodies. Colonies 
were first stained with antibodies against K5 as in section 2.10.2. Following 
incubation with the first secondary antibody, cells were blocked again with 
1% NGS. Blocking buffer was removed and the diluted antibody against K18 
was added and incubated overnight at 4°C. Overnight antibody was removed 
and the cells washed 4 times with 1% NGS in PBS. The second secondary 
antibody was added and incubated at room temperature for 1 hour. The 
samples were washed again and mounted as described above.   
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Table 6. Antibodies For Immunocytochemistry  
Target Primary Antibody Secondary Antibody 
Ki67 
(Proliferation) 
Rabbit polyclonal to Ki67 
(Abcam #ab15580) 5µg/ml 
Goat anti rabbit IgG FITC 
(Southern Biotech) 4µg/ml 
K5 (Basal) Mouse monoclonal (clone 
XM26) (Abcam #ab17130) 
5µg/ml 
Goat anti mouse IgG1 FITC 
(Southern Biotech) 4µg/ml 
K5 (Basal) Rabbit polyclonal (Abcam 
#ab24647) 4µg/ml 
Goat anti rabbit IgG FITC 
(Southern Biotech) 4µg/ml 
K18 
(Luminal) 
Mouse monoclonal (clone 
C-04) to cytokeratin 18 
(Abcam #ab668) 5µg/ml 
Goat anti mouse IgG1 FITC 
(Southern Biotech) 4µg/ml 
Goat anti mouse IgG H&L 
TRITC (Abcam #ab6786) 
α2β1 
Intergrin 
(stem cell) 
Mouse monoclonal (clone 
16B4) to (Abcam #30483) 
1µg/ml 
Goat anti mouse IgG1 FITC 
(Southern Biotech) 4µg/ml 
CD44 (stem 
cell) 
Mouse monoclonal (clone 
G44-26) (BD Biosciences) 
5µg/ml 
Goat anti mouse IgG1 FITC 
(Southern Biotech) 4µg/ml 
Oct-4 (stem 
cell) 
Rabbit Polyclonal  4µg/ml Goat anti rabbit IgG FITC 
(Southern Biotech) 4µg/ml 
Bmi1 (stem 
cell) 
Rabbit Polyclonal (Abcam 
#ab38295) 4µg/ml 
Goat anti rabbit IgG FITC 
(Southern Biotech) 4µg/ml 
 
2.10.4 Image Analysis 
Colonies were analysed using an Olympus Total Internal Reflection inverted 
confocal microscope and Fluoview 2000 software. All photographic images 
were taken using a 10 times (x10) or 20 times (x20) objective. Laser power 
and voltage was set using control samples. Z stack images were taken at an 
interval of 1 µm and composite images were produced for both DAPI and 
FITC channels and a merged image. Large type 1 colonies were too wide to 
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image in 1 frame so mosaic images were produced using the same Z-stack 
dimensions and stitched together using the software. To determine the 
proportion of positive cells in a colony, the samples were viewed at x20 
magnification. If the colony was small (<200 cells) all cells were counted and 
the positive fraction (green) calculated as a percentage of the total number of 
cells (DAPI stained nuclei). The proportion of positive cells in larger colonies 
was estimated by counting at least 200 cells in 5 random frames.  
 
2.11 Incucyte Analysis of Clonal Growth 
The clonogenic assay is based on the growth of colonies from single cells. To 
check the proportion of colonies that arose from single cells, colony growth 
was monitored using the Incucyte Live Cell Imaging System. DU145 cells 
were trypsinised and seeded at clonal density into 6 well plates. Phase 
contrast photographs of each well were taken at intervals of 4 hours by the 
Incucyte System for the duration of the 2 week incubation period. Incucyte 
images were viewed and each colony was tracked from when cell first 
adhered to the plastic to the end of the growth period. The number of cells 
from which the colony developed and the merging of colonies observed and 
the number of colonies derived from single cells calculated. The results are 
from 4 separate experiments from 4 individual flasks of DU145 cells.  
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2.12 Peptide Phage Display  
2.12.1 The Ph.D.™-7 Phage Library 
The Ph.D.™-7 library was purchased from New England Biolabs, UK. The 
library is based on a combinatorial library of random heptapeptides fused to a 
minor coat protein (pIII) of M13KE phage. The displayed peptide (7-mer) is 
expressed at the N-terminus of pIII and is present in 5 copies. The peptide is 
followed by a short spacer (Gly-Gly-Gly-Ser) and then the wild-type pIII 
sequence. The library consists of approximately 109 sequences amplified 
once to yield approximately 100 copies of each sequence in 10 µl of the 
supplied phage. The manufacturer’s guidlines for panning against live cells 
were followed. 
2.12.2 Culture of Host E.coli 
E.coli host strain ER2738 (genotype F´proA+B+ lacIq Δ(lacZ)M15 
zzf::Tn10(TetR)/ fhuA2 glnV Δ(lac-proAB) thi-1 Δ(hsdS-mcrB)5) was 
purchased from New England Biolabs, (Hitchin, UK). This strain is a fhuA2 
version of E. coli NM522 in which the F' can be selected for using 
tetracycline. The stock was streaked on Lysogeny Broth (LB) agar, Miller 
plates (Sigma-Aldrich) supplemented with 20µg/ml tetracycline hydrochloride 
(Sigma-Aldrich) (LB-tet plates) and incubated overnight at 37°C. One colony 
was selected using a plastic loop and transferred to 5ml of Lysogeny Broth 
(LB) (Sigma-Aldrich) and incubated overnight at 37°C with vigorous shaking 
at 300 rpm. The ER2738 suspension culture was diluted 1:1 with sterile 
glycerol (Sigma-Aldrich) and stored at -80°C to create a new host stock. 
Colonies streaked onto LB-tet plates were stored at 4°C for up to one month.  
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2.12.3 Phage Titrations 
To titrate the Ph.D.™-7  library, one colony of ER2738 cultured on LB-tet 
plates was selected and cultured in 5ml of LB with shaking at 300rpm at 
37°C until the culture reached mid-log phase (OD600 ~ 0.5) (approximately 6 
hours). Meanwhile, LB agar plates containing 50µg/ml isopropyl-β-D-
thiogalactoside (IPTG) (Sigma-Aldrich), 40µg/ml 5-Bromo-4-chloro-3-indolyl-
β-D-galactoside (Xgal) (Invitrogen) were pre-warmed to 37°C in the 
incubator. Top agar (10g LB media (Sigma) 2.7g agarose (Invitrogen) per 
litre) was prepared by melting in the microwave and kept warm in a 45°C 
water-bath. Phage dilutions were prepared from 101 - 1012 in LB and 10µl of 
each dilution was used to infect 200µl of the mid-log ER2738 cells. The 
infected cultures were vortexed briefly and incubated at room temperature for 
5 minutes. Each dilution was added to 3ml of top agar, mixed by swirling and 
immediately poured onto one of the pre-warmed LB/IPTG/Xgal plates. The 
plates were allowed to set at room temperature for 15 minutes then inverted 
and  transferred to a 37°C incubator for 18 hours. The M13 cloning vector 
used to manufacture the Ph.D.™-7  library carries the lacZα gene which 
results in blue plaques when cultured on media containing IPTG and Xgal. 
Contamination of wild type phage that do not contain a LacZ insert produce 
white plaques which are larger and fuzzier than blue plaques.  The number of 
blue clones (Figure 11) is used to calculate the concentration of phage in the 
sample.  
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Figure 11. Titration of phage on IPTG/X-Gal LB plates.  
Phage in the Ph.D.™-7  library carry the lacZα gene which results in blue 
plaques when they infect the ER2738 strain of E.Coli.  
 
 
2.12.4 Sequencing of the Ph.D.™-7  Library 
Fifty clones from the purchased Ph.D.™-7  were isolated and sequenced to 
confirm that no repeated sequences or motifs were present.  Well-separated 
colonies were selected using a 1000µl pipette tip from titration plates 
following 18 hours of incubation. Each colony was transferred to a sterile 
12ml culture tube containing 1.5ml of overnight ER2738 suspension culture 
(1 colony in 5ml LB shaken at 300rpm at 37°C overnight) diluted 1:100 in LB 
and incubated for 5 hours at 37°C with vigorous shaking. Single-stranded 
DNA was then isolated and sequenced.  
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 Single stranded DNA extraction 2.12.4.1
The clones were transferred to 1.5ml Eppendorf tubes and centrifuged at 
12,000 rpm for 5 minutes to remove E.coli. The supernatant was removed 
and transferred to a clean tube and single-stranded DNA was extracted using 
the M13 ssDNA extraction spin kit (Qiagen, UK). To 1ml of phage 
supernatant, 10µl of precipitation buffer was added and incubated for 5 
minutes. The phage supernatant was added to the spin column and 
centrifuged in a microfuge at 8,000 rpm for 15 seconds. 700µl MLB lysis 
buffer (Qiagen kit) was added to each spin column and centrifuged tolyse 
phage and bind DNA to the column. The MLB step was repeated with a 1 
minute incubation of MLB. The supernatant was removed and the column 
was washed by the addition of 700µl of PE buffer (Qiagen kit) was added to 
each tube and centrifuged. 50µl of DNase free dH2O (Invitrogen) was added 
to the spin column and incubated at room temperature for 10 minutes to elute 
the DNA. The tubes were centrifuged again and ssDNA in solution collected 
in a fresh microfuge tube.  
To ensure enough ssDNA had been isolated for sequencing each the ssDNA 
from each clone was visualised by agarose gel electrophoresis and 
compared to 25-100ng/µl of a known M13 ssDNA standard (New England 
Biolabs). A 1.2% agarose gel was cast containing 0.5µg/ml ethidium bromide 
(Sigma-Aldrich).  DNA samples and the M13 ssDNA standard were diluted 
1:1 with dH2O and 1µl 10x Blue Juice loading dye (Sigma-Aldrich). 10µl of 
each sample was added to each well and the gel was run at 6 volts per cm 
for 45 minutes. The gel was viewed under UV and the samples compared to 
M13 ssDNA standard Figure 12.  
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Figure 12. Agarose gel electrophoresis of ssDNA from phage clones. 
An M13 ssDNA standard was diluted to 50-150ng/µl and run alongside 
ssDNA from phage clones to quantify the amount of ssDNA obtained from 
Qiagen M13 ssDNA extraction.  
 
 DNA Sequencing and Analysis 2.12.4.2
100ng of DNA from each sample was sequenced by Scientific Support 
Services at the Wolfson Institute for Biomedical Research, UCL, using ABI 
technology using the primer sequence 5´- HOCCC TCA TAG TTA GCG TAA 
CG –3 (Invitrogen). Sequences were read using CLC Sequence Viewer 6 
software and the variable region of each clone identified and translate to an 
amino acid sequence. Amino acid sequences were input into Pratt version 
2.1 pattern recognition software (http://www.ebi.ac.uk/Tools/pratt/index.html). 
When given a set of unaligned protein sequences, the Pratt tool finds 
patterns matching a minimum number of these sequences. Pratt first 
searches the space of patterns and compiles a list of the most significant 
patterns (according to a non-statistical significance measure) found to be 
matching at least 4 sequences (Jonassen et al., 1995). Patterns and motifs 
repeated within and between sequences were identified.  
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2.12.5 Preparation of Target cells 
Epithelial cells from samples of benign prostatic hyperplasia were used for 
positive selection of phage. HUVEC cells were used for the negative 
selection. Both cell types were seeded onto collagen coated 6 well plates and 
panning was performed when the cells reached 80% confluence (usually 
about 3 days).  
Prostate epithelial cells were seeded in 60mm Petri-dishes containing 
mitomycin C treated fibroblasts at a density of 100 per dish and incubated for 
12 days. Large type 1 colonies were ring cloned as previously described 
(chapter 3), pooled and seeded at a density of 5x104 cells per well into 6 well 
plates with 3 ml PrEGM. Cells were incubated until 80% confluent for phage 
panning.  
Human umbilical vein endothelial cells (HUVECs) were provided by 
Professor M O’Hare and maintained in Endothelial Growth Medium (EGM) 
supplemented with EGM Bullet Kit (Lonza, UK). The cells were passaged 
when 80% confluent and replated at a dilution of 1:6. 5x104 HUVECs were 
seeded into each well of a 6 well plate and used for negative panning 
selection when 80% confluent.  
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2.12.6 Phage Panning  
Four phage experiments were undertaken: A negative selection step was 
included after the first round using HUVEC cultures to remove phage that 
adhered to non-prostate cells and plastic or collagen binders.. The first two 
experiments used a different patient sample for each round of panning. The 
third and fourth experiments used only 1 patient sample to minimise phage 
loss due to sample variation. The post incubation washes were increased in 
stringency by raising the acidity of the wash buffer to reduce the number of 
non-specific and low affinity binders. 
 
Table 7. Overview of Phage Display Panning Conditions 
Experiment 
Number 
Number of patient samples Wash Stringency 
1 4 (1 for each round) Mild 
2 4 (1 for each round) Stringent 
3 1 (1 for all rounds) Mild 
4 1 (1 for all rounds) Stringent 
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Figure 13. Phage Display Protocol. 
Procedure used in this study to pan against prostate epithelial cells using 
HUVECs as a negative selection step. 
 
 Round 1 (Day 1) 2.12.6.1
The medium was removed from prostate epithelial cells and the cells were 
washed twice with 3ml of 50mM Tris-HCL pH 7.5, 150mM NaCl (TBS). The 
cells were blocked with 3ml of 2% Bovine serum albumin (BSA) (Sigma-
Aldrich) in DMEM for 30 minutes at room temperature to reduce non-specific 
binding of phage. Blocking solution was removed and 10µl of Ph.D-7 library 
containing 2x1011 phage in 3ml of DMEM was added and incubated at room 
temperature for 1 hour with gentle shaking. Supernatant containing non-
binding phage was removed and the cells were washed 5 times for 5 minutes 
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each with TBS-T (0.05% Tween 20 in TBS)  Two ml of 0.2M Glycine-HCL 
(pH 2.2) containing 1 mg/ml BSA was added to elute the phage from the 
target cells. The cells were rocked for 20 minutes and 300 µl 1M Tris-HCL, 
pH 9.1 added to neutralise the elution buffer and the phage suspension was 
transferred to a microtube.  A small volume of the phage was titrated (as 
section 2.12.3.) to determine the number of eluted phage. A colony of 
ER2738 was cultured in LB suspension over night at 37°C with shaking at 
300rpm.  
 Phage Amplification (Days 2 and 3) 2.12.6.2
The first round eluate was transferred to a 50ml Erlenmeyer flask containing 
20ml of overnight ER2738 culture diluted 1:100 in LB and incubated for  4 ½  
hours at 37°C with shaking at 300 rpm. The culture was transferred to a 
centrifuge tube and centrifuged at 12,000g for 10 minutes at 4°C. The 
supernant was removed and a 1/6th  volume of 20% polyethylene glycol-8000 
(Sigma-Aldrich), 2.5 M NaCl (Sigma-Aldrich) (PEG / NaCl)  was added and 
allowed to precipitate overnight at 4°C. The mixture was centrifuged for 10 
minutes at 12,000g to pellet the precipitate the phage and the supernatant 
was removed. The phage pellet was resuspended in 1ml TBS and the phage 
was reprecipitated for 1 hour on ice. The phage precipitation was microfuged 
at 14,000rpm for 10 minutes. The supernatant was removed and the phage 
particles resuspended in 200µl TBS.  Phage were titered as in step 2.12.3. 
 Round 2, 3 and 4 (Days 4 – 12) 2.12.6.3
In rounds 2-4 a negative panning step was added to subtract non-prostate 
cell binders. Medium was removed from HuVECs and washed with 5ml TBS. 
2x1011 phage from round 1 amplified eluate, diluted in 3ml DMEM, were 
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added to the HUVECS and incubated at 4 °C for 1 hour with gentle shaking 
at 60rpm. Meanwhile, the medium was removed from the prostate epithelial 
cells and the cells blocked with 3ml blocking solution for 30 minutes at room 
temperature. The blocking solution was removed and the cells. Non-binding 
phage were removed from the well containing HUVECs and transferred to 
the prostate epithelial cells. The HUVECs were washed twice with 1ml TBS-T 
and the supernatant added to the well containing prostate epithelial cells. 
Phage were incubated for 1 hour at 4°C with gentle shaking. Non-binding 
phage were removed and the cells were washed according to stringency 
(Table 8). Phage were eluted by the addition of 1ml 0.2 M Glycine-HCL (pH 
2.2), 1 mg/ml BSA and gently shaken for 20 minutes. 300 µl of 1M Tris-HCL, 
pH 9.1, was added to neutralise the elution buffer and the phage suspension 
was transferred to a microtube.  A small volume of the phage were titrated 
(as section 1.2.) to determine the number of eluted phage. After elution, 
phage were amplified, precipitated and titered as previously described. 
Following the fourth round of panning the phage eluate was not amplified and 
phage titration plates were set up to enable clone selection. 
 
Table 8. Phage Panning Wash Protocols.  
Stringency Protocol 
Mild 5 times 5 minutes with TBS-T (0.5% Tween-
20) 
Stringent 4 times for 5 minutes with 0.5% TBS-T, 
once for 1 minute with 76mM citrate buffer 
pH 3.5.  
To optimise phage binding, different wash stringencies were used to select 
for high and low affinity binders during phage display panning.  
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 Clone Selection 2.12.6.4
One hundred well separated plaques were selected and amplified in 2 ml of 
1:100 dilution of overnight ER2738 suspension culture as described in 
2.12.4. After 5 hours incubation at 37 °C with shaking, the culture was 
transferred in equal parts to two Eppendorf tubes. One of the Eppendorfs 
was diluted 1:1 with sterile glycerol and stored at -20°C and  remaining the 
phage were used for ssDNA extraction and sequencing (see section 
2.12.4.1). Clones which occurred at least twice were identified by Pratt 
analysis (2.12.4.2) and further amplified for phage binding assays. 
2.12.7 Clone Binding Assays 
Each phage clone was amplified and titered to determine adequate numbers 
of each clone for each binding assay.  Two assays were used to determine 
the strength of binding of the clones and the pooled fourth round eluate in 
comparison to insert-less M13 control phage particles: a titration assay and a 
whole cell enzyme-linked immunosorbent assay (ELISA). 10 µl of each clone 
to be amplified, fourth round eluate and PhD7 library (New England Biolabs) 
were added to 20 ml 1:100 dilution of overnight ER2738 suspension culture 
in LB media in separate sterile Erlenmeyer flasks and cultured for 6 hours at 
37 °C with vigorous shaking at 300rpm. The contents of each flask were 
decanted into sterile 50 ml tubes and centrifuged at 12,000 x g for 10 minutes 
at 4 °C. The supernatant was removed and placed in a clean tube and 
centrifuged again. The top 16ml of supernatant was placed in a clean tube 
and the phage were precipitated by adding 3.2 ml PEG/NaCl and allowing to 
precipitate at 4 °C overnight. The precipitated phage were centrifuged at 4 °C 
12,000 x g for 15 minutes and the supernatant was removed. The phage 
pellet was re-spun for 1 minute and the remaining liquid carefully removed 
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with a 1ml pipette. The phage pellet was resuspended in 1ml TBS and 
transferred to a 1.5 ml Eppendorf tube and microfuged at 13,200 rpm for 10 
minutes to remove any remaining host cells. The supernatant was transferred 
to a clean tube and the phage was re-precipitated for 60 minutes on ice by 
adding 200µl PEG/NaCl solution. The precipitate was centrifuged at 13,200 
rpm for 10 minutes at 4°C and the supernatant removed. The phage pellet 
was resuspended in 200 µl of TBS and the concentration of phage 
determined by IPTG/Xgal titration (Section 2.12.3).  
 Titration Binding Assay 2.12.7.1
1 x 105 Prostate epithelial cells were seeded into 24 well plates with 1ml 
PrEGM and incubated overnight at 37°C in 5% CO2. The medium was 
removed and the cells were washed twice with 1ml 0.05% TBS-T and the 
cells were blocked with 500µl of pre-warmed blocking buffer (2% BSA in 
DMEM) at 37°C for 30 minutes. An empty 24 well plate was also treated in 
the same way to test for background binding. Blocking buffer was removed 
and 1x1011 test phage clones, pooled round 4 clones and unselected PhD7 
library clones were incubated in duplicate in the test well and blank wells in 
150µl DMEM for 1 hour at 37°C. Then the wells were washed four times with 
1ml TBS-T at room temperature, for 5 minutes per wash. Binding phage were 
eluted by adding 0.5ml of 0.2 M Glycine-HCL for 20 minutes with gentle 
rocking at room temperature and neutralised with 75 µl of Tris-HCL and 
transferred to a clean tube. The number of phage eluted was titered following 
the procedure in section 2.12.3 at dilutions of  101 – 106. The number of 
phage binding minus background binding was calculated by subtracting the 
number of phage recovered from wells containing target cells from those 
recovered from blank wells.  
107 
 
 Whole Cell ELISA 2.12.7.2
2x104 Prostate epithelial cells were seeded into each well of a 96 well plate 
with 200µl PrEGM and incubated overnight at 37°C in 5% CO2. The medium 
was removed and the cells were washed twice with 200µl 0.05% TBS-T and 
the cells were blocked with 200µl blocking buffer (2% BSA in DMEM) at 4°C 
for 30 minutes. Blocking buffer was removed and 1x1011 test phage (clones, 
pooled round 4 clones and insert-less phage) were incubated in duplicate in 
the test wells and blank wells in 100µl DMEM for 1 hour at 4°C. The wells 
were washed four times with 200µl PBS-T at 4°C for 5 minutes each. Cells 
were fixed with 100µl 4% PFA at 4°C for minutes and washed once with 
TBS. Each well was blocked with 200µl blocking buffer for 45 minutes at 
room temperature. Blocking buffer was removed and 100µl horseradish 
peroxidise-conjugated anti-M13 antibody (GE Healthcare) diluted 1/5000 in 
blocking buffer was added to each well and incubated for 1 hour at room 
temperature. The antibody solution was removed and the wells washed five 
times with TBS-T. 200µl of 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic 
acid) (ABTS) substrate dissolved in 0.05M phosphate-citrate buffer (both 
Sigma-Aldrich) was added to each well and allowed to develop in the dark for 
60 minutes. Absorbance was measured at 405nm for 1 second per read on 
plate reader.  
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2.12.8 BLAST Search  
A BLAST search of the SWISSPROT (http://www.ncbi.nlm.nih.gov/blast/) 
database with the phage peptide sequences was carried out to identify 
homology with proteins of interest in Homo sapiens. Only proteins with a 
minimum of 5 matching residues were compared.   
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3 Results: Colony Forming Ability and Culture Conditions  
3.1 Chapter Introduction and Aims 
Culture conditions can influence colony forming efficiency, but the effects on 
the morphology of the colonies produced and the proliferative capacity of 
individual colonies have not been studied. The aim of this study was to 
identify the colonies formed by prostate cancer cell lines DU145, LNCaP and 
PC-3 and determine the effect of culture conditions (seeding density, serum 
concentration, type of medium and substrate) on the proportion of each 
colony type and the cell number of individual colonies. This study will 
investigate whether colony forming ability is property of only a proportion of 
cells within a population or whether all cells within a cell line are clonogenic 
under optimum conditions.  
3.2 Hypotheses 
The work in this chapter will answer the following hypotheses:  
1. All cells in a cell line are potentially stem cells. 
2. Ability to form a stem cell colony is dependent on culture conditions. 
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3.3 Chapter Objectives 
The following objectives were designed to test the hypotheses: 
1. Classify the morphology of colonies derived from the prostate cancer 
cell lines DU145, PC-3 and LNCaP, under standard clonogenic assay 
conditions. 
2. Characterise colonies on the basis of morphology and size. 
3. Confirm the single cell origin of colonies. 
4. Test the effects of culture conditions on the clonogenicity, morphology 
and size of the 3 prostate cancer cell line colonies, including: 
a. Cell seeding density 
b. FBS concentration 
c. Type of cell culture medium 
d. Cell substrate 
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3.4 Results 
3.4.1 Prostate Cancer Cell Line Colony Forming Ability 
200 DU145 and PC-3 and 500 LNCaP cells were seeded into 60mm petri-
dishes as single cells and incubated for 2 weeks. Colonies were fixed and 
stained for counting and measurement. Under standard conditions in RPMI-
1640 with 10 % FBS on tissue cultured treated plastic, the colony forming 
efficiency of DU145 was 27.4 ± 0.8 (mean ± standard error of the mean 
(S.E.M)), PC-3 was 22.8 ± 12.2 and LNCaP was 5.8 ± 3.5%  based on 4 
independent experiments (Figure 17 a).  
 Prostate Cancer Colony Morphology 3.4.1.1
Both DU145 (Figure 14) and LNCaP (Figure 16) cells formed three types of 
colony termed type 1, 2 and 3. Type 1 colonies were large and consisted 
mainly of small, tightly packed cells, with a generally smooth perimeter. Type 
3 colonies contained enlarged, flattened cells. Type 2 colonies were of 
intermediate size and consisted of a mixture of cell types, with small tightly 
packed cells in the middle are larger flattened cells at the edges. LNCaP 
colonies were very densely packed and stained deeply with crystal violet. 
They also tended to form colonies with more jagged edges than type 1 
colonies. PC-3 cells formed only two types of colony which were similar in 
morphology to type 2 and 3 colonies (Figure 15). Type 2 colonies were large, 
but only the cells in the middle were tightly packed, whereas type 3 colonies 
were sparse throughout the whole colony.   
The relative proportions of the 3 colony types for each cell line are shown in 
Figure 17 b-d. Type 1 colonies were the most abundant type formed by 
DU145 and LNCaP cells, whereas Type 3 colonies were the least abundant. 
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PC-3 cells formed approximately equal number of Type 2 and 3 colonies, 
although the number of Type 3 colonies was more variable.  
 
Figure 14. DU145 Colonies.  
Single DU145 cells were seeded at low density into 60 mm petri-dishes (A). 
Single cells formed 3 morphological types of colony termed Type 1(B), 2 (C) 
and 3 (D). Type 1 colonies (E) contained small, densely packed cells with 
smooth edges. Type 2 colonies (F) contained a mixture of small tightly 
packed and larger more diffuse cells at the colony edge. Type 3 colonies (G) 
consisted of only enlarge flattened cells. 
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Figure 15. PC-3 Colonies.  
Single PC-3 cells were seeded at low density into 60 mm petri-dishes (A). 
Single cells formed 2 morphological types of colony termed Type 2 (B) and 3 
(C). No type 1 colonies were observed. Type 2 colonies (D) contained a 
mixture of small tightly packed and larger more diffuse cells at the colony 
edge. Type 3 colonies (E) consisted of only enlarge flattened cells.  
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Figure 16. LNCaP Colonies.  
Single LNCaP cells were seeded at low density into 60 mm petri-dishes (A). 
Single cells formed 3 morphological types of colony termed Type 1(B), 2 (C) 
and 3 (D). Type 1 colonies (E) contained small, densely packed cells, and it 
was not possible to identify single cells. Type 2 colonies (F) contained a 
mixture of small tightly packed and larger more diffuse cells. Type 3 colonies 
(G) consisted of only enlarge flattened cells.  
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Figure 17. Colony forming efficiency of prostate cancer cells. 
Total colony forming efficiency (a) and the colony forming efficiency of each 
type of (b) DU145, (c) LNCaP and (d) PC-3 cells. Bars represent Mean ± 
S.E.M of 4 experiments. 
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 Prostate Cancer Colony Size 3.4.1.2
The properties of each colony type were determined from measurements of 
20 colonies under standard conditions. Colony area, the number of cells per 
colony and number of cells per mm2 are displayed in Table 9. LNCaP cells 
tended to form 3-dimensional colonies, which rendered estimation of the 
number of cells in LNCaP colonies impossible.   
Type 1 DU145 colonies contained the most cells, and had the highest cell 
density of per mm2 of 1470, nearly double the cell density of type 2 colonies 
of 753 cells per mm2. The difference in cell densities between the colony 
types is due both to the differences in cell size and how tightly the cells are 
packed. Both type 2 and 3 colonies contain some cells which are not in direct 
contact with other cells.  
From the number of cells per colony, the minimum number of cell divisions to 
achieve that number can be estimated (Figure 18). The largest Type 1 
DU145 colonies underwent up to 13 cell divisions and Type 2 colonies up to 
12, however type 3 colonies only divided 9 times within the 2 week incubation 
period. Type 2 PC-3 colonies underwent up to 11 cell divisions, whilst type 3 
underwent up to 10 divisions.   
 
  
117 
 
Table 9. Prostate Cancer Colony Size.  
Cell 
Line 
Colony 
Type 
Area (mm2) Total Number 
Cells 
Cell Density (per 
mm2) 
DU145 1 2.16 (0.32) 3176 (569) 1470 (400) 
2 1.24 (0.21) 932 (201) 753 (218) 
3 0.92 (0.15) 240 (51) 261 (73) 
PC-3 2 2.37 (0.38) 1420 (285) 568 (66) 
3 1.53 (0.23) 221 (62) 139 (23) 
LNCaP 1 1.34 (0.28) - - 
2 0.82 (0.09) - - 
3 0.58 (0.07) - - 
Mean colony area and number of cells per colony cultured under standard 
conditions. Estimation of the number of cells was not possible for the LNCaP 
cell line due to the structure of the colonies.  Mean and  S.E.M in 
parentheses of twenty colonies in 3 individual experiments. 
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Figure 18. Distribution of Cancer Colony Sizes. 
Comparison of the number of cells and number of cell divisions of the 
different colony types in DU145 and PC-3 cell lines. Distribution of the area 
and cell number of colonies formed by DU145 and PC-3 cells. (Mean ± SEM 
of 20 colonies in 3 individual experiments). 
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3.4.2 Seeding Density and Clonogenicity  
A clonogenic assay was used to determine the effect of cell seeding density 
on the number of DU145, PC-3 and LNCaP colonies. Between 20 and 500 
cells were seeded in a single cell suspension in triplicate and following 14 - 
21 days incubation the CFE, the types of colonies and the sizes of colonies 
were determined. Figure 19, which shows the number of colonies at each 
seeding density, shows that there was no effect of on the number of colonies 
formed by any of the three cell lines (p > 0.05). At a seeding destiny of 500 
cells per dish, which was optimum for LNCaP, both PC-3 and DU145 
colonies were too confluent to count accurately.  
 
 
Figure 19. The effect of cell seeding density on colony forming efficiency.  
The cell lines DU145, PC-3 and LNCaP. 20-500 cells were seeded in 
triplicate into 60 mm diameter petri-dishes and incubated for 14–21 days. 
Mean ± S.E.M of 3 experiments.  
  
0
10
20
30
40
50
60
0 100 200 300 400 500
 N
u
m
b
e
r 
o
f 
C
o
lo
n
ie
s
 
Number of Cells Seeded 
DU145
PC-3
LNCaP
120 
 
 Seeding Density and Colony Morphology 3.4.2.1
Colonies were scored as Type 1, 2 or 3 based on colony size and 
morphology and the CFE of each colony type was determined as a 
percentage of the number of plated cells (Figure 20). Prostate cancer colony 
morphology is unaffected by seeding density (p > 0.05). Although a higher 
seeding density tended to increase the number of type 1 LNCaP colonies, 
the high variability meant that this observation was not statistically significant 
in this experiment (p > 0.05).  
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Figure 20. The effect of Seeding Density on Colony Morphology. 
The colony forming efficiency of each of the different colony types as a 
percentage of the number of cells seeded. a)  DU145, b) PC-3 and  c)  
LNCaP. Mean ± S.E.M of 3 experiments. 
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 Seeding Density and Colony Size 3.4.2.2
Mean colony area and cell number of twenty colonies of each type are 
displayed in Table 10. As previously mentioned, estimation of the number of 
cell per LNCaP colony was not possible due to the 3-dimensional nature of 
LNCaP cell colonies. Although higher seeding density appears to result in 
larger colonies, due to the larger variation in colony size this was not 
significant. Indeed, seeding density had no effect on colony size of any of the 
three cell lines (p>0.05) and also appears to not affect the potential for some 
colonies to consist of very large numbers of cells, as a few extremely larger 
colonies were observed at each seeding density.  
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Table 10. Seeding Density and Colony Size  
Cell 
Line 
Seeding 
Density 
Type 1 Type 2 Type 3 
Colony 
Area 
(mm2) 
Cell 
Number 
Per 
Colony 
Colony 
Area 
(mm2) 
Cell 
Number 
Per 
Colony 
Colony 
Area 
(mm2) 
Cell 
Number 
Per 
Colony 
DU145 
200 
1.85 
(0.03) 
2716 
(46) 
1.77 
(0.07) 
1338 
(55) 
0.88 
(0.12) 229 (30) 
100 
1.68 
(0.32) 
2468 
(473) 
1.67 
(0.57) 
1259 
(433) 
0.88 
(0.19) 229 (49) 
50 
1.85 
(0.65) 
2713 
(957) 
1.24 
(0.12) 901(80) 
0.63 
(0.09) 164 (26) 
20 
0.94 
(0.19) 
1381 
(286) 
1.03 
(0.34) 
773 
(258) 
0.65 
(0.07) 169 (19) 
PC-3 
200 
- - 2.08 
(0.44) 
1183 
(251) 
1.05 
(0.19) 146 (27) 
100 
- - 2.05 
(0.41) 
1163 
(233) 
1.03 
(0.11) 143 (15) 
50 
- - 1.45 
(0.46) 
823 
(259) 
0.90 
(0.06) 125 (8) 
20 
- - 1.13 
(0.13) 643 (76) 
0.85 
(0.06) 118 (8) 
LNCaP 
500 
1.34 
(0.25) 
- 0.53 
(0.06) 
- 0.48 
(0.15) 
- 
200 
0.78 
(0.21) 
- 0.60 
(0.11) 
- 0.76 
(0.20) 
- 
100 
1.00 
(0.15)  
- 0.66 
(0.31) 
- 0.39 
(0.39) 
- 
50 
0.53 
(0.20) 
- 0.26 
(0.00) 
- 0.40 
(0.11) 
- 
Colony size and number of cells per colony  at each seeding density. Twenty 
colonies were measured at each seeding density. No Type 1 PC-3 colonies 
were observed. Estimation of the number of cells was not possible for the 
LNCaP cell line due to the structure of the colonies.  Mean and S.E.M of 3 
experiments in parentheses.  
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3.4.3 FBS concentration and Clonogenicity 
A clonogenic assay was used to test the effect of FBS concentration on the 
CFE, colony morphology and colony size of DU145, PC-3 and LNCaP cell 
lines. As show in Figure 21, FBS concentration had a considerable effect on 
the CFE of all three cell lines.   
The three cell lines responded differently to FBS modification. Both DU145 
and PC-3 demonstrated an increase in CFE when cultured in a concentration 
of FBS up to 20%, although this was not significantly greater than standard 
conditions of 10% (p > 0.05). LNCaP cells on the other hand, demonstrated a 
preference for lower concentrations of FBS, with a peak CFE of 22.3% ± 
6.9% when cultured at 5%, although again, this was not significantly higher 
than standard conditions (p > 0.05). Both extremely high (50%) and low (1%) 
resulted in reduced CFE in all three cell lines, with only very few colonies 
observed when culture with 1% (p < 0.05). 
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Figure 21. Colony forming efficiency of the prostate cancer cell lines. 
DU145, PC-3 and LNCaP when cultured as single cells with 1 - 50% FB S in 
RPMI-1640. Results displayed as the mean of three independent 
experiments ± S.E.M.  
 
 FBS Concentration and Colony Morphology 3.4.3.1
The types of prostate cancer colonies formed when cultured in different FBS 
concentrations is displayed in Figure 22. As with observed with total CFE, the 
proportions of colony types can be modified by FBS concentration.  
The Type 1 colonies were the most sensitive of the DU145 colonies to the 
suboptimal serum concentrations. At both 5 and 50 % serum concentrations, 
there was a marked reduction in Type 1 and 2 colonies, but no change in the 
number of Type 3 colonies, compared to the optimum concentrations of 10 
and 20 %. A similar pattern was observed in PC-3 cells, where at suboptimal 
FBS concentrations, there was a significant reduction in the number of Type 
2 colonies, but the number of Type 3 colonies remained stable, although this 
was less marked when cultured with 50 % FBS than in DU145 cells. All three 
types of LNCaP colonies were affected equally by the change in FBS 
conditions and the proportions of each type remained relatively stable.  
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Figure 22. The Effect of FBS on Colony Morphology.  
Colony forming efficiency of each colony type formed by the prostate cancer 
cell lines a) DU145, b) PC-3 and c) LNCaP when cultured as single cells with 
1 - 50% FBS in RPMI-1640. Mean ± S.E.M of 3 independent experiments.   
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 FBS Concentration and Colony Size 3.4.3.2
Serum concentration affected both colony area and the number of cells in 
each colony Table 11. The colony size of all three cell lines was reduced by 
culture in FBS concentrations sub-optimal for CFE. Type 1 colonies were 
most sensitive to sub-optimal serum concentrations. Type 1 DU145 colonies 
cultured with 5% FBS were significantly smaller than at all other 
concentrations (p < 0.05) with Type 1 colony size and cell number less than 
half those seen at higher serum concentrations. The optimum FBS 
concentration of 20 % FBS produced DU145 Type 1 and 2 colonies which 
were larger (2.61 and 2.16 mm2 respectively) than at all other concentrations 
(p < 0.05). PC-3 colonies were also sensitive to low and higher FBS 
concentrations, and Type 2 colonies culture at 5 and 50 % were smaller than 
when cultured in standard conditions (p < 0.05). No concentration of FBS 
increased PC-3 colony size compared to the standard concentration of 10% 
(p > 0.05). All three type of LNCaP colony were sensitive to FBS 
concentration. Culture of LNCaP in the optimum FBS concentration of 5% 
FBS significantly increased the size of all three colony types compared to 
standard conditions (p<0.05).  
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Table 11. Serum Concentration and Colony Size 
Cell 
Line 
FBS 
(%) 
Type 1 Type 2 Type 3 
Colony 
Area 
(mm2) 
Cell 
Number 
Per 
Colony 
Colony 
Area 
(mm2) 
Cell 
Number 
Per 
Colony 
Colony 
Area 
(mm2) 
Cell 
Number 
Per 
Colony 
DU145 
50 
2.45 
(0.43) 
3604 
(641) 
1.66 
(0.12) 
1252 
(92) 
1.26 
(0.35) 330 (91) 
20 
2.61 
(0.28) 
3838 
(414) 
2.16 
(0.33) 
1630 
(247) 
1.04 
(0.18) 272 (47) 
10 
1.56 
(0.29) 
2291 
(440) 
1.40 
(0.33) 
1052 
(247) 
0.99 
(0.18) 259 (47) 
5 
0.86 
(0.11) 
1265 
(161) 
0.97 
(0.15) 
733 
(112) 
0.51 
(0.05) 133 (13) 
PC-3 
50 
- - 1.84 
(0.15) 
1047 
(80) 
1.21 
(0.08) 168 (11) 
20 
- - 2.26 
(0.37) 
1283 
(210) 
0.88 
(0.21) 123 (29) 
10 
- - 2.58 
(0.27) 
1467 
(154) 
1.05 
(0.16) 145 (22) 
5 
- - 1.54 
(0.06) 875 (32) 
0.78 
(0.14) 108 (19) 
LNCaP 
50 
0.53 
(0.01) 
- 0.24 
(0.03) 
- 0.43 
(0.01) 
- 
20 
1.05 
(0.44) 
- 0.43 
(0.12) 
- 0.46 
(0.10) 
- 
10 
1.00 
(0.30) 
- 0.43 
(0.07) 
- 0.48 
(0.17) 
- 
5 
1.41 
(0.10) 
- 0.53 
(0.08) 
- 0.48 
(0.06) 
- 
Colony size and number of cells per colony  at each FBS concentration. 
Twenty colonies were measured at each seeding density. No type 1 PC-3 
colonies were observed.  Estimation of the number of cells was not possible 
for the LNCaP cell line due to the structure of the colonies.   Mean and S.E.M 
in parentheses of 3 individual experiments.  
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3.4.4 Substrate and Clonogenicity 
A clonogenic assay was used to test the effect of different substrates on the 
clonogenicity of the prostate cancer cell lines DU145, PC-3 and LNCaP, 
shown in Figure 23.  Substrate modification did not increase the CFE of any 
of the three cell lines. Culture on 2µg/cm2 type 1 rat tail collagen significantly 
decreased the CFE of PC-3 cells from 27.1 ± 2.4 to 7.8 ±1.9% (p<0.01). 
Although not significant, the optimum substrates for DU145 and PC-3 cells 
were 2µg/cm2 type 1 rat tail collagen and 3T3 feeder layer respectively. No 
increase in LNCaP CFE was observed compared to tissue culture plastic.  
 
 
Figure 23. The effect of growth substrate on colony forming efficiency.  
Substrates tested were: Tissue culture treated plastic (Nunc), 2µg/cm2 Type 
1 rat tail collagen, 50ng/ cm2 Fibronectin, 50ng/ cm2 Laminin, 50ng/ cm2 
Vitronectin and a feeder layer of Mitomycin C treated Swiss 3T3 cells at a 
density of 104 cells/ cm2. Mean ± S.E.M of 3 individual experiments. 
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 Substrate and Colony Morphology 3.4.4.1
The type of colonies formed when cultured on different growth substrates is 
displayed in Figure 24, as a proportion of the number of cells seeded. As 
observed with total CFE, modification of substrate had little effect on the 
morphology of DU145 or LNCaP colonies, although a moderate increase in 
the proportion of Type 2 and 3 DU145 colonies was observed when cultured 
with 2µg/cm2 type 1 rat tail collagen (p < 0.05). The opposite effect was 
observed in PC-3 type 2 colonies, in which culture on collagen reduced type 
2 CFE from 15.8 ± 1.2% to only 0.8% ± 0.3%, less than all other substrates 
(p < 0.05). The largest effect on colony morphology was observed in the PC-
3 line when supported by a 3T3 feeder layer, although this was not 
statistically significant (p<0.05).  
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Figure 24. The Effect of Growth Substrate on Colony Morphology.  
Colony forming efficiency of each colony type formed by the prostate cancer 
cell lines a) DU145, b) PC-3 and c) LNCaP when cultured with commonly 
used substrates in 10% FBS, RPMI-1640. Substrates tested were: Tissue 
culture treated plastic (Nunc), 2µg/cm2 Type 1 rat tail collagen, 50ng/ cm2 
Fibronectin, 50ng/ cm2 Laminin, 50ng/ cm2 Vitronectin and a feeder layer of 
Mitomycin C treated Swiss 3T3 cells at a density of 104 cells/ cm2. mean ± 
S.E.M of three independent experiments.  
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 Substrate and Colony Size 3.4.4.2
The effect of substrate modification on DU145 and PC-3 colony size was 
more pronounced than CFE or colony morphology (Table 12). Type 1 and 2 
colonies were more sensitive to the modification than Type 3 and some large 
increases in proliferation were observed. The size of LNCaP colonies were 
unaffected by substrates. 
Both collagen and the feeder layer significantly increased the size of DU145 
type 1 colonies to 6.56 ± 1.04mm2 and 4.16 ± 0.18mm2 respectively (p < 
0.05). These are more than twice the size of colonies grown on tissue culture 
treated plastic. Collagen also increased the size of both Type 2 and 3 
colonies (p < 0.05). Culture on collagen also increased the number of 
extremely large colonies with 88.4 % of Type 1 colonies containing 4096 
(which equates to 12 or more divisions) or more cells, compared to 30% of 
those cultured on plastic.  Collagen also increased the number of colonies 
that had undergone at least 14 cell divisions (>16,384) cells to 6.5 % of the 
Type 1 colonies. As with DU145 cells, culture on collagen increased the 
mean size of both Type 2 and 3 PC-3 colonies (p < 0.05), but not the number 
of colonies which had undergone at least 13 cell divisions.  
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Table 12. Substrate and Colony Size. 
Cell 
Line 
Substrate Type 1 Type 2 Type 3 
Colony 
Area 
(mm2) 
Cell 
Number 
Per 
Colony 
Colony 
Area 
(mm2) 
Cell 
Number 
Per 
Colony 
Colony 
Area 
(mm2) 
Cell 
Number 
Per 
Colony 
DU145 
Plastic 
2.59 
(0.77) 
3815 
(1139) 
1.58 
(0.54) 
1188 
(405) 
1.21 
(0.00) 315 (10) 
Collagen 
6.56 
(0.74) 
9641 
(1087) 
3.07 
(0.12) 
2314 
(94) 
1.72 
(0.19) 450 (50) 
Fibronectin 
2.88 
(0.28) 
4237 
(408) 
1.69 
(0.02) 
1275 
(12) 
0.89 
(0.13) 232 (35) 
Laminin 
1.76 
(0.19) 
2589 
(281) 
1.17 
(0.04) 883 (27) 
0.68 
(0.09) 177 (23) 
Vitronectin 
3.38 
(0.78) 
4973 
(1141) 
1.94 
(0.21) 
1465 
(162) 
0.86 
(0.01) 224 (10) 
3T3 
4.16 
(0.13) 
6115 
(184) 
2.51 
(0.49) 
1892 
(368) 
0.16 
(0.00) 42 (4) 
PC-3 
Plastic 
- - 2.14 
(0.14) 
1217 
(77) 
1.09 
(0.13) 152 (18) 
Collagen 
- - 2.84 
(0.53) 
1613 
(303) 
3.17 
(0.67) 441 (93) 
Fibronectin 
- - 2.32 
(0.09) 
1316 
(49) 
0.99 
(0.13) 138 (18) 
Laminin 
- - 1.81 
(0.34) 
1026 
(190) 
0.91 
(0.16) 127 (23) 
Vitronectin 
- - 2.34 
(0.28) 
1331 
(158) 
1.27 
(0.07) 177 (9) 
3T3 
- - 2.44 
(0.29) 
1388 
(167) 
0.94 
(0.11) 131 (16) 
LNCaP 
Plastic 
0.67 
(0.14) 
- 0.25 
(0.08) 
- 0.13 
(0.05) 
- 
Collagen 
0.40 
(0.08) 
- 0.19 
(0.06) 
- 0.16 
(0.03) 
- 
Fibronectin 
0.96 
(0.16) 
- 0.39 
(0.05) 
- 0.33 
(0.05) 
- 
Laminin 
0.53 
(0.01) 
- 0.29 
(0.19) 
- 0.35 
(0.07) 
- 
Vitronectin 
0.81 
(0.21) 
- 0.50 
(0.10) 
- 0.14 
(0.03) 
- 
3T3 
0.79 
(0.12) 
- 0.35 
(0.16) 
- 0.22 
(0.13) 
- 
Colony size and number of cells per colony when cultured on commercially 
available substrates. Substrates tested were: Tissue culture treated plastic 
(Nunc), 2µg/cm2 Type 1 rat tail collagen, 50ng/ cm2 Fibronectin, 50ng/ cm2 
Laminin, 50ng/ cm2 Vitronectin and a feeder layer of Mitomycin C treated 
Swiss 3T3 cells at a density of 104 cells/ cm2.  Estimation of the number of 
cells was not possible for the LNCaP cell line due to the structure of the 
colonies. Twenty colonies were measured at each seeding density. Mean 
and S.E.M of 3 independent experiments in parentheses.  
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3.4.5 Growth Medium and Clonogenicity 
A clonogenic assay was used to test the proportion of DU145, PC-3 and 
LNCaP cells that are capable of forming colonies of greater than 32 cells 
when cultured in different commercially available media. The media tested 
were RPMI-1640, DMEM low glucose, DMEM high glucose, Hams F12, 
Hams F12/ DMEM and AMEM. The cells were adapted to the various media 
before the CFE was measured, and some profound effects on CFE were 
observed. 
For all 3 cell lines, when compared to RPMI 1640, the use of Hams F12, 
Hams F12/ DMEM and AMEM resulted in small increases in the CFEs. (p < 
0.05) (Figure 25). Culture with AMEM gave the highest CFE for both DU145 
and PC-3 cells 64.2% ± 5.8% and 52.9 ± 5.7% respectively. Ham’s F12 was 
optimal for LNCaP cells, with 15.2 ± 9.3 % of cells formed colonies. 
Interestingly, DMEM reduced the CFE of all three cell lines compared to all 
other culture media (p < 0.05).  
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Figure 25. The effect of growth substrate on colony forming efficiency.  
The colony forming efficiency of prostate cancer cells.  Mean ± S.E.M of 
three independent experiments. 
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 Culture Media and Colony Morphology 3.4.5.1
The changes in total CFE observed in all three cell lines when cultured in 
different media were mainly due to changes in the proportion of Type 1 
colonies, as shown in Figure 26. In sub-optimal conditions, significantly fewer 
(p < 0.05) Type 1 colonies developed in low glucose DMEM, compared to all 
other media except high glucose DMEM. AMEM increased the number of 
both type 1 and 2 colonies formed by DU145, LNCaP and PC-3 cells (p < 
0.05).  
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Figure 26. The effect of culture media on colony morphology.  
Colony forming efficiency of each colony type formed by the prostate cancer 
cell lines a) DU145, b) PC-3 and c) LNCaP when cultured as single cells with 
commonly used substrates in 10% FBS, RPMI-1640. Mean ± S.E.M of three 
independent experiments . 
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 Media and Colony Size 3.4.5.2
In contrast to the clear effects on CFE, there was little or no influence on the 
area or cell number of the DU145 or LNCaP colonies. However, culture with 
AMEM did significantly increase the size of  PC-3 Type 2 colonies (p < 0.05), 
resulting in some very large colonies. As well as being detrimental to CFE, 
DMEM also inhibited colony proliferation resulting in significantly smaller PC-
3 and LNCaP colonies.  
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Table 13. Media and Colony Size 
Cell 
Line 
Substrate Type 1 Type 2 Type 3 
Colony 
Area 
(mm2) 
Cell 
Number 
Per 
Colony 
Colony 
Area 
(mm2) 
Cell 
Number 
Per 
Colony 
Colony 
Area 
(mm2) 
Cell 
Number 
Per 
Colony 
DU145 
RPMI -1640 
1.66 
(0.20) 
2442 
(288) 
0.67 
(0.07) 804 (50) 
0.71 
(0.18) 185 (50) 
DMEM Low 
Glucose 
1.82 
(0.15) 
2671 
(218) 
0.97 
(0.10) 729 (72) 
0.54 
(0.10) 142 (25) 
DMEM High 
Glucose 
1.64 
(0.26) 
2406 
(380) 
0.65 
(0.10) 487 (77) 
0.84 
(0.28) 221 (74) 
Ham's F12 
1.00 
(0.16) 
1465 
(242) 
0.54 
(0.09) 409 (65) 
0.33 
(0.19) 87 (50) 
Ham's F12/ 
DMEM 
1.34 
(0.22) 
1965 
(318) 
0.64 
(0.10) 480 (76) 
0.90 
(0.32) 235 (83) 
AMEM 
1.77 
(0.29) 
2600 
(421) 
0.93 
(0.15) 
699 
(111) 
0.43 
(0.16) 112 (42) 
PC-3 
RPMI -1640 
- - 2.60 
(0.35) 
1487 
(200) 
1.10 
(0.1) 153 (13) 
DMEM Low 
Glucose 
- - 1.72 
(0.10) 978 (56) 
1.00 
(0.2) 140 (27) 
DMEM High 
Glucose 
- - 1.05 
(0.16) 599 (92) 
0.70 
(0.19) 97 (26) 
Ham's F12 
- - 3.6  
(0.39) 
2071 
(255) 
1.36 
(0.30) 189 (42) 
Ham's F12/ 
DMEM 
- - 2.55 
(0.31) 
1456 
(177) 
1.27 
(0.18) 176 (24) 
AMEM 
- - 4.70 
(0.41) 
2683 
(232) 
1.35 
(0.08) 188 (10) 
LNCaP 
RPMI -1640 
1.02 
(0.14) 
- 0.41 
(0.19) 
- 0.19 
(0.01) 
- 
DMEM Low 
Glucose 
0.31 
(0.04) 
- 0.15 
(0.04) 
- 0.09 
(0.02) 
- 
DMEM High 
Glucose 
0.63 
(0.09) 
- 0.14 
(0.04) 
- 0.23 
(0.06) 
- 
Ham's F12 
0.94 
(0.46) 
- 0.46 
(0.37) 
- 0.48 
(0.34) 
- 
Ham's F12/ 
DMEM 
0.80 
(0.02) 
- 0.60 
(0.00) 
- 0.34 
(0.17) 
- 
AMEM 
1.00 
(0.03) 
- 0.46 
(0.15) 
- 0.36 
(0.06) 
- 
Colony size and number of cells per colony when cultured with different 
growth media supplemented with 10% FBS. Twenty colonies of each type 
were measured for each experimental condition. Mean and S.E.M of three 
independent experiments in parentheses.  
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 Optimised Conditions 3.4.5.3
As each cell line responded differently to the alterations in culture conditions 
a combination of optimum conditions was defined from the above results. 
The optimum conditions for each cell line are listed below in Table 14. CFE, 
number of each colony type and colony size under optimum conditions were 
compared to standard conditions of culture on tissue culture treated plastic in 
RPMI-1640 supplemented with 10 % FBS.  
 
Table 14. Optimal Conditions for Clonogenicity of Prostate Cancer Cells.  
Cell Line Seeding Density 
(cells per dish) 
FBS 
Concentration 
Medium Substrate 
DU145 200 20% AMEM Collagen 
PC-3 200 20% AMEM Feeder 
layer 
LNCaP 500 5% AMEM Plastic 
  
 
Only PC-3 cells demonstrated a moderate increase in the CFE when cultured 
under combined optimum conditions (p<0.05), mainly due to an increase in 
the number of type 2 colonies (Figure 27). DU145 and LNCaP cells showed 
no advantage of combined optimum conditions. Indeed, DU145 CFE was 
significantly reduced when cultured in AMEM, with 120% FBS on collagen 
(p<0.05) compared to standard conditions, mainly due to the significant 
decrease in type 2 colonies (p<0.01).  
141 
 
 
Figure 27. Optimised Colony Forming Efficiency. 
The colony forming efficiency and the type of colonies formed when cultured 
in optimal conditions specific for each cell line, compared to control 
conditions of 200 cells per tissue culture treated plastic dish, cultured in 
RPMI-1640 supplemented with 10% FBS. a DU45, b PC-3, c LNCaP. Mean ± 
S.E.M of 3 independent experiments. 
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 Optimised Colony Size 3.4.5.4
Culture in optimised conditions did not increase the size of either LNCaP or 
PC-3 colonies, however it did result in a significant increase in the size of 
type 1 and type 3 DU145 colonies from a mean of 2.17mm2 ± 0.15 to 4.57 ± 
0.42 mm2 (type 1) and 0.23 ± 0.01 mm2 to 0.59 ± 0.02  mm2 (type 3), which is 
over double the number of cells (p<0.01).  
 
Table 15. Size of Prostate Cancer Colonies Under Optimised Conditions.  
Cell 
Line 
Condition Type 1 Type 2 Type 3 
Colon
y 
Area 
(mm2
) 
Cell 
Numbe
r Per 
Colony 
Colon
y 
Area 
(mm2
) 
Cell 
Numbe
r Per 
Colony 
Colon
y 
Area 
(mm2
) 
Cell 
Numbe
r Per 
Colony 
DU145 Control 2.17 
(0.15) 
3187 
(226) 
1.25 
(0.18) 
942 
(139) 
0.23 
(0.01) 59 (4) 
Optimised 4.57 
(0.42) 
6721 
(616) 
1.89 
(0.22) 
1423 
(134) 
0.59 
(0.02) 154 (6) 
PC-3 Control - - 4.97 
(0.24) 
2823 
(138) 
1.12 
(0.08) 
156 
(12) 
Optimised - - 5.98 
(0.12) 
3328 
(123) 
1.19 
(0.11) 
166 
(16) 
LNCaP Control 1.01 
(0.11) 
- 0.46 
(0.04) 
- 0.19 
(0.03) 
- 
Optimised 0.85 
(0.07) 
- 0.46 
(0.02) 
- 0.22 
(0.05) 
- 
Colony size and number of cells per colony when cultured under optimal 
conditions specific for each cell line compared to control conditions of 200 
cells per tissue culture treated plastic dish, cultured in RPMI-1640 
supplemented with 10% FBS. Twenty colonies of each type were measured 
for each experimental condition. Mean and S.E.M of three independent 
experiments in parentheses.  
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3.4.6 Incucyte Analysis of Single Cell Cloning 
The quality of single cell suspensions for the purpose of cloning has not been 
checked systematically. Single DU145 cells were seeded into 6 well plates at 
clonal density and their growth tracked for 14 days by the Incucyte Live Cell 
Imaging System (Figure 28). In each of five separate experiments, the origins 
of 30-50 colonies were determined by back-tracking to monitor initial 
adhesion and subsequent growth. The number of cells at initial cell 
attachment and whether the cell merged with other colonies was determined.  
Although the majority of colonies were derived from single cells, it was 
observed that some colonies originated from more than one cell or from 
colonies which merged and by the time of fixation appeared to be one colony 
(Figure 29). Of the type 1 colonies, 72.9% ± 9.8% were derived from single 
cells, compared to 89.5 ± 5.2% and 89.2% ± 5.5% of type 2 and 3. Type 1 
colonies were more likely to be the product of more than one cell or colonies 
which had merged. Merged colonies which were indistinct from single cell 
colonies, merged within 9 days of culture. After 9 days the merged colonies 
were clearly the product of 2 or more colonies.  
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Figure 28. Clonal Tracking of DU145 Colonies.  
The origin of colonies were tracked on the Incucyte system to observe the 
origin of each colony. At day 1 single cells which have adherent to the 
surface of the plate can be clearly observed. 
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Figure 29. Origin of DU145 Colonies.  
DU145 colony growth was tracked by time lapse photography (Incucyte). The 
number of colonies originating from 1 or more cells was determined. Colonies 
which were derived from a single cell upon initial adherence, but merged with 
other colonies were also determined. Results are displayed as mean ± S.E. 
from 5 independent experiments tracking 40 cells per experiment.  
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3.5 Discussion 
The aim of this study was to identify the types of colonies formed by prostate 
cancer cell lines and to determine the extent to which the proportion of each 
colony type and number of cells in individual colonies are altered by culture 
conditions. The type 1 colonies, were most sensitive to unfavourable culture 
conditions, but increases in the proportion of type 1 colonies were modest. 
The results indicate that culture conditions can reduce the proportions of 
colonies, but can only increase the colony proportion by a small amount 
compared to our standard conditions. In some cases, cell number, but not 
CFE, was increased, suggesting that proliferation and colony forming ability 
are controlled in part by distinct factors.  
3.5.1 Clonogenicity and Colony Morphology 
The total number of colonies formed (CFE) varied depending on cell line, with 
approximately 50% of DU145 cells forming colonies compared to less than 
5% of LNCaP cells, under standard conditions. Other cell lines also have 
varying degrees of clonogenicity (Locke et al., 2005, Li et al., 2008, Yu et al., 
2008, Pfeiffer and Schalken, 2010). It is likely that the cells that fail to form 
colonies are killed during passaging or fail to attach upon plating or are 
terminally differentiated at the time of passage. This difference in colony 
forming ability clearly suggests that cell line population is highly 
heterogeneous in terms of their colony forming ability and proliferative 
capacity. The large range of colony sizes also demonstrates a high degree of 
heterogeneity within the cell line in terms of population doubling and cell 
cycle duration. Intrinsic differences in colony forming ability of cell lines 
suggests that have differing stem cell fractions driving clonogenic growth.   
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Both DU145 and LNCaP cells form three types of colony. The colonies were 
similar to the keratinocyte colonies described by Barrandon and Green.  
Colony definitions were set based on a combination of observations from 
previous studies and measurements of the colonies seen in this study. It is 
important to note that the classification of colony morphology is subjective 
which is why strict criteria were set. In previous studies, the colonies are 
referred to the Barrandon and Green description of colonies holoclone, 
meroclone and paraclone which correspond to Type 1, 2 and 3 respectively 
(Barrandon and Green, 1987b) therefore are predicted to be derived from SC 
and early and late TACs respectively. Similar colonies have been observed in 
other cancer cell lines and by Pfeiffer and Schalken (2009) who studied the 
same cell lines. 
Unlike DU145 and LNCaP cells, PC-3 cells did not form colonies with a type 
1 morphology, and only formed type 2 and 3 colonies, both of which 
contained loosely packed cells around the edges. These observations may 
be due to impaired cell–cell adhesion through E-cadherin due to a lack of 
alpha-catenin expression in PC-3 cells (Morton et al., 1993). In contrast the 
study by Li et al (Li et al., 2008) reported the existence of holoclones within 
the PC-3 cell population. These differences may arise due to the subjective 
nature of scoring colonies, and there can be overlap between colony types. It 
is also possible that these differences are due to varying culture conditions 
between laboratories.  
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3.5.2 The Effect of Culture Conditions on Clonogenicity 
Seeding density had little effect on overall colony forming efficiency or the 
colony sizes of any of the cell lines tested. Previous studies have suggested 
that seeding at lower densities may results in an increased number 
holoclones, but this was not observed in this study (Pfeiffer and Schalken, 
2010). However, FBS concentration, substrate and the type of culture 
medium all had effects on colony formation. The greatest effect was 
observed when altering FBS concentration. Type 1 and Type 2 colonies tend 
to be the most sensitive to modifications, whereas type 3 remained relatively 
stable.  
 FBS Concentration 3.5.2.1
FBS concentration influenced the CFE and colony size of all three cell lines. 
DU145 and PC-3 cells displayed maximum CFE when cultured with 20% 
FBS, whilst high serum conditions appeared to be detrimental to the growth 
of LNCaP. It is worth noting that conditions that were optimal for CFE were 
also optimal for the growth of Type 1 colonies for both DU145 and LNCaP 
cells and resulted in the largest colonies, suggesting that Type 1 colonies are 
most sensitive to changes in FBS concentration.  
Only a modest increase in the proportion of Type 1 colonies was observed.. 
LNCaP have a higher CFE at relatively low FBS concentrations and type 1 
colonies were particularly sensitive to toxic effects of high serum 
concentrations.  
FBS concentration routinely varies from 5 and 20% FBS which may account 
for some differences in observation of CFE, colony morphology and colony 
size between studies. The content of bovine serum albumin (BSA) and other 
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proteins and growth factors can vary widely between batches of serum and 
impede or support cellular growth (Talbot et al., 2004). These results suggest 
that the concentration of serum used maybe an important factor when  
designing a clonogenicity experiment as cell lines are affected in different 
ways, increasing the possibility of getting misleading results and imparing 
reproducibility. The species of origin of the serum may also significantly alter 
CFE, particularly when culturing primary cells (Baker et al., 1988). The effect 
of FBS concentration on colony size has also been studied for the capillary 
human tumour clonogenic assay (Ali-Osman and Beltz, 1988). Like this study 
it was observed that the requirements of different primary cultures and cell 
lines differ with varying culture conditions and each cell type has different 
requirements. Cells, such as LNCaP, which are androgen receptor positive 
may be particularly sensitive to hormones contained within FBS 
(Horoszewicz et al., 1983).  
 Media 3.5.2.2
Type 1 colonies were most sensitive to changes in the type of media. AMEM 
increased the CFE of all three cell lines and increased the cellular 
proliferation of Type 1 colonies and Type 2 PC-3 colonies. The effect of 
media composition on the viability and morphology of cells is well known, 
(Cox and Gesner, 1968). Despite this, as with FBS, cell lines are routinely 
cultured in different growth media in different laboratories, which can 
significantly affect the results of clonogenic assays, due to the wide range of 
commercially available media which vary in concentration and composition of 
components such as glucose, amino acids supplements and vitamins.  These 
cell lines, however, may have adapted to their differing culture conditions 
over time and only one week pre-incubation within this study may not 
150 
 
represent the results of fully conditioned cell lines. An example of this is 
DMEM which contains 44 mM bicarbonate and  is designed for culture at 
10% CO2 atmosphere, however is often incubated in 5% CO2  (as in this 
study) which raises the pH of the media and may account for the sensitivity of 
the cell lines and the lower CFEs observed in this study, as cells are known 
to be more sensitive to changes in pH at low clonal density, particularly within 
the first 24 hours of culture (Mackenzie et al., 1961). This also suggests that 
pH may be a further condition of interest.  
 Substrate 3.5.2.3
Unlike modification of FBS and media, changes in substrate had little effect 
on the CFE or the types of colony formed, but had a substantial effect on the 
size of colonies. All three DU145 and LNCaP colony types and type 3PC-3 
colony sizes were affected by the substrate used and some particularly large 
Type 1 colonies were observed when cultured on collagen. These results are 
in contrast to previous work on keratinocytes in which the type of substrate 
used had no effect on CFE or colony size (Daniels et al., 1997). Some 
substrates are known to reduce cell attachment times by interaction with cell 
surface integrins which increases the number of cell divisions (Engler et al., 
2006).  
3.5.3 Single Cell Origin 
Using the Incucyte to track cell growth it was found that the majority of 
DU145 colonies are derived from single cells. A proportion of colonies were 
derived by the fusion of two colonies or from small clumps of cells. It is well 
known that some cell lines, such as LNCaP, are more prone to clumping and 
therefore produce fewer single cell derived colonies (Horoszewicz et al., 
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1983).  Single cell suspension of primary cells can difficult to obtain and 
require rigorous mechanic and enzymatic digestions, which may damage the 
cells and result in reduced colony forming efficiency. The type of colonies 
produced will also be skewed towards larger holoclones.  
3.5.4 Chapter 3 Conclusions 
This chapter investigated the effect of culture conditions on clonogenicity and 
colony morphology of prostate cancer cell lines. The aim was test if the 
proportion of stem cells can be altered by culture conditions. The prostate 
cancer cell lines DU145 and LNCaP form three types of colony, whilst PC-3 
form two. There is some degree of plasticity that enables small modifications 
in the numbers of type 1, 2 and 3 colony forming cells within a population 
when culture conditions allow, but there also appears to be factors regulating 
the proportion of CFE and growth rate. This indicates that heterogeneity and 
the number of stem cells within prostate cancer cell lines is relatively stable 
and not a product of the cellular microenvironment, which supports the CSC 
model. CFE and the proportion of each of the colony type may be controlled 
by unknown intrinsic mechanisms which control self-renewal and 
differentiation.  Further characterisation of these colonies is required to 
confirm their identity and once characterised may be a useful model for 
biomarker discovery which target CSCs and improve understanding of their 
role in cancer.  
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4 Chapter 4: Characterisation of Prostate Cancer Colonies 
4.1 Chapter Introduction and Aims 
Barrandon and Greens work suggests that colonies with holoclone 
morphology are derived from stem cells with a high proliferative capacity 
whilst meroclones are derived from transit amplifying cells and paraclones 
from differentiated cells (Barrandon and Green, 1987b). Only holoclones are 
capable of extensive proliferation and self-renewal, whilst meroclones have a 
limited proliferative capacity and cannot self-renew and paraclones are 
incapable of further proliferation. The terms holoclone, meroclone and 
paraclone have since become synonymous with colonies derived 
respectively from stem, early and late stage transit amplifying (Barrandon 
and Green, 1987b, Pellegrini et al., 1999). 
Consequently colony morphology has been used extensively as a surrogate 
assay to identify and characterise stem cells derived from normal primary 
tissue  including skin (Tudor et al., 2004, Tudor et al., 2007), (Mavilio et al., 
2006, Murayama et al., 2007), follicular (Rochat et al., 1994) and limbal 
(Pellegrini et al., 2001, Shortt et al., 2007) tissues. Holoclones, meroclones 
and paraclones have also been observed  in cancer cell lines, including 
pancreatic (Jeter et al., 2011), head and neck (Harper et al., 2007), breast 
(Liu et al., 2012) and prostate cancer (Locke et al., 2005, Wei et al., 2007, Li 
et al., 2008, Pfeiffer and Schalken, 2010, Zhang and Waxman, 2010, Beaver, 
2012) cell lines . In these studies an increased number of holoclones is 
regarded as enrichment for cancer stem cells (CSC) and used to study CSC 
marker expression as a surrogate CSC assay. 
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In the previous chapter, it was observed that the prostate cancer cell lines 
DU145 and LNCaP form 3 different types of colonies (Beaver, 2012). These 
colonies are robust and are affected little by varying culture conditions, 
suggesting an inherent hierarchy within the cell lines in terms of short term 
proliferative potential. Because we wanted to select stem cells and their 
progeny for use as targets in phage display experiments, we checked the 
validity of colony morphology by re-cloning the different colony types. 
Surprisingly we found that both type 1 and 2 colonies are able to form 
secondary type 1 colonies (Figure 31). This observation calls into question 
the widely held and applied assumption that colonies with the three 
characteristic morphologies are derived from stem, early and late transit-
amplifying cells respectively. We therefore set out to re-investigate the 
relationship between clonogenicity and stem cell capacity by studying the 
colony forming ability, transplantation capacity and marker expression of 
each morphological type of colony derived from the prostate cancer cell line 
DU145. We tested the hypothesis that the colonies differ in the proportion, 
rather than the presence or absence, of stem cells. 
4.2 Hypothesis 
On the basis of Barrandon and Greens studies colony morphology reflects 
the nature of the founding cell. Stem cells form type 1 colonies (holoclones), 
whilst transit amplifying cells form type 2 colonies (meroclones) and late 
transit amplifying cells form type 3 colonies (paraclones). Colonies that 
contain stem cells have an infinite proliferative potential, can self-renew and 
are tumourigenic.  
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4.3 Objectives  
To test this hypothesis that the three types of colony derived from DU145 
cells were compared for their ability to self-renew, differentiate and form 
tumours in vivo.  These features were investigated using the following 
experiments: 
1. Serial cloning to test long term proliferative capacity 
2. Serial passage in bulk culture to test long term proliferative capacity of 
the entire colony. 
3. Sphere formation in non-adherent conditions to determine self-renewal 
capacity. 
4. Serial xenotransplantation in Nude mice. 
5. Immunocytochemistry to examine expression of differentiation and 
stem cell markers.  
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4.4 Material and Methods 
To characterise DU145 colonies each colony type, identified in chapter 2, 
was compared for serial clonogenicity, long term serial passage ability, 
capacity for form spheres in non-adherent conditions, tumourigenicity and 
stem cell marker expression. This experimental plan is shown in Figure 30. 
 
 
Figure 30. Characterisation of DU145 Colonies Experimental Plan.  
Single DU145 cells form colonies of three types, with distinct morphologies, 
termed type 1, 2 and 3. The stem cell traits of self-renewal, proliferative 
capacity, tumourigenicity and differentiation of each colony were compared 
by serial passage, serial cloning, sphere formation, serial xenotransplantation 
and marker expression. 
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4.5 Results 
4.5.1 Secondary Cloning 
In order to measure secondary CFE, 30 colonies of each type of colony were 
cloned and plated at 200 cells/6cm dish in triplicate and the numbers of each 
type of colony produced were measured (Figure 31). Type 1 and 2 colonies 
produced similar numbers of secondary colonies overall with CFEs of 32.8 ± 
3.2 % and 32.5 ± 3.3% respectively, whereas type 3 colonies produced few 
or no secondary colonies. The main difference between type 1 and 2 
colonies was the number of secondary type 1 colonies each produced. Type 
1 colonies produced mainly type 1 colonies (19.5 ±2.2%), whereas type 2 
colonies produced slightly more type 2 colonies (16.3 ± 1.9%) than type 1 
(p>0.05, 2-tailed independent t-test). 
  
 
Figure 31. Types of Secondary Colonies. 
DU145 colonies of each morphology were ring cloned and cultured at clonal 
density and the number and type of secondary colonies was observed. Mean 
± S.E.M. of three individual experiments.  
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The relationship between colony size and ability to form a clone was also 
analysed.  There is no clear relationship between type 1 or 2 colony size and 
colony forming efficiency, as shown in Figure 32. Small original colonies were 
just as likely to have high secondary CFEs as large ones. However colonies 
with a CFE of less than 10% were all derived from type 2 colonies containing 
fewer than 1200 cells.  
 
Figure 32. The Relationship Between Colony Size and Secondary CFE.  
DU145 colonies were measured to determine the number of cells per colony. 
Colonies were cloned and cultured at 200 cells per dish to determine 
secondary CFE.  
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4.5.2 Serial Cloning  
In order to measure the serial colony forming capacity of each colony type, 3 
type 1 and 3 type 2 colonies were picked, and re-cloned at 200 cells/6cm 
dish in triplicate. Each colony was serially cloned a further 16 times or until 
terminal. Type 1 colonies derived from type 2 colonies were also serially 
cloned. Based on the estimate of the number of cells in each colony, it was 
possible to calculate the number of cell divisions needed to produce each 
colony, although this calculation assumed no cell loss and identical 
reproductive capacity throughout the colony. 
Type 1 colonies are able to reproduce colonies of all three types over the 17 
generations of this study (Figure 33), which is equates to more than 200 
populations doublings (Table 16). Type 2 colonies were terminal after 6-8 
generations following about 66 population doublings. Type 1 colonies derived 
from an initial type 2 colony underwent at least 117 population doublings 
before termination after 9-11 generation. These colonies were smaller than 
the type 1 colonies derived from a type 1 colony (Table 16).  
CFE and colony morphology were more stable and consistently higher within 
the type 1 lineage cultures than type 2. From the second generation 
onwards, the ability of type 2 colonies to form further colonies gradually 
declines, until terminal. Type 1 colonies from an initial type 2 colony 
demonstrate an initial CFE similar to type 1, which is stable until about 4-5 
generations, but gradually declined until terminal.  
The proportion of the types of colonies was also altered over the generations 
of cloning. Initially both type 1 and 2 colonies produce all three colony types, 
but in subsequent generations the colonies formed by type 2 colonies shift 
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towards the more differentiated colony type. Although initially type 2 colonies 
can form all three colony types, second generation and onwards clones are 
mainly type 2 and 3 colonies and only very rare type 1 colonies were 
observed after 4 generations. Type 1 colonies demonstrated a stable CFE 
and proportion of each colony type throughout each generation, with type 1 
the dominant colony morphology. Type 1 colonies from an initial type 2 
colony generated all three colony types at each generation, but the 
proportion of type 2 colonies decreased along with reduced CFE, possibly 
due to their smaller size.  
  
160 
 
 
Figure 33. Serial Cloning of DU145 colonies. 
Type 1, 2 and 3 DU145 colonies were serially cloned and the number and 
type of subsequent colonies was at each generation was observed. Mean 
and S.E.M of three individual experiments. 
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Table 16. Serial Cloning Population Doublings 
Generation Type 1  Type1 from 
Type 2 
Type 2 
1 3222 (11) 1650 (10) 1650 (10) 
2 4385 (12) 2752 (11) 801 (9) 
3 11700 (13) 3728 (11) 1104 (10) 
4 3320 (11) 5344 (12) 1364 (10) 
5 7695 (12) 3029 (11) 668 (9) 
6 3521 (11) 2843 (11) 947 (9) 
7 5470 (12) 1849 (10) 636 (9) 
8 3029 (11) 1923 (10) - 
9 7847 (12) 2237 (11) - 
10 3728 (11) 665 (9) - 
11 12693 (13) 3222 (11) - 
12 9728 (13) - - 
13 8789 (13) - - 
14 9273 (13) - - 
15 7249 (12) - - 
16 5221 (12) - - 
17 7889 (12) - - 
Total Number  
of Divisions 
204 117 66 
Each colony type was serially cloned and the proliferative capacity of each 
clone determined. Colony size was used to estimate the number of cell 
divisions at each generation displayed as mean cell number and minimum 
number of cell divisions in brackets. The sum of divisions at each generation 
provides an estimate of how many total cell divisions the original cell which 
formed the original colony of each type can undergo. Results are the mean of 
three (type 1 and type 2) or two experiments (type 1 from type 2).  
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4.5.3 Serial Passage in Bulk Culture 
In order to demonstrate infinite proliferative capacity at high cell density, in 
three separate experiments 5 holoclones and 5 meroclones were ring-cloned 
and transferred to T25cm flasks for serial passaging under routine 
maintenance conditions. The number of colonies surviving to 20 passages is 
shown in Table 17. 14/15 Type 1 colonies and 10/15 Type 2 colonies 
reconstituted the DU145 monolayer and were passaged at least 20 times. 
Again no type 3 cells were observed to adhere to the tissue culture flask or 
survived to become confluent.  
Initially, cells from type 1 grew faster than those from type 2 colonies and 
reached confluence in an average of 23 ±10 days compared to 35 ± 12 days. 
However, after 4 weeks, the growth rates of cells derived from the 2 colony 
types were similar and each clone reverted to the typical morphology of 
DU145 cells grown in a monolayer. 
 
Table 17. Proliferative Capacity of Each Colony Type. 
Colony Type Survival Time to reach 20 
passages in days 
(mean ± S.E.M) 
1 14/15 (93%) 70  (14) 
2 10/15 (67%) 82  (14) 
3 0/15 (0%) - 
 
Number of DU145 colonies that could be passaged more than 20 times and 
how long it took each colony become initially confluent. Each colony type was 
serially passaged and the proliferative rate and time to reach confluence was 
monitored.  
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4.5.4 Sphere Formation 
Non-adherent culture and the formation of spheres is frequently used as an 
assay for self-renewing stem cells (Reynolds and Weiss, 1992). In three 
separate experiments, three colonies of each type were harvested and plated 
at 1000 cells/well of a 6 well plate in triplicate in Matrigel. The sphere forming 
efficiency of each colony type was determined as a percentage of the 
number of cells seeded. Spheres were identified after two weeks incubation 
under non-adherent conditions (Figure 34). Cells that had formed misshapen 
aggregates which clumped and were not of a uniform shape were not 
counted and it was deemed that these were senescent, dead cells and debris 
(Schatton and Frank, 2010). 
Type 1 colonies had a sphere forming efficiency of 15.3% ± 3.1% compared 
to 5.9% ± 2.7% for type 2 colonies (p<0.05). The spheres formed by type 1 
colonies were also larger than those of type 2 colonies: mean diameter 105 
µm ± 5.1 µm versus 63 µm  ± 6.3 µm. Type 3 colonies were unable to form 
spheres.  
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Figure 34. DU145 spheres.  
Single cells derived from type 1 and 2 colonies form spheres when cultured 
for 2 weeks in 1:1 MatrigelTM: growth medium.   
 
4.5.5 Tumourigenicity 
DU145 Colonies of each type were transplanted subcutaneously into the 
flanks of nude mice. The data for the type 1 colonies were based on 
individual colonies, whereas those for type 2 and 3 colonies were based in 
part on more than one colony being combined to produce the number of cells 
required.  
Both type 1 and 2, but not type 3 colonies, were able to initiate tumor 
development in nude mice (Table 18), as confirmed by tumour histology 
(Figure 35). There was little difference between type 1 and 2 colonies in their 
ability to develop cancers and as few as 1000 cells from either type were 
able to generate tumours, shown in situ in Figure 35. The colonies produced 
fewer tumours than a  monolayer, but latency and final tumour weights were 
comparable.  
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The main differences between tumours derived from type 1 and type 2 
colonies were latency and final tumour weights. One average, type 2 derived 
tumours were palpable 10 days later than type 1 derived tumour. Tumours 
formed by an injection of only 1000 type 2 cells took at least 61.5 ± 3.2 days 
to become palpable compared to 49.5 ± 12.6 days for 1000 type 1 cells. 
Tumours from 1000 type 2 cells did not grow as large over the 12 week 
period as the type 1 derived tumours and weighed only 32 ±12 mg following 
dissection compared to 147 ± 78 mg for the same number of type 1 derived 
cells (p<0.05) .  
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Table 18. Tumorigenicity of DU145 colonies 
Cell Type No. cells 
injected 
Tumor 
Incidence 
Latency in 
days (S.E.) 
Tumor 
Weight in mg 
(S.E.) 
DU145 
Monolayer 
10000 5/6 37.8 (11) 79 (49) 
1000 4/8 41.8 (9) 194 (163) 
Type 1 
 
10000 4/9 30.5 (8) 171 (28) 
1000 4/12 49.5 (12.6) 147 (78) 
Type 2 
 
10000 2/7 47 (4) 154 (57) 
1000 4/16 61.5 (3.2) 32 (12) 
Type 3 1000 0/4 - - 
VC 0 0/12 - - 
DU145 colonies were pooled and were injected subcutaneously into the 
flanks of nude mice in a mixture of 1:1 MatrigelTM in RPMI-1640. Vehicle 
control (VC) animals received an injection of MatrigelTM in RPMI alone. 
Tumour latency was determined on the basis of the first day tumours were 
palpable and animals sacrificed after 12 weeks and tumours weighed.  
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Figure 35. Tumours derived from DU145 colonies.  
Cells from DU145 colonies were injected subcutaneously into the flanks of 
nude mice. A. Representative tumours in situ. B. H&E stained tumour 
sections.  
 
 
Tumour volume was measured weekly and is plotted in Figure 36. Type 1 
colonies had a shorter latency and faster growth rate than type 2 colonies or 
cells grown in a monolayer, when injected at a density of 10000 cells per 
injection site. When transplanted with 1000 cells the tumours derived from a 
monolayer and type 1 colonies exhibited similar growth rates which faster 
than those derived from type 2 colonies. 
A 
B 
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Figure 36. DU145 tumour growth rates.  
10000 or 1000 DU145 cells derived from either type 1 or type 2 colonies or a 
monolayer were injected subcutaneously into the flanks of nude mice. The 
tumours were measured by digital callipers across 2 diameters at 180° 
weekly and tumour volume calculated (mean ± S.E.M) 
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Cells were isolated from the transplanted tumours and cultured in vitro in a 
clonogenic assay and recapitulated the three colony types in similar 
proportions to the original cell line (Figure 37). The overall CFE was lower 
than the original cell line due to high cell death during tissue digestion and 
obtaining a single cell suspension.   
 
 
 
Figure 37. Clonogenicity of DU145 Derived Tumours.  
Following dissection, tumours were digested in collagenase to produce a 
single cell suspension. 200 cells were seeded into petri dishes to determine 
colony forming efficiency (%) and the types of colonies formed by tumours of 
parent colonies. Bars represent the mean and SEM of 4 individual tumours.  
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 Secondary Tumourigencity 4.5.5.1
To determine if tumours could be serially transplanted, tumours derived from 
type 1 and 2 colonies were digested, expanded and injected subcutaneously 
into the flanks of secondary mice. Both type 1 and 2 derived tumours formed 
secondary tumours at the same efficiency of 2/6 injections (Table 19). The 
latency of type 2 derived tumours was longer than tumours from type 1 
colonies, but there was no difference in final tumour size.  
 
Table 19. Secondary Tumourigenicity 
Cell Type No. cells 
injected 
Tumor 
Incidence 
Latency in 
days (S.E.M) 
Tumor 
Weight in mg 
(S.E.M) 
Type 1 10000 2/6 38.5 (2.4) 165.5 (73) 
Type 2 10000 2/6 50 (9) 105 (45) 
VC 0 0/6 - - 
Cells derived from primary DU145 tumours were injected subcutaneously into 
the flanks of nude mice in a mixture of 1:1 MatrigelTM in RPMI-1640. Vehicle 
control (VC) animals received an injection of MatrigelTM in RPMI alone. 
Tumour latency was determined on the basis of the first day tumours were 
palpable and animals sacrificed after 12 weeks and tumours weighed. 
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4.5.6 Marker Expression 
DU145 colonies were cultured in 24 well plates, fixed with PFA and stained 
with antibodies against Ki67, K5, K18, α2β1 integrin, CD44, Bmi1 and Oct4. 
Cells were imaged by fluorescent confocal microscopy and the number of 
positive cells was determined, as shown in Figure 55. All results are the 
mean and SE of three experiments, in which at least 10 colonies were 
counted.  
 Ki67 – Proliferation 4.5.6.1
Ki67 expression is a marker for proliferative cells and is absent from resting 
(G0) cells.  Type 1 colonies (Figure 38) contained the most (86.6 ± 3.6%) 
proliferating cells compared to 71.7 ± 3.3% in type 2 (Figure 39) and 58.9 ± 
7.5% in type 3 (Figure 40) colonies. Ki-67 expression was spread evenly 
throughout the colonies with similar proportions of dividing cells in the middle 
and outer edges of the colony.  
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Figure 38. DU145 Type 1 Ki67 Expression 
The proliferative fraction of DU145 type 1 colonies types was determined by 
Ki67 staining. The percentage of Ki67 positive cells was determined by 
counting the number of green (FITC) cells as a proportion of blue DAPI 
positive nuclei. Representative colonies shown. Bar = 100µm.  
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Figure 39. DU145 Type 2 Ki67 Expression 
The proliferative fraction of DU145 type 2 colonies types was determined by 
Ki67 staining. The percentage of Ki67 positive cells was determined by 
counting the number of green (FITC) cells as a proportion of blue DAPI 
positive nuclei. Representative colonies shown. 
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Figure 40. DU145 Type 3 Ki67 Expression 
The proliferative fraction of DU145 type 3 colonies types was determined by 
Ki67 staining. The percentage of Ki67 positive cells was determined by 
counting the number of green (FITC) cells as a proportion of blue DAPI 
positive nuclei. Representative colonies shown. Bar = 100µm 
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 Cytokeratin Expression 4.5.6.2
Colonies were stained for K5 expression, a basal epithelial marker and K18 a 
luminal epithelial marker in prostate cells. No K5 expression was observed in 
any of the three colony types (Figure 41). In contrast, all three colony types 
were positive for K18 which was expressed evenly throughout the colony as 
(Figure 42).  
  
176 
 
 
Figure 41. DU145 Cytokeratin 5 Expression 
Lack of expression of the basal epithelial marker K5 by DU145 colonies.  
Type 1, 2 and 3 colonies were stained by immunocytochemistry with 
monoclonal antibodies against the target and detected with a FITC 
conjugated secondary antibody (green) and counter stained with DAPI (blue). 
Representative colonies shown. Bar = 100µm. 
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Figure 42. DU145 Cytokeratin 18 Expression 
Expression of the luminal epithelial marker CK18 by DU145 colonies.  Type 
1, 2 and 3 colonies were stained by immunocytochemistry with monoclonal 
antibodies against the target and detected with a FITC conjugated secondary 
antibody (green) and counter stained with DAPI (blue). Representative 
colonies shown. Bar = 100µm. 
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 Putative Stem Cell Marker Expression 4.5.6.3
DU145 colonies were stained for the putative cancer stem cell markers α2β1, 
CD44 Oct4 and Bmi1. Only type 1 and 2 colonies contained cells which 
express the cell surface integrin α2β (Figure 43 to Figure 45). Type 1 
colonies stained more brightly than type 2 colonies, especially at colony 
edges, and contained significantly more positive cells: 76.2 ± 7.0% compared 
to 13.3 ± 3.0 % (p < 0.05). All three types of DU145 colony contained cells 
which expressed CD44 (Figure 46), but type 1 and 2 colonies contained 
more positive cells than type 3 (p<0.05, One-way ANOVA). Again staining 
tended to be brighter at the colony edge, particularly in type 1 colonies.  
Oct4 and Bmi1 were expressed in the cytoplasm and nucleus of type 1 and 
2, but not type 3 colonies, as shown in Figure 49 to Figure 51 and Figure 52 
to Figure 54. Unlike CD44 and α2β integrin, cells staining intensity was 
spread evenly throughout the colony.  
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Figure 43. DU145 Type 1 α2β1 integrin Expression 
Expression of the putative prostate cancer stem cell marker α2β1 integrin by 
DU145 colonies. Type 1 colonies were stained by immunocytochemistry with 
monoclonal antibodies against the target and detected with a FITC 
conjugated secondary antibody (green) and counter stained with DAPI (blue). 
Representative colonies shown. Bar = 100µm. 
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Figure 44. DU145 Type 2 α2β1 integrin Expression 
Expression of the putative prostate cancer stem cell marker α2β1 integrin by 
DU145 colonies. Type 2 colonies were stained by immunocytochemistry with 
monoclonal antibodies against the target and detected with a FITC 
conjugated secondary antibody (green) and counter stained with DAPI (blue). 
Representative colonies shown. Bar = 100µm. 
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Figure 45. DU145 Type 3 α2β1 integrin Expression 
Expression of the putative prostate cancer stem cell marker α2β1 integrin by 
DU145 colonies. Type 3 colonies were stained by immunocytochemistry with 
monoclonal antibodies against the target and detected with a FITC 
conjugated secondary antibody (green) and counter stained with DAPI (blue). 
Representative colonies shown. Bar = 100µm. 
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Figure 46. DU145 Type 1 CD44 Expression 
Expression of the putative prostate cancer stem cell marker CD44 by DU145 
colonies.  Type 1 colonies were stained by immunocytochemistry with 
monoclonal antibodies against the target and detected with a FITC 
conjugated secondary antibody (green) and counter stained with DAPI (blue). 
Representative colonies shown. Bar = 100µm. 
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Figure 47. DU145 Type 2 CD44 Expression 
Expression of the putative prostate cancer stem cell marker CD44 by DU145 
colonies.  Type 2 colonies were stained by immunocytochemistry with 
monoclonal antibodies against the target and detected with a FITC 
conjugated secondary antibody (green) and counter stained with DAPI (blue). 
Representative colonies shown. Bar = 100µm. 
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Figure 48. DU145 Type 3 CD44 Expression 
Expression of the putative prostate cancer stem cell marker CD44 by DU145 
colonies.  Type 3 colonies were stained by immunocytochemistry with 
monoclonal antibodies against the target and detected with a FITC 
conjugated secondary antibody (green) and counter stained with DAPI (blue). 
Representative colonies shown. Bar = 100µm. 
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Figure 49. DU145 Type 1 Oct4 Expression 
Expression of the stem cell marker Oct4 by DU145 colonies.  Type 1 colonies 
were stained by immunocytochemistry with monoclonal antibodies against 
the target and detected with a FITC conjugated secondary antibody (green) 
and counter stained with DAPI (blue). Representative colonies shown. Bar = 
100µm. 
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Figure 50. DU145 Type 2 Oct4 Expression 
Expression of the stem cell marker Oct4 by DU145 colonies.  Type 2 colonies 
were stained by immunocytochemistry with monoclonal antibodies against 
the target and detected with a FITC conjugated secondary antibody (green) 
and counter stained with DAPI (blue). Representative colonies shown. Bar = 
100µm. 
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Figure 51. DU145 Type 3 Oct4 Expression 
Expression of the stem cell marker Oct4 by DU145 colonies.  Type 3 colonies 
were stained by immunocytochemistry with monoclonal antibodies against 
the target and detected with a FITC conjugated secondary antibody (green) 
and counter stained with DAPI (blue). Representative colonies shown. Bar = 
100µm. 
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Figure 52. DU145 Type 1 Bmi1 Expression 
Expression of the stem cell marker Bmi1 by DU145 colonies.  Type 1 
colonies were stained by immunocytochemistry with monoclonal antibodies 
against the target and detected with a FITC conjugated secondary antibody 
(green) and counter stained with DAPI (blue). Representative colonies 
shown. Bar = 100µm. 
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Figure 53. DU145 Type 2 Bmi1 Expression 
Expression of the stem cell marker Bmi1 by DU145 colonies.  Type 2 
colonies were stained by immunocytochemistry with monoclonal antibodies 
against the target and detected with a FITC conjugated secondary antibody 
(green) and counter stained with DAPI (blue). Representative colonies 
shown. Bar = 100µm. 
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Figure 54. DU145 Type 3 Bmi1 Expression 
Expression of the stem cell marker Bmi1 by DU145 colonies.  Type 3 
colonies were stained by immunocytochemistry with monoclonal antibodies 
against the target and detected with a FITC conjugated secondary antibody 
(green) and counter stained with DAPI (blue). Representative colonies 
shown. Bar = 100µm. 
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Figure 55. Heterogeneity of marker expression of DU145 colonies.  
Type 1, 2 and 3 DU145 colonies were stained by immunocytochemistry with 
antibodies against the target and detected with a FITC conjugated secondary 
antibody. The proportion of cells positive for each marker was determined as 
a percentage of the total number of cells counted. Type 1 and 2 colonies 
contained more CD44 positive cells than type 3. Type 1 colonies contained 
more α2β1 integrin positive cells that type 2 (p<0.05 Oneway ANOVA). 
Results are the mean of 20 individual colonies ± S.E.M.  
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4.6 Discussion 
The aim of this study initially was to validate colony forming morphology as a 
method of selecting stem cell colonies. Tumours are believed to contain a 
hierarchy of cells derived from cancer stem cells, which can self-renew and 
differentiate to produce the multiple cell types observed within the cancer. To 
be considered a CSC, a cell must be able to self-renew, differentiate and be 
serially tumourigenic. The results of this study show that both type 1 and 2 
colonies contain cells capable of self-renewal. The evidence strongly 
suggests that type 1 and 2 colonies differ only in the proportions of stem cells 
each contains and that colony morphology of human cancer cell lines cannot 
be used reliably as a surrogate marker for stem cell origin.  
4.6.1 Secondary Colonies 
In the first experiment it was noted that both type 1 and 2 colonies were able 
to form all three colony types, suggesting that they both contain stem cells. 
Type 1 colonies formed more type 1 colonies than type 2, suggesting that 
they contain a higher proportion of CSCs. CFE was unaffected by colony 
size, which suggests that colony morphology and not size determines the 
proportion of CSCs.  Type 3 colonies were terminal and could not be 
propagated by cloning. The ability of both type 1 and 2 colonies to for form 
secondary type 1 colonies was a surprising finding, and suggested that type 
2 colonies were also the progeny of CSCs, not TA cells. These results show 
that the type 2 colony contains stem cells which can self-renew, are highly 
proliferative and can form all three colony types.  
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4.6.2 Self-renewal 
The ability of both type 1 and 2 colonies to produce further type 1 and 2 
colonies suggests they both contain cells with a capacity for self-renewal. 
Self-renewal was further demonstrated in both colony types by sphere 
formation. Sphere formation has previously been shown to enrich for prostate 
stem cells expressing CSC markers CD24, CD44 and α2β1integrin 
(Garraway et al., 2010). DU145 cells can be cultured as spheres for at least 
1.5 years without loss of stemness (Rybak et al., 2011).  
4.6.3 Proliferative Capacity 
Both type 1 and 2 colonies contained highly proliferative cells which, when 
serially cloned, could be cultured for more than 100 divisions. However type 
1 colonies derived from type 2 colonies were terminal after around 110 
divisions. When cultured in bulk culture at higher cell seeding density, both 
type 1 and 2 colonies were immortal and could be cultured for at least 20 
passages, had similar growth rates and regenerated the morphology of the 
DU145 monolayer. This suggests that although type 2 colonies contain stem 
cells with self-renewal capacity, there are significantly less than within type 1 
colonies, and consequently are more likely to be lost when serially cloned 
over extended periods of time. Cells may be diluted out or lost during the ring 
cloning process and so the lower number of stem cells within the type 2 
colonies makes the chances of loss greater than type 1 colonies.  
4.6.4 Tumourigenicity 
Cancer stem cells are usually considered immortal and undergo many cell 
divisions to drive tumour growth (Keith, 2004) and in this study both type 1 
and 2 colonies were able to be serially engrafted in nude mice. Serial 
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xenotransplantation is considered the gold standard for the identification for 
CSCs (Clarke et al., 2006). Type 2 colonies had a longer latency than type 1 
colonies and formed smaller tumours, again suggesting that type 1 colonies 
contain a higher proportion of CSCs.  
4.6.5 Marker Expression 
Cytokeratin staining showed that all three colony types express the luminal 
epithelial marker CK18, but not the basal marker CK5 (Wang et al., 2001). 
Because cell division is restricted mainly to the basal layer in normal 
prostate, it has been suggested that prostate cancer stem cells might have a 
basal phenotype (Maitland et al., 2011). However, DU145 cells uniformly 
express cytokeratins characteristic of the differentiated luminal cells and yet 
have stem cell capacity. Cytokeratins may be down regulated in long term  in 
vitro culture (Waseem et al., 1999).  
CD44 and α2β1 integrin are markers that are claimed in several studies 
(Lokeshwar et al., 1995, Patrawala et al., 2006) to enrich for a prostate 
cancer stem cell population and were expressed by the majority of the cells 
in DU145 colonies. α2β1 integrin was expressed at high levels in both type 1 
and 2 colonies and at lower levels in type 3 colonies, whilst CD44 was only 
observed in type 1 and 2 colonies. CD44 has been shown to enrich for 
tumour initiating cells and is controlled by microRNAs such as miRNA-708 
(Saini et al., 2012) and microRNA miR-34a (Liu et al., 2011). A contrasting 
study has shown no difference between the growth rates of PC-3 cells in high 
cell density culture based on CD44 and α2β1 expression (Zhang and 
Waxman, 2010), so these markers alone do not confirm CSC identity.  
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Type 1 and 2 colonies were positive for BMI-1, an oncogene suggested to 
play a role in stem cell self-renewal (Jiang et al., 2009) which has been 
shown previously to be up-regulated in pancreatic holoclones (Jeter et al., 
2011). The embryonic stem cell marker Oct-4 was observed in type 1 and 2 
colonies, but not in type 3 colonies, suggesting a role in self-renewal and 
differentiation (Trosko, 2006). Previous studies have shown that stem cell 
colony formation is controlled by factors involved in self-renewal, such as 
Nanog (Jeter et al., 2009, Jeter et al., 2011) and telomerase activity (Marian 
et al., 2010). 
4.6.6 Comparison With Previous Studies 
A number of studies using prostate (Locke et al., 2005, Li et al., 2008, Pfeiffer 
and Schalken, 2010, Zhang and Waxman, 2010) pancreatic (Jeter et al., 
2011) colorectal (Ferrand et al., 2009), breast (Liu et al., 2012), head and 
neck squamous cell carcinoma (Harper et al., 2007) and uveal melanoma 
(Kalirai et al., 2011) cancer cell lines  have tried to validate the use of colony 
morphology as a surrogate for colonies derived from stem cells, transit-
amplifying cells and differentiating cells. The results are surprisingly disparate 
and are in contrast to our findings. All previous studies conclude that 
holoclones have a greater ability to be passaged in bulk culture (Li et al., 
2008, Jeter et al., 2011) or by serial cloning (Locke et al., 2005, Pfeiffer and 
Schalken, 2010, Kalirai et al., 2011, Tan et al., 2011) than paraclones, and 
that paraclones with a differentiated morphology have a very limited 
proliferative potential. In these studies, meroclones were either not studied 
(Locke et al., 2005, Pfeiffer and Schalken, 2010) or could only be propagated 
for about 3 months compared to more than 6 months for holoclones (Li et al., 
2008). The ability of cells derived from meroclones to generate secondary 
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holoclones has been observed in only one study and in that study few 
holoclones were formed from meroclones (Jeter et al., 2011).  
Previous studies have shown that only holoclones are tumorigenic in vivo (Li 
et al., 2008, Jeter et al., 2011) or that holoclones form larger, faster growing 
tumours than paraclones (Ferrand et al., 2009, Miloszewska et al., 2010, 
Zhang and Waxman, 2010). Again, the majority of these studies only 
compared holoclones and paraclones. The ability of some paraclones to form 
tumours in some of these studies is paradoxical as it indicates that some 
paraclones contain stem cells. This phenomenon may be in part due to 
improved immune-deficient murine models. This observation has been 
demonstrated in melanoma where approximately 25% of all tumour cells are 
tumourigenic in immunocompromised NOD/SCID interleukin-2 receptor 
gamma chain null (Il2rg-/-) mice (Quintana et al., 2008), a much larger 
number than previously believed.   
Holoclones formed by the prostate cancer cell line PC3 are highly 
tumorigenic, can be passaged long term and express the cancer stem cell 
markers α2β1+ CD44+ (Li et al., 2008). However, holoclones and 
meroclones are difficult to distinguish in cultures of PC3 (Pfeiffer and 
Schalken, 2010, Beaver, 2012). PC3 colonies varied in their ability to form 
holoclones and meroclones, with no relationship between primary and 
secondary colony morphology (Pfeiffer and Schalken, 2010).   and therefore 
this cell line may not be appropriate for the study of cancer stem cells.  
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4.7 Chapter Conclusions 
The results of this study show that the colony morphology of cancer cell lines 
cannot be used to distinguish an origin from stem or transit-amplifying cells. 
Colonies derived from the prostate cancer cell line DU145 with the 
morphology of holoclones and meroclones differ only in the proportion of 
stem cells each contains. In cancer, stem cell capacity may be shifted further 
down the cellular hierarchy towards differentiation, resulting in transit 
amplifying cells acquiring stem cell properties. These more mature stem cells 
are capable of self-renewal and differentiation, but require fewer cell divisions 
to become terminally differentiated.  
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5 Results: Identification and Characterisation of Prostate 
Epithelial Colonies 
5.1 Chapter Introduction and Aims 
Benign Prostatic Hyperplasia (BPH) is a frequent problem in elderly men that 
results from hyperplasia of the prostatic stromal and epithelial cells. Large 
nodules are formed in the periurethral region of the prostate which can 
compress the urethra to causing obstruction and interference with the flow of 
urine. Transurethral resection of the prostate (TURP) is a surgical procedure 
often used to alleviate symptoms of BPH, by creating a channel through the 
prostate and thus reducing constriction upon the urethra. TURP is a good 
source of primary prostate tissue and can be used to study non-malignant 
prostate cells.  
Prostate epithelial cells from TURP samples form 2 types of colony which 
exhibit significant heterogeneity in terms of proliferation and cytokeratin 
expression, which were termed type I and type II (Hudson et al., 2000). Type 
II exhibit similar morphology to Barrandon and Green’s holoclones 
(Barrandon and Green, 1987b), whereas type I colonies are similar to 
paraclones. The aim of this chapter was to further characterize the colonies 
formed by prostate epithelial cells from BPH samples, with a view to their use 
in the discovery of therapeutic targets by phage display.    
5.2 Hypothesis  
Prostate epithelial colony morphology is predictive of the type of founding 
cells. Colonies that contain stem cells have a greater proliferative potential, 
can self-renew, and can differentiate to form both colony types.  
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5.3 Objectives  
The objectives were to: 
1. Identify colonies derived from prostate epithelium. 
2. Characterise colonies based on morphology and size. 
3. Measure proliferative capacity  
4. Demonstrate self-renewal by the ability to form secondary colonies 
with the same morphology as the primary clone and capacity to form 
spheres in non-adherent conditions. 
5. Assess capacity for differentiation by expression of differentiation and 
stem cell markers.   
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5.4 Materials and Methods 
 
 
Figure 56. Characterisation of prostate epithelial colonies experimental plan.  
Single primary prostate epithelial cells form colonies of different types, with 
distinct morphologies, termed type 1, 2. The stem cell traits of self-renewal, 
proliferative capacity and marker expression of each colony were compared 
by serial passage, serial cloning, sphere formation, and 
immunocytochemistry. 
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5.5 Results 
5.5.1 Colony Forming Efficiency  
To study the heterogeneity of the cell population 1000 prostate epithelial cells 
from each of 12 patient samples were seeded as single cells into 60mm petri-
dishes on a mitomycin C treated Swiss 3T3 feeder layer. Colonies were fixed 
and stained for counting and measurement. The CFE of prostate epithelial 
cells varied between 0.03% and 8.8% CFE, with a mean and S.E. of 3.7 ± 
0.8 % (Table 20). The single cell origin of colonies could not be analysed due 
to the amount of cellular debris which affected the imaging capacity of the 
Incucyte system. 
Table 20. CFE of Prostate Epithelial Colonies. 
Patient 
Number 
Total % CFE 
of All 
Colonies ≥ 32 
cells 
% CFE 
Type 1 
Colonies 
% CFE of 
Type 2 
Colonies 
1 5.3 2.6 2.7 
2 4.7 1.8 2.9 
3 4.9 1.4 3.5 
4 8.8 2.4 6.4 
5 0.4 0.2 0.2 
6 7.9 2.7 5.2 
7 0.1 0.0 0.1 
8 4.4 1.4 3.0 
9 0.3 0.1 0.2 
10 0.7 0.2 0.5 
11 1.8 0.3 1.5 
12 5.3 2.6 2.7 
Mean 3.7 1.3 2.4 
S.E.M 0.8 0.3 0.6 
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5.5.2 Colony Morphology 
Two distinct colony types were observed termed type 1 and type 2 (Figure 
57). Type 1 colonies were very large with small, tightly packed cells. Type 2 
colonies were smaller with flattened enlarged cells with an indistinct 
perimeter. There was patient to patient variability in the types of colonies 
formed. Generally, more type 2 colonies were observed than type 1. Between 
0.1% and 2.7% of cells formed type 1 colonies and between 0.1% and 6.4% 
of cells formed type 2 colonies.   
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Figure 57. Prostate Epithelial Colony Morphology.  
Single prostate epithelial cells were seeded at low density into 60 mm petri-
dishes supported by mitomycin C treated Swiss 3t3 cells (A). Single cells 
formed 2 morphological types of colony termed Type 1(B), 2 (C). Type 1 
colonies (D) contained small, densely packed cells with smooth edges. Type 
2 colonies (E) contained a mixture of small tightly packed and larger more 
diffuse cells at the colony edge.  
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To determine the characteristics of the colony types, twenty colonies of each 
type were measured and the number of cells per colony was determined. 
Colony area, the number of cells per colony and number of cells per mm2 are 
displayed in Table 20. Both type 1 and 2 colonies varied widely in terms of 
colony size and cell density. Type 1 colonies were very large, with a mean 
area of 16.5 ± 2.6 mm2, which was much larger than type 2 colonies which 
were 4.3 ± 0.9 mm2.  Type 1 colonies were also more densely packed and 
consisted of much larger number of cells.  
 
Table 21. Prostate Epithelial Colony Characteristics 
Colony 
Type 
Area (mm2) Total Number Cells Cell Density (per mm2) 
1 16.5 (2.6) 25668 (4674) 1614 (182) 
2 4.3 (0.9) 1278 (161) 372 (79) 
Colonies derived from single epithelial cells were fixed, stained and 
measured to determine colony size and the number of cells in each colony. 
Results are the mean and S.E.M of twenty colonies from 3 patients.  
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The minimum number of cell divisions to achieve the number of cells in each 
colony (assuming no cell loss) can be estimated. The distribution is shown in 
Figure 58. Type 1 colonies underwent a minimum of 11 cell divisions, 
although most had divided at least 13 times within the 2 week incubation 
period. A small number of colonies were very fast growing and produced a 
60-80,000 cells which took at least 16 cell divisions from the single founding 
cell. Type 2 colonies were slower growing and had undergone between 7 and 
11 cell divisions in the same time period to produce a maximum of 3500 
clonal daughter cells from the parent cell.  
 
 
Figure 58. Distribution of Prostate Epithelial Colony Size.  
Colonies formed by single prostate epithelial cells were fixed and the number 
of cells per colony was determined. The minimum number of cell doublings 
(divisions) was estimated assuming no cell loss. Results are the mean and 
S.E.M of 20 colonies of each type from 3 patients.  
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5.5.3 Secondary Cloning 
In order to measure secondary CFE, 30 of each type of colony were ring 
cloned and plated at a density of 200-5000 cells per 6cm dish in triplicate. 
Neither type 1 or 2 colonies were able to form secondary colonies when 
seeded at low density, instead producing a sparse monolayer (Figure 59). 
Therefore the proliferative capacity of the colonies was measured by serial 
passage at high density, which supported further growth. 
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Figure 59. Secondary Cloning of Prostate Epithelial Cells. 
(A) Neither Type 1 and 2 colonies were able to from distinct secondary 
colonies when ring cloned and seeded into collagen coated petri dishes 
supported by feeder cells. (B) Cells formed a sparse monolayer of enlarged 
cells.  
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5.5.4 Serial Passage 
In order to demonstrate proliferative capacity in prostate epithelial colonies 
were bulk cultured at high cell density. Using colonies from 3 different 
patients, 5-6 type 1 and 2 colonies were ring-cloned and transferred to 
T25cm flasks for serial passaging under routine maintenance conditions. 
Cells were monitored daily and serially passaged until terminal.  
 
 
 
Figure 60. Primary Prostate Epithelial Cells. 
Cells derived from type 1 colonies form a monolayer when cultured at high 
cell density. Cells from type 2 colonies failed to grow further. 
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When cultured at high density, 16/18 type 1 colonies compared to only 3/16 
type 2 colonies survived to form a monolayer, which could be successfully 
passaged at least once. Type 1 colonies survived an average of 31± 2 days, 
which was longer than type 2 colonies which survived only 23 ± 8 days 
(Table 22). The majority of type 1 colonies could be passaged twice and then 
cells became enlarged and failed to proliferate further so were deemed 
senescent. The majority of type 2 cells were enlarged and senescent after 
only 1 passage and many became detached from the plate. The three type 2 
colonies which reached confluence did not adhere to the fresh tissue culture 
flask when passaged.  
 
Table 22. Proliferative Capacity of Prostate Epithelial Cells 
Colony Type Survival (%) Passages 
mean ± S.E.M 
Days Proliferative  
mean ± S.E.M 
1 16/18 (89%) 2.1  (0.2) 31  (2) 
2 3/16 (19%) 1.0 ± (0.0) 23 ± (8) 
Colonies derived from prostate epithelial cells were ring cloned and 
transferred to T25cm flasks and serially passaged. Colonies which survived 
and to be passaged at least once and how long each colony was proliferative 
were determined. 
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5.5.5 Sphere Formation 
Non-adherent culture and the formation of spheres is frequently used as an 
assay to measure self-renewing stem cells (Galli et al., 2003, Garraway et 
al., 2010). In five separate experiments, 3 each of colony type were 
harvested and plated at 1000 cells/well of a 6 well plate in triplicate. The 
sphere forming efficiency of each colony type in MatrigelTM was determined 
as a percentage of the number of cells seeded. Spheres were identified as 
large rounded balls of cells which grew in the course of the two weeks 
incubation under non-adherent conditions. Only type 1 colonies could form 
spheres in non-adherent culture, at an efficiency of 13.5 ± 8.3 % with mean 
diameter of 63 ±3 µm, pictured in Figure 61.  
 
 
Figure 61. Prostate Epithelial Spheres.  
Prostasphere formed by culture of prostate epithelial cells in Matrigel. Only 
type 1 colonies were able to from spheres when ring cloned and transferred  
to a mixture of 1:1 PrEGM: Matrigel.  
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5.5.6 Immunocytochemistry 
Prostate epithelial colonies were cultured in 60 mm Petri-dishes, fixed with 
PFA and stained with antibodies against Ki67, K5, K18, α2β1 integrin, CD44, 
Bmi1 and Oct4. Cells were imaged by fluorescence confocal microscopy and 
the number of positive cells was determined. All results are the mean and 
S.E.M of three experiments, from three patient samples, in which at least 20 
colonies were counted.  
 
 Ki67 staining 5.5.6.1
Figure 63 and Figure 62 show that Type 1 colonies contain more actively 
proliferating cells than type 2 colonies. 87.4 ± 2.1% of type 1 compared to 
38.0 ± 9.8% of type 2 cells stained positive for Ki67 (Figure 64) (p<0.01 
unpaired t-test). Positive cells were spread evenly throughout the colony, with 
similar numbers observed at the centre and periphery.  
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Figure 62. Ki67 Expression by Prostate Epithelial Colonies.  
Colonies were stained by immunocytochemistry with antibodies against the 
Ki67 and detected with a FITC conjugated secondary antibody. The 
proportion of cells positive for each marker was determined as a percentage 
of the total number of cells counted. Results are the mean 20 colonies from 
three patients ± S.E.M. 
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Figure 63. Prostate Epithelial Type 1 Colony Ki67 Expression 
The proliferative fraction of type 1 prostate epithelial colonies was determined 
by Ki67 staining. Colonies were stained by immunocytochemistry with 
monoclonal antibodies against Ki67, detected with a FITC conjugated 
secondary antibody (green) and counter stained with DAPI (blue). 
Representative colonies shown. Bar = 100µm 
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Figure 64. Prostate Epithelial Type 2 Colony Ki67 Expression 
The proliferative fraction of type 2 prostate epithelial colonies was determined 
by Ki67 staining. Colonies were stained by immunocytochemistry with 
monoclonal antibodies against Ki67, detected with a FITC conjugated 
secondary antibody (green) and counter stained with DAPI (blue). 
Representative colonies shown. Bar = 100µm 
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 Cytokeratin Expression 5.5.6.2
Co-staining with antibodies against K5 and K18 showed that both type1 and 
type 2 prostate colonies are of epithelial origin (Figure 65). Type 1 colonies 
(Figure 66) contained cells expressing mainly the basal epithelial marker K5, 
whereas type 2 colonies (Figure 67) contain a mixture of luminal and basal 
cells as shown by K5 and K18 staining. 
 
 
Figure 65. Cytokeratin expression by Prostate Epithelial Colonies.  
Colonies were stained by immunocytochemistry with antibodies against the 
K5 and K18 and detected with FITC and TRITC conjugated secondary 
antibodies. The proportion of cells positive for each marker was determined 
as a percentage of the total number of cells counted. Results are the mean 
20 colonies from three patients ± S.E.M. 
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Figure 66. Prostate Epithelial Type 1 Colony Cytokeratin Expression 
Expression of K5 and K18 by type 1 prostate epithelial colonies. 
Immunocytochemistry with monoclonal antibodies against K5, detected with 
a FITC conjugated secondary antibody (green) and against K18 detected by 
a TRICT conjugated secondary antibody (red) and counter stained with DAPI 
(blue). Representative colonies shown. Bar = 100µm 
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Figure 67. Prostate Epithelial Type 2 Colony Cytokeratin Expression 
Expression of K5 and K18 by type 2 prostate epithelial colonies. 
Immunocytochemistry with monoclonal antibodies against K5, detected with 
a FITC conjugated secondary antibody (green) and against K18 detected by 
a TRICT conjugated secondary antibody (red) and counter stained with DAPI 
(blue). Representative colonies shown. Bar = 100µm 
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 Stem Cell Markers 5.5.6.3
The number of cells expressing stem cell markers in prostate epithelial 
colonies was determined by immunocytochemistry and is shown as a 
proportion of the total number of cells in Figure 76. Type 1 prostate epithelial 
colonies stained brightly for the putative SC marker CD44 (Figure 68), 
whereas the proportion of CD44 positive cells was lower in type 2 cells 
(Figure 69) (p<0.05 unpaired t-test) and cells did not stain as brightly. In 
contrast, only a few type 1 and no type  2 colonies contained cells positive for 
the putative SC marker α2β1 integrin, which stained weakly (Figure 70 and 
Figure 71). Most cells in type 1 colonies were Bmi1 positive (Figure 74), and 
significantly more seen compared to type 2 colonies (Figure 75) (p<0.05). No 
Oct4 was observed in either colony type (Figure 72 and Figure 73).  
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Figure 68. Prostate Epithelial Type 1 Colony CD44 Expression  
Colonies were stained by immunocytochemistry with monoclonal antibodies 
against CD44, detected with a FITC conjugated secondary antibody (green) 
and counter stained with  DAPI (blue). Bar = 100µm 
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Figure 69. Prostate Epithelial Type 2 Colony CD44 Expression 
Colonies were stained by immunocytochemistry with monoclonal antibodies 
against CD44, detected with a FITC conjugated secondary antibody (green) 
and counter stained with  DAPI (blue). Bar = 100µm 
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Figure 70. Prostate Epithelial Type 1 Colony α2β1 integrin Expression. 
Colonies were stained by immunocytochemistry with monoclonal antibodies 
against α2β intergin, detected with a FITC conjugated secondary antibody 
(green) and counter stained with  DAPI (blue). Representative colonies 
shown. Bar = 100µm   
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Figure 71. Prostate Epithelial Type 2 Colony α2β1 integrin Expression.  
Colonies were stained by immunocytochemistry with monoclonal antibodies 
against α2β intergin, detected with a FITC conjugated secondary antibody 
(green) and counter stained with  DAPI (blue). Representative colonies 
shown. Bar = 100µm 
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Figure 72. Prostate Epithelial Type 1 Colony Oct4 Expression.  
Colonies were stained by immunocytochemistry with monoclonal antibodies 
against Oct4, detected with a FITC conjugated secondary antibody (green) 
and counter stained with  DAPI (blue). Bar = 100µm 
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Figure 73. Prostate Epithelial Type 2 Colony Oct4 Expression.  
Colonies were stained by immunocytochemistry with monoclonal antibodies 
against Oct4, detected with a FITC conjugated secondary antibody (green) 
and counter stained with  DAPI (blue). Bar = 100µm 
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Figure 74. Prostate Epithelial Type 1 Colony Bmi1 Expression.  
Colonies were stained by immunocytochemistry with monoclonal antibodies 
against Bmi1, detected with a FITC conjugated secondary antibody (green) 
and counter stained with  DAPI (blue). Bar = 100µm 
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Figure 75. Prostate Epithelial Type 2 Colony Bmi1 Expression.   
Colonies were stained by immunocytochemistry with monoclonal antibodies 
against Bmi1, detected with a FITC conjugated secondary antibody (green) 
and counter stained with DAPI (blue). Bar = 100µm 
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Figure 76. Prostate Epithelial Stem Cell Marker Expression. 
Type 1 and 2 colonies were stained by immunocytochemistry with antibodies 
against each marker and detected with a FITC conjugated secondary 
antibody. The proportion of cells positive for each marker was expressed as 
a percentage of the total number of cells counted. Results are the mean of 20 
colonies from each of 3 patients ± S.E.M. 
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5.6 Discussion 
The aim of this study was to identify and characterise colonies formed by 
prostate epithelial cells to test their suitability as surrogates for stem cells. 
Two colony types were observed, which differed in proliferative and self-
renewal capacity and marker expression. Type 1 colonies contained cells 
which could self-renew and were highly proliferative, whereas type 2 colonies 
contained fewer self-renewing cells and demonstrated little further 
proliferation. These results demonstrated a colony forming hierarchy within 
the prostate epithelium, of which cells with stem cell traits form large type 1 
colonies. Cytokeratin staining suggests that these cells may originate from 
the basal compartment of the epithelium.  
5.6.1 Clonogenicity and Colony Morphology 
Significant heterogeneity was observed between patient samples in terms of 
colony forming efficiency and the morphology of colonies. The majority of 
cells were unable to form colonies in this in vitro environment and either did 
not attach to the collagen coated plate or failed to grow.  
The colony morphology of prostate epithelial cells was similar to Barrandon 
and Greens holoclones and meroclones, which suggest that the larger type 1 
colonies are the highly proliferative stem cell derived colonies. (Barrandon 
and Green, 1987b). These colony morphologies have also previously been 
observed by Hudson et al., 2000 in prostate derived epithelial colonies.  
5.6.2 Proliferative Capacity 
Size and morphology of prostate epithelial colonies reflected both their short 
and longer term proliferative capacity. Cells which form type 1 colonies have 
a greater capacity for proliferation in both short and long term culture than 
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type 2 colonies.  Cells which formed type 1 colonies proliferated rapidly, 
undergoing at least 11 cell divisions in 2 weeks and contained a high 
proportion of actively cycling Ki67+ cells. Type 2 colonies were smaller, 
underwent fewer divisions and contained few actively cycling Ki67+ cells. 
However, within each colony type the size and number of cells per colony 
was highly variable, suggesting a more complex proliferative hierarchy.  
In long term culture, most type 1, but only a few type 2 prostate epithelial 
colonies proliferated extensively to become confluent and could be further 
passaged. Type 2 colonies quickly became senescent, whilst type 1 colonies 
proliferated for longer but also senesced. These results demonstrated that 
the epithelial fraction of the prostate contains cells with significant clonogenic 
and proliferative heterogeneity. As only type 1 colonies contain cells which 
are capable of extensive proliferation and self-renewal, stem cell traits, this 
observation suggests that type 1 colonies are derived from stem cells, 
whereas type 2 are derived from transit amplifying cells which have a 
variable proliferative capacity.  
Colonies became senescent too rapidly to be serially cloned. Neither type 1 
or 2 colonies could form further colonies when ring cloned and cultured at low 
density. Although a layer of feeder cells was used, regulation of 
differentiation may be more affected by low density cell culture and cells 
differentiated and lost their self-renewal capacity at a faster rate than in high 
density culture (Peehl, 2005).  
5.6.3 Self-renewal  
Only type 1 colonies contained cells which could self-renew to form spheres 
in non-adherent conditions. Again this suggests that only type 1 colonies are 
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derived from and contain self-renewing stem cells. Prostate spheres are 
enriched for cells expressing prostate basal and luminal cytokeratins 
(34βE12 and K18) which recapitulate the basic spherical structure of the 
prostatic epithelium with both basal and luminal epithelial layers identified by 
cytokeratin expression (Garraway et al., 2010). This observation again 
suggests the stem cell capacity of type 1, but not type 2 colonies. 
5.6.4 Marker Expression 
Cytokeratin staining showed that most type 1 colonies displayed a basal 
phenotype (K5), whereas type 2 colonies contained a mixture of basal and 
luminal cells (K5 and K18) or just luminal (K18) cells. This observation 
suggests that type 1 colonies are derived from basal cells, whilst type 2 are 
from intermediate or luminal cells. As prostate epithelial stem cells are 
predicted to reside in the basal compartment of the prostate (Robinson et al., 
1998), these results again suggest that type 1 colonies are derived from 
proliferative stem cells. 
Expression of both the putative stem cell markers CD44 and α2β1 integrin 
was higher in type 1 than type 2 colonies, although type 2 colonies still 
contained many CD44 positive cells. CD44 and α2β1 integrin have both been 
used as stem cell markers in normal (Collins et al., 2001) and neoplastic 
prostate (Collins et al., 2005, Patrawala et al., 2006, Patrawala et al., 2007). 
Neither marker is a reliable stem cell marker in this setting as CD44 is 
expressed in both colony types and although α2β1 integrin is expressed only 
in type 1 colonies, staining was weak. These markers may be down-
regulated when cultured in vitro and therefore this study does not exclude 
their relevance in freshly isolated tissue. Protein expression changed caused 
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by cell culture may also account for the lack of Oct4 staining in either colony 
type. However, the self-renewal marker Bmi1 was expressed strongly in type 
1 colonies, suggesting other self-renewal mechanisms, unrelated to 
transcription factor control. These may include the role of Bmi1 in p63 and β-
catenin signalling, suggesting that Bmi1 is required for activity of another self-
renewal pathway (Lukacs et al., 2010).  
5.6.5 Technical Issues 
Overall colony forming efficiency and the proportion of each colony type 
varied widely between patients. This variability in CFE can be attributed to 
individual patient variation or tissue and cellular damage caused by the laser 
during surgery. Although cell isolation methods were the same for each 
patient, removal time of the tissue and damage caused by the laser treatment 
were variable due to differences in operator, laser power and size of the 
prostate (Das et al., 2000). Tissue digestion to achieve a single cell 
suspension may cause significant cell death due to harsh the enzymatic 
digestion (Freshney, 2005) which may kill cells already damaged by surgery 
(Lupold and Rodriguez, 2004).  Removal of larger viable cell clumps by the 
cell strainer may also reduce the colony forming efficiency by reducing the 
proportion of epithelial cells compared to other cell types.   
Although the culture of primary cells in vitro is a useful technique for studying 
the properties of individual cells, the cells are not immortal and can only be 
cultured for a finite time. The prostate epithelial cells used in this study, could 
only be passaged for a limited time, becoming senescent and failed to form 
secondary colonies. The digestion and subsequent culture of primary cells 
can significantly affect their gene expression, particularly cell surface 
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antigens (Boquest et al., 2005).  The problem of senescence can be 
overcome by immortalisation, but this alters the cells so that they may not be 
representative, especially in terms of proliferative capacity (Miki et al., 2007).  
5.6.6 Comparison to Previous Work 
The two types of colony prostate epithelial colony in this study are similar in 
both morphology and proliferative capacity to holoclones and meroclones 
formed by keratinocytes (Barrandon and Green, 1987b). Both holoclones and 
type 1 prostate epithelial colonies contain a large number of cells and have 
an extensive proliferative capacity. Both meroclones and type 2 prostate 
epithelial colonies contain a smaller number of cells and a have limited 
proliferative capacity. However, no small paraclone type prostate epithelial 
colonies were observed. The morphologies of the two prostate epithelial 
colony types were also similar to those formed by mouse epidermis, but 
these colonies could be serially cloned, whereas prostate colonies could not 
(Tudor et al., 2004, Wolff and Mason, 2012). 
In a previous study by Hudson et al, 2000, two types of colonies derived from 
prostate epithelium were also observed. The morphologies, proliferative 
capacities and cytokeratin expressions are similar in both studies. Large 
colonies were able to recapitulate the basic ductal structure of the prostate 
when cultured in Matrigel, which consisted of both basal and luminal layers 
determined by the expression of cytokeratins (Hudson et al., 2000). This 
provides further evidence that large type 1 colonies are derived from and 
contain stem cells which can differentiate to regenerate the prostatic duct.  
Although in this study, prostate epithelial colonies have been characterised in 
vitro, their ability to reconstitute the prostatic gland in vivo is unclear. In vivo 
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regeneration of the prostate gland is seen as the ultimate proof of stem cell 
function. This has previously been shown in the mouse prostate in which Lin-
Sca-1+CD133+CD44+CD117+ mouse prostate stem cells can generate a 
prostate after transplantation (Leong et al., 2008). Single cell transplantation 
of single cells derived from type 1 colonies supported by rat urogenital 
mesenchyme (rUGM) would demonstrate the potency of the putative stem 
cell fraction.  
5.7 Chapter Conclusions 
Prostate epithelial cells obtained from patients with BPH form two types of 
colony which differ in proliferative and self-renewal capacity and marker 
expression. Type 1 colonies have a high proliferative and self-renewal 
capacity and express basal epithelial and putative stem cell markers. Type 2 
colonies have a limited proliferative and no self-renewal capacity, express 
luminal epithelial makers and contain few cells positive for putative stem cell 
markers. Based on these characteristics, it is likely that type 1 colonies are 
derived from stem cells and type 2 from transit amplifying cells, however in 
vivo regeneration data is required to confirm this conclusion.  
.  
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6 Results: Targeting of Prostate Stem Cells By Peptide 
Phage Display 
6.1.1 Chapter  Aims 
The aim of this part of the study was to identify peptides which target 
proliferating human primary prostate epithelial cells in vitro by using phage 
display technology. In previous chapters it was demonstrated that actively 
dividing clonogenic cells are tumourigenic and contain cells demonstrating 
CSC traits. For new therapies it is essential to target proliferative cells to cure 
prostate cancer. Previous studies have identified peptides which bind to 
prostate cancer cell lines. However, no peptides have progressed to clinical 
trials. The prostate is a non-essential organ therefore panning against 
primary human prostate epithelial cells may offer an alternative model system 
for target discovery. 
The Ph.D.™-7 library from New England Biolabs was selected which displays 
a random sequence of 7 amino acids on the pIII coat protein. This library has 
only 7 residues therefore selects for high affinity binders compared to 
libraries of 12 or more residues (Shrivastava et al., 2005)., The Ph.D.™-7 
library was panned initially against primary human prostate epithelial cells, in 
four individual experiments, which differed in  the number of patient samples 
and stringency of the wash steps.  In experiments 1 and 2 different patient 
samples were used in each of 4 rounds of panning, whilst in experiments 3 
and 4, cells from the same patient were used in each round of panning. 
Either mild (experiments 1 and 3) or stringent (experiments 2 and 4) wash 
steps to were used to select for lower of high affinity binders.  As selection of 
prostate specific markers was required, a negative selection step was 
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included to remove any phage which binds to HUVECs, collagen or tissue 
culture plastic. Following four rounds of panning the phage clones were 
sequenced and their relative binding efficiencies to prostate epithelial cells 
determined.  
 
6.2 Hypothesis 
Peptide phage display can be used to identify novel targets which bind 
specifically to proliferative prostate epithelial cells.  
 
6.3 Objectives 
1. Choose phage display library and confirm clonal diversity. 
2. Pan library against primary prostate epithelial cell following a negative 
selection step against HUVECs to deplete non-prostate binders using 
the strategy in Figure 13. 
3. Sequence phage clones and identify repetitive motifs. 
4. Identify high affinity binders using titration and ELISA binding assays.  
  
236 
 
6.4 Results 
6.4.1 Naïve Ph.D.™-7 Library Randomness 
To confirm the randomness and suitability of the naive Ph.D.™-7  library, 
forty clones form the purchased library were isolated and sequenced 
(Appendix 1). No sequence was observed more than once and analysis with 
Pratt pattern recognition software identified no repetitive motifs of three 
amino acids or greater, confirming the randomness, diversity and suitability of 
the library for this study. However the presence of one clone coding for a 
stop codon was identified: clone 30, sequence QPFY*NA where * indicates 
the stop codon.  
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6.4.2 Experiment 1 
 Phage Recovery  6.4.2.1
In panning experiment 1 the number of phage particles recovered after each 
round of panning were titrated on IPTG / Xgal plates (Table 23). Following 
the first and second rounds of panning only 0.005% of the input phage were 
recovered. The proportion recovered increased following the third round of 
panning, and 0.7% of input phage were recovered following the fourth and 
final round. An increase in phage recovery suggested that the phage pool 
was being enriched, so clones from the third and fourth rounds of experiment 
1 were selected for sequencing and further analysis. 
 
Table 23. Experiment 1 Phage Recovery.  
Round Recovery (%) 
1 0.005 
2 0.014 
3 0.400 
4 0.700 
The number of phage recovered as a percentage of input phage after each 
round of panning. 
 
 Sequences of Third Round Clones  6.4.2.2
Following three rounds of panning with the prostate epithelial cells the 40 
phage clones were isolated and sequenced. No repeat sequences were 
observed more than once in the pool (Appendix 2). Sequence pattern 
analysis showed that although there were no repeat sequences, pattern 
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motifs had started to appear. There were 5 motifs of 3 amino acids WRP, 
TPP, LSR, LSL  and  PTS  which appear at least twice, equating to 5% of the 
phage population each.  
 Fourth Round Clone Sequences 6.4.2.3
As no repeat sequences were observed after 3 rounds of panning, phage 
were panned against the target a fourth time.  One hundred phage clones 
from the fourth round eluate were sequenced and analysed (Appendix 3) and 
out of these, the 12 sequences HAIYPRH,  SILPYPY,  STASYTR,  KLPGWSG,  
LPSYHVP,  STFTHPR,  GETRAPL, WPTLQWA, SSLPLRK, SAPSSKN, ANTLRSP,  
AFPVSHN  were repeated twice or more (Table 24). HAIYPRH was the most 
abundant clone which represented 5% of the phage pool. Interestingly, the 
only smaller motifs greater than 3 amino acids which appear more times than 
the number of whole clones were S-x-L-P which appears in 7% of the phage 
population, P-R-H (6%) and R-x-P and Y-x-R which both appear in 10%. The 
clone SAPSSKN also appeared in the third round of cloning.  
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Table 24. Phage Clone Patterns.  
Pattern Hits 
HAIYPRH 5 
SILPYPY 4 
STASYTR 3 
KLPGWSG 3 
LPSYHVP 2 
STFTHPR 2 
GETRAPL 2 
WPTLQWA 2 
SSLPLRK 2 
SAPSSKN 2 
ANTLRSP 2 
AFPVSHN 2 
TFTH 3 
PVSH 3 
MPTP 2 
STFT 3 
Patterns identified following four rounds of panning against prostate epithelial 
cells. Only patterns which occur 2 more time in 100 sequenced cl9ones are 
shown.  
 
6.4.3 Comparison of Clones with BLAST 
Comparison of selected sequences to known human protein sequences by 
SWISSPROT BLAST showed that none of the 12 amino acid sequences 
selected had 100% homology to any known sequence. The maximum 
homology observed was 6/7 residues and all homologies shown are between 
5/7 and 6/7 (Table 25). No homologous protein was common to more than 
one clone and all the clones were homologous to more than one completely 
different protein.  
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Table 25. Proteins Homologous to Experiment 1Phage Clones. 
Original 
sequence 
Homologue Name 
AFPVSHN AFPVSH  Gap junction delta-3 protein 
AFPVSNN Myotubularin-related protein 2  
AFPLSHN  Collagen alpha-2(VI) chain 
AFPISH  Gap junction delta-2 protein 
ANTLRSP ANTLKSP UHRF1 binding protein 1-like 
ANTLRS Leucine-rich repeat and WD repeat-containing 
protein   
NTLRAP Homeobox protein VENTX 
NTLRTP Arylsulfatase D 
NTLRTP Neurexin-1-alpha 
NTLRNP ATP-binding cassette sub-family A member 12 
ANTARSP PHD finger protein 3 
ANTLR Zinc finger protein 524  
TLRSP Methyltransferase-like protein 9 
ANTLR  Phosphate carrier protein, mitochondrial 
GETRAPL ETRAPL OTU domain-containing protein 7A 
GETRAP Melanoma-associated antigen F1 
GETRVPL Double C2-like domain-containing protein beta 
GETRVPL Oxysterol-binding protein-related protein 3 
ETRSPL DNA excision repair protein ERCC-6-like 
GETRSP G patch domain and ankyrin repeat-containing 
protein 1 
GETRSP MutS protein homolog 4 
GDTRAP Sal-like protein 3 
ETRAP Regulating synaptic membrane exocytosis 
protein   
HAIYPRH HAIY-RH E3 ubiquitin-protein ligase Itchy homolog 
HALYPR Non-lysosomal glucosylceramidase 
AIYRRH Urokinase-type plasminogen activator 
HAIYTR Semaphorin-3E 
HAIYER Malonyl-CoA-acyl carrier protein transacylase, 
mitochondrial 
KLPGWSG LPGWSG  Multiple epidermal growth factor-like domains 
protein 
LPGWS  Integrator complex subunit 9 
LPGWTG  Delta-like protein 4 
LPGWS Kin of IRRE-like protein 2 
LPGWS Serine/threonine-protein kinase N2 
LPGWAG Platelet endothelial aggregation receptor 1 
PGWSG Transmembrane protein 88B 
PGWSG Melatonin receptor type 1B 
PGWSG ubiquitin-protein ligase NEURL1B 
PGWSG Multiple epidermal growth factor-like domains 
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protein  
LPSYHVP LPSYQVP  R3H domain-containing protein 2  
LPSYHCPGVP Egl nine homolog 2 
PSYHIP  Transmembrane 7 superfamily member 3 
LESYHVP 
 
Leucine-rich PPR motif-containing protein, 
mitochondrial 
SAPSSKN SAPSSK Neuronal acetylcholine receptor subunit beta-2 
SAPSSK Alpha-protein kinase 3 
SAPSSEN Ubiquitin-associated protein 2 
SILPYPY SILPYP MAX gene-associated protein 
SILQYPY Eukaryotic translation initiation factor 2-alpha 
kinase 3 
LPYPY Glutathione peroxidase 2 
SILPLPY Proactivator polypeptide-like 1 
SILPY GTPase RhebL1 
SILPY Acyl-coenzyme A thioesterase 12 
SSLPLRK SSLPLR Erythrocyte membrane protein band 4.2 
SSLSLRK 
 
PH domain leucine-rich repeat-containing 
protein phosphatase 2 
LPLRK Metalloproteinase inhibitor 4 
LPLRK Coiled-coil domain-containing protein 74A 
LPLRK B-cell lymphoma 3 protein 
STASYTR TASYTR Olfactory receptor 2T6 
STAQYTR Receptor-type tyrosine-protein phosphatase eta 
TATYTR zacytidine-induced protein 2 
ASYTR  Dermatan-sulfate epimerase 
TASYSR ubiquitin-protein ligase TRIM37 
ASYTR Sorbin and SH3 domain-containing protein 2 
STFTHPR TFTHP Placenta-specific protein 4  
TFTHP Taste receptor type 2 member 60 
TFTHP Sialic acid-binding Ig-like lectin 15 
TFTHP Zinc finger protein 398 
STFTH Transmembrane emp24 domain-containing 
protein 7 
STFTH  FERM and PDZ domain-containing protein 3  
TFKHPR Testis-expressed sequence 15 protein 
WPTLQWA WPTQQW Regulator of G-protein signaling 9 
PTLQW Gem-associated protein 2 
WPTLQ A/G-specific adenine DNA glycosylase 
PTLQW 
 
Protein sidekick-1 
 
242 
 
6.4.4 Binding of Individual Clones 
The 12 clone sequences identified in experiment 1 following four rounds of 
panning that occur 2 or more time within the 100 clones sequenced were 
investigated further for their binding efficiency. Individual clones were 
incubated with prostate epithelial cells or blank wells and the binding 
efficiency assessed using both a titration and whole cell ELISA assays. 
Results were compared to wild type phage from the unselected Ph.D.™-7 
and the entire experiment 1 fourth round eluate.  
As shown by the titration binding assay, (Figure 77) none of the 12 isolated 
phage clones or the round 4 eluate pool demonstrated increased binding 
efficiency to prostate epithelial cells compared to blank wells or wild type 
phage by binding titration assay. A large number of GETRAPL and 
STAYSTR phage clones were bound to patient 1 cells, but this was not 
observed in samples from the other 3 patients. The clones HAIYPRH, 
SILPYPY, KLPGWSG, ANTLRSP and SAPSSKN appear to bind specifically 
to the tissue culture plastic as many at least 100 - 1000 times more phage 
were recovered than when cultured with target cells. The low binding 
efficiency of pooled round 4 clones is no higher than the naive unselected 
library, so no increased binding efficiency is observed after 4 rounds of 
panning.  
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Figure 77. Titration Binding Assay.  
Comparing the phage clones selected from the fourth round of panning, the 
whole 4th round eluate and wild type phage control number. The number of 
phage particles recovered after binding to the prostate epithelial cells (PrEC) 
and titered on IPTG / Xgal plates was compared to blank wells. Results are 
the mean 4 patient samples ± SEM.  
 
 
Titration results were confirmed by whole cell ELISA (Figure 78). Clones 
were incubated with the target cells and detected using an anti-M13 antibody. 
The clones failed to demonstrate increased binding to the target cells 
compared to blank wells or wild type phage. A higher signal was observed in 
some of the blank wells, which was higher than in wells containing cells. 
Round 4 phage also did not bind more strongly than the naive library for 
either patient sample. The clones WPTLQWA and LSPYHVP exhibited 
particularly high background binding to blank wells.  
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Figure 78. Whole cell ELISA. 
Comparing the binding of phage clones selected from the fourth round of 
panning, the whole 4th round eluate and wild type control. The binding as 
determined by optical density at 405nm was compared to blank wells. 
Results are the mean 4 patient samples ± S.E.M.   
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6.4.5 Experiment 2, 3 and 4 
As no prospective clones were identified in experiment 1, the phage panning 
procedure was repeated and the stringency of the wash steps increased to 
selecte for higher affinity binders and reduce non-specific binding 
(experiment 2). Increased stringency of the washing step did not reduce the 
number of phage recovered after the first two steps, as would be expected. 
There was also no increase in the number of phage recovered following 
panning rounds 3 and 4 (Table 26).  
The panning procedure was repeated again using only 1 patient sample for 
all four rounds of panning to reduce the inter-patient variability and using both 
mild stringent washes in tandem experiments (experiment 3 and 4). 
Experiments 3 and 4 also failed to demonstrate an increase in phage 
recovery following several rounds of panning (Table 26).  However, to 
confirm this finding, binding assays were done on the whole fourth round 
phage pool.  
 
Table 26. Experiment 2, 3 and 4 Phage Recovery.  
Round 4 Patient Samples 1 Patient Sample 
Stringent 
(Experiment 2) 
Mild  
(Experiment 3) 
Stringent 
(Experiment 4) 
1 0.003 0.006 0.002 
2 0.001 0.001 0.012 
3 0.028 0.001 0.011 
4 0.003 0.001 0.013 
The number of phage recovered as a percentage of input phage after each 
round of panning. 
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6.4.6 Panning Experiments 2, 3 and 4 Binding Assays 
The ability of the amplified fourth round phage from experiments 2, 3 and 4  
to bind to the target cells compared to tissue culture plastic and wild type 
phage was analysed by titration (Figure 79) and whole cell ELISA (Figure 80) 
assays. Again, no significant increase in binding was observed compared to 
wild type or phage or when cultured on tissue culture plastic. These results 
suggest that there no enrichment of prostate epithelial cells specific clones 
under these conditions therefore clones from these experiments were nor 
sequenced.  
 
Figure 79. Phage Display Experiment 2, 3 and 4 Titration Binding Assay. 
Titration binding assay comparing whole 4th round eluate and wild type phage 
controls. The number of phage particles recovered after binding to the 
prostate epithelial cells (PrEC) and titered on IPTG / Xgal plates was 
compared to blank wells. There was no increased binding of the panned 
phage clones was observed. Results are the mean 4 patient samples ± 
S.E.M. 
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Figure 80. Phage display experiment 2, 3 and 4 whole cell ELISA.  
Binding assay to compare the binding of phage panned against prostate 
epithelial cells against background binding to a blank well and wild type 
phage control. The binding as determined by optical density at 405nm was 
compared to blank wells. There was no increased binding of the panned 
phage clones. Results are the mean 4 patient samples ± SEM. 
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6.5 Discussion 
The aim of this experiment was to identify peptides that target proliferative 
prostate epithelial cells. However, although initial results were promising, no 
potential peptides were identified. Panning of the Ph.D.™-7  peptide phage 
display library against adherent epithelial cells resulted in only 1 of 4 
experiments demonstrating phage enrichment. Phage were sequenced and 
the enriched sequences were identified. However, these sequences did not 
show any increased binding to prostate epithelial cells.  
6.5.1 Experiment 1 Clones 
The 12 phage clones selected in experiment 1 showed no increased binding 
when analysed by either a titration assay or whole cell ELISA. The whole 
pool of round 4 clones also failed to demonstrate any increased affinity for 
prostate epithelial cells, although the increase in phage recovery during 
panning suggested that enrichment was taking place. It is likely that following 
four rounds of panning, plastic binders, phage clones with a selective 
advantage and clones with a low affinity for the target were enriched (Vodnik 
et al., 2011).  
Eight of the 12 isolated clones have been previously identified, all using the 
Ph.D.™-7  library against a wide variety of targets (Table 27). Interestingly 
HAIYPRH has been identified by several previous studies (Vodnik et al., 
2011), but has also been observed in amplified phage pools when not 
panned against a target (Brammer et al., 2008). The amplification of 
HAIYPRH was faster than all other clones in the Ph.D.™-7  library 
suggesting that it has a proliferative advantage.  The ability of HAIYPRH 
displaying clones to out-compete other phage was traced to a mutation in G 
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to A the Shine–Dalgarno (SD) sequence. This sequences codes for gIIp, 
which is a protein involved in phage replication, imparting to the SD 
sequence better complementarity to the 16S ribosomal RNA (rRNA) 
(Brammer et al., 2008). HAIYPRH with a wild-type SD sequence was found 
to amplify normally. Despite this, HAIYPRH has also been shown to bind to 
human transferrin receptor and is a promising candidate carrier for the 
intracellular delivery of therapeutics (Lee et al., 2001).  
The sequences STFTHPR and SSLPLRK were both shown in the same study 
to bind to human immunodeficiency virus type 1 integrase (Desjobert et al., 
2004). However, their target affinity was significantly lower than other clones 
selected, suggesting a proliferative advantage or binding to plastic or BSA. 
The sequence SILPYPY appears in two studies panning the phd7 library 
against ribosomal idiosyncratic pseudoknot structure (h18) (Llano-Sotelo et 
al., 2009) and 8C11 and 8H3 mAbs, which bind to neutralizing epitopes of 
hepatitis E virus (Gu et al., 2004), although the study lacks binding assays so 
a full comparison is not possible.  
Other sequences that have been previously identified all have low affinity to 
the target in competition and gene delivery assays (Work et al., 2004, 
Matsuno et al., 2008, Sawada and Mihara, 2012),  With the exception of 
SAPSSKN which showed great affinity for the anti-hepatitis C virus mAb 
target (Barban et al., 2000). The sequences KLPGWSG, LPSYHVP, 
AFPVSHN and WPTLQWA have not been previously identified.  
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Table 27. Previously Identified Phage Clones.  
Sequence Target 
ANTLRSP poly(l-lactide) (PLLA) crystalline films (Matsuno et al., 
2008) 
GETRAPL Vascular smooth muscle cell (Work et al., 2004) 
HAIYPRH No target (Brammer et al., 2008) 
Human transferrin receptor (Lee et al., 2001) 
SAPSSKN Antibody against Hepatitis C Virus (Barban et al., 2000) 
SILPYPY 
 
Ribosomal idiosyncratic pseudoknot structure (h18) 
(Llano-Sotelo et al., 2009) 
8C11 and 8H3 mAbs, which could conformationally bind 
to neutralizing epitopes of HEV. (Gu et al., 2004) 
SSLPLRK 
STFTHPR  
Human immunodeficiency virus type 1 integrase 
(Desjobert et al., 2004) 
STASYTR Nanofibers constructed of β-sheet peptides (Sawada and 
Mihara, 2012) 
AFPVSHN 
KLPGWSG, 
LPSYHVP 
WPTLQWA 
Not previously identified 
Clones isolated in this study which have been identified previously by the 
Ph.D.™-7 library against a range of targets . 
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6.5.2 Target unrelated phage  
Panned phage pools are thought to consist of 3 possible types: high affinity 
target specific binders, lower affinity target specific binders and a population 
of ‘‘target-unrelated phage’’ displaying ‘‘target-unrelated peptides’’ (TUP). 
The latter may react with components of the screening system, such as the 
solid phase BSA or tissue culture vessels (Menendez and Scott, 2005).  
Several sequences are known to bind to plastic, including FHWTWYW  and 
WHWRLPS and binders to BSA including FHEFWPT and FHENWPS 
(Menendez and Scott, 2005, Brammer et al., 2008). Known plastic and BSA 
binders were not identified in this study. Binders to plastic tend to have an 
abundance of aromatic amino acid residues (usually W) which are crucial to 
hydrophobic interactions. Two W residues separated by one, two or three 
random amino acids frequently bind to plastic (Adey et al., 1995). The 
peptides selected in this study are unlikely to be selected by binding to plastic 
or BSA as the blank wells in the binding assays show no higher binding than 
the insert-less phage. The subtractive panning step should have removed the 
majority of plastic binders along with those that bound to HUVECs.  
Other clones that were recovered independently of their affinity could be 
selected by an advantage in replication enabling them to remain in the phage 
pool. Faster propagation of certain phage clones may be an intrinsic property 
of the displayed peptide itself, without any causative mutation, which 
increases infectivity. Alternatively the phenomenon may be the result of a 
mutation in the phage genome, as seen in HAIYPRH, which influences the 
ability of the virus to infect host bacteria or accelerates the process of phage 
particle assembly (Vodnik et al., 2011). It is suggested that selection of 
rapidly propagating target-unrelated peptides is favoured when only low 
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affinity ligands for a specific target are present in a phage display library 
(Vodnik et al., 2011). 
6.5.3 Patient Samples 
The failure of this experiment to find any potential targets to prostate 
epithelial cells may be due to the patient samples which the library was 
panned against. Two selection strategies were attempted: panning against a 
different patient sample at every round and panning against only one patient 
sample for four rounds. Both methods have issues which may be detrimental 
to selection efficacy.   
In the first and second experiments 4 patient samples were used. Patient to 
patient variability may result in a range of ways in which clones were lost 
including the proteins expressed, level of expression, cell viability, cellular 
damage and differentiation state. Gene and protein expression in BPH tissue 
can vary between patients (Luo et al., 2001) and the histopathology of BPH 
can vary widely (Di Silverio et al., 2003).  Cellular damage during tissue 
processing may also results in sample variability. Cell damage may cause up 
or down-regulation of potential targets, a phenomenon known in vivo for heat 
shock protein (Rylander et al., 2006). Target expression in only 3 out of 4 
samples would significantly affect subsequent rounds of panning as many of 
the target binders would be lost. One way to counteract this anomaly would 
be to pan against several mixed patient samples within the same well, 
although this is approach made difficult by the limited availability of fresh 
tissue.  
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Long term cell culture of primary cells results in their differentiation and 
eventual senescence. Additionally, although there are likely to be differences 
between in situ and cultured cells, isolation and culture of cells in vitro may 
also down-regulate possible targets (Peehl, 2005). The stage of cell 
differentiation would be an increased problem for the 3rd and 4th experiments 
which involved panning against 1 patient sample only. Although patient to 
patient variation was eliminated by this design, the longer the cells were 
cultured for is a limitation of this method. Time from initial cell digestion and 
seeding to the fourth round of panning was nearly four weeks, although in 
this time cell morphology was unchanged. Prostate epithelial cells have a 
limited proliferative lifespan of approximately 30 cell divisions over 6 weeks in 
vitro (Peehl, 2005) (see chapter 3) before becoming terminally differentiated 
and senescent.  In this time cells may undergo many phenotypic changes 
influenced by genetic instability and selective culture conditions (Rhee et al., 
2001). Any useful targets that were present in the first rounds of panning may 
have been down-regulated by the fourth round and the binding clones lost. 
Although cryopreservation of primary cell samples at an early stage may, to 
some extent, counteract this problem, cryopreservation itself can change cell 
characteristics, and cause cell damage and loss (Karlsson and Toner, 1996).  
6.5.4 Assay Improvement 
Several methods could be used to improve this assay, including modification 
of panning conditions, immobilisation of target at higher density (increased 
seeding density) and use of different  peptide libraries such as T7 lytic 
phage-displayed peptide libraries, which exhibit less sequence bias in 
comparison to M13 phage-displayed peptide libraries (Krumpe et al., 2006).  
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Panning conditions in previously published work vary widely. The conditions 
in this study closely follow the New England Bioscience protocol specific for 
the Ph.D.-7 library. Further optimisation of the protocol may result the 
identification of prostate specific clones. Different incubation temperatures, 
particularly at either room temperature or 4°C, may prevent internalisation of 
the phage peptide or increase or reduce binding times. Blocking is an 
important step in the panning protocol to reduce non-specific binding. In this 
study samples were blocked with 2% BSA, but this may not efficiently 
prevent non-specific binding (Xiao and Isaacs, 2012). Therefore some other 
studies have used ‘Marvel’ powdered milk, as it contains a wider mix of 
proteins. Elution and phage recovery could be further optimised. In this study, 
phage were eluted by chemical disturbance of target-phage bonds which 
were disrupted by a low pH solution, although there is evidence that this may 
be inefficient (Yu et al., 2004). Therefore other methods may be needed to 
elute and collect all binding phage. Additionally, the number of rounds of 
phage panning could be reduced, to reduce the number of amplification of 
phage with a replicative advantage (Vodnik et al., 2011). However, following 
only 3 rounds of panning in this study, no or only a minimal increase in phage 
recovery was observed.  
6.5.5 Alternative Systems 
Advancements in phage display techniques have allowed Fab, Fv or a linker 
stabilised single chain scFv antibody fragments to be displayed on outer 
phage coat proteins, creating antibody phage display libraries (Clackson et 
al., 1991, Carmen and Jermutus, 2002) . Synthetic (Silacci et al., 2005), 
naïve (de Haard et al., 1999) and immune (Sommavilla et al., 2010) libraries 
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are panned in a similar way to peptide libraries and have been used to 
generate antibody fragments to a range of antigens.  
An advantage of displaying human antibody fragments is their reduced risk of 
an immune response in patients. Antibody phage display technology has 
successfully lead to the development of the drug several drugs including 
HUMIRA (Human Monoclonal Antibody in Rheumatoid Arthritis) a human 
anti-TNF alpha monoclonal antibody (also known as adalimumab and D2E7) 
(Kempeni, 1999) used for the treatment of multiple autoimmune diseases 
including rheumatoid arthritis, Crohn's disease, psoriasis and psoriatic 
arthritis (Leonardi et al., 2011, Rubin et al., 2011). Panitumumab (formerly 
ABX-EGF) is another phage display developed human monoclonal antibody 
specific to EGFR (Yang et al., 2001) used in the treatment of EGFR 
expressing metastatic colo-rectal cancer of patients with wild type KRAS 
(Peeters et al., 2008). Several other phage mAbs have progress to pre-
clinical and clinical trial, with the majority targeting growth factors implicated 
in immune dysfunction and cancer progression (Ronca et al., 2012). In this 
study, using antibody phage display would have the same drawbacks as 
peptide phage display and it is also harder to identify the targets as direct 
sequencing is difficult.   
In vivo panning of peptide and antibody phage display libraries can be 
utilised to identify tissue and organ specific sequences by injecting 
intravenously into mice and harvesting the organs. It has been utilised 
particularly in the area of gene therapy. The drawback of this technique is 
that some organs capture too many phages (Pasqualini and Ruoslahti, 
1996). Also, when panned against a murine model, the difference between 
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mouse and human expression is not accounted for. In vivo panning has been 
performed in humans with appropriate ethical approval in one patient with a B 
cell tumour who had an intracranial bleed and was pronounced brainstem 
dead (Arap et al., 2002). Although some interesting motifs were identified, 
including a known mimotope of interleukin-11, this experiment is not easily 
repeatable due to the ethical issues (George et al., 2003). An alternative 
approach is to grow human tissue in immunocompromised animals. In vivo 
panning against human tumour xenografts has identified potential breast 
(Passarella et al., 2009) and prostate cancer biomarkers (Newton et al., 
2006) and functional adhesion molecules related to metastasis (Sadanandam 
et al., 2007). Peptides that home specifically to tumour blood vessels have 
been coupled to anticancer drugs such as doxorubicin to increase drug 
efficacy (Arap et al., 1998, Li et al., 2006).  However, no molecules identified 
by peptide phage display have gone into clinical trials.  
6.5.6 Alternative System: Non-phage based systems 
Alternative systems have been developed which are similar to the phage 
display system. These include a peptide displaying Bacterial FliTrx System in 
which a phagemid vector allows the display of peptides directly on the 
surface of E.coli using major bacterial flagellar protein and thioredoxin 
(Zitzmann et al., 2005). This technique has been used to identify potential 
prostate cancer specific peptides. However, bacterial display systems have 
proven to be inferior to conventional phage systems (Lunder et al., 2005b). 
RNA and DNA aptamers are a recent technology and have shown promise 
(Baines and Colas, 2006). This technique involves the systematic evolution 
of ligands by exponential enrichment (SELEX) using a oligonucleotide library. 
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The process is based on an in vitro selection approach, similar to phage 
display, in which DNA or RNA molecules are selected by their ability to bind 
their targets with high affinity and specificity (Ulrich et al., 2006).  Several 
aptamers are currently being tested in preclinical and clinical trials and the 
anti-VEGF aptamer pegaptanib received FDA approval for the treatment of 
human ocular vascular disease (Ulrich et al., 2006). This system has an 
advantage over traditional phage display system as it does not require 
amplification in a bacterial host, which can lead to the selection of clones with 
a reproductive, infective or proliferative advantage.  
6.6 Chapter Conclusions 
Although the Ph.D-7 peptide phage display system identified some potential 
candidate clones, which were enriched for by multiple rounds of panning, 
these clones did not specifically bind to prostate epithelial cells strongly 
enough to be considered as potential therapeutic or diagnostic targets. An 
alternative approach is required to identify new ways to target and deliver 
therapies which specifically target stem cells within the prostate.  
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7 Discussion and Conclusions 
7.1 Summary of Findings 
 Two out of three prostate cancer cell lines form colonies with three 
morphologies.  
 The number of colonies is minimally altered by changing culture 
conditions. 
 Two types of DU145 colonies contain cells with stem cell traits of high 
proliferative and self-renewal and tumourigenicity. 
 Prostate epithelial colonies from patients with BPH form two types of 
morphological colony. 
 Only large holoclone type prostate epithelial colonies are capable of 
extensive proliferation and self-renewal. 
 Phage display panning against larger prostate epithelial colonies failed 
to yield potential therapeutic targets. 
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7.2 Relationship between Stem Cells and Clonogenicity 
The aim of this study was to explore the relationship between clonogenicity 
and stem cells. Both somatic and cancer stem cells are defined by the traits 
of self-renewal and potency. During homeostasis or in response to injury 
somatic SCs must be able to regenerate all types of cell observed within the 
tissue. CSCs are believed to escape killing by conventional therapies and 
proliferate extensively to regenerate the tumour (Clarke et al., 2006) 
The clonogenic assay is frequently used as a surrogate assay to identify the 
progeny of SCs in normal epithelial (Pellegrini et al., 2001) and cancer 
(Patrawala et al., 2006) populations. However the relationship between 
clonogenicity and stem cells is not fully understood. From the results of this 
study, it is clear that clonogenic cells are derived from cells with different in 
vitro proliferative capacities. Further analysis shows that colony morphology 
and colony size is predictive of stem cell function. Larger colonies formed by 
both normal and cancer cells have the greatest proliferative and self-renewal 
potential, whereas the smallest colonies have limited self-renewal potential 
and cannot self-renew. However, intermediate type 2 cancer colonies also 
contained cells with stem cell traits. Serial xenografting of type 1 and 2 
cancer colonies further established their stem cell traits. This result suggests 
that the relationship between clonogenicity and SCs differs in normal and 
cancer populations.  
The differences in self-renewal capacity suggest that cancer cells may be 
capable of aberrant self-renewal. The ability of some cells in type 2 
(meroclone) colonies to form secondary type 1 colonies (holoclones) and 
proliferate indefinitely suggests that some cancer cells maintain the capacity 
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for self-renewal further down their cellular hierarchy, as shown in Figure 81. 
Early transit amplifying cancer cells may undergo either symmetrical or 
asymmetrical divisions to produce one or more daughter cells with the same 
proliferative and self-renewal potential as the parent cell. Upon differentiation 
self-renewing transitional cells can undergo fewer cell divisions before 
termination. Alternatively there may be a hierarchy of CSCs which maintain 
self-renewal capacity but become fully differentiated in fewer cell divisions. In 
contrast only stem cells in prostatic epithelium can self-renew, a property that 
is quickly lost during differentiation in adherent cell culture. The cause of 
abnormal self-renewal and differentiation of cancer stem cells is unknown, 
although increased expression of Bmi1 and Oct4 in cancer colonies suggests 
that alterations in self-renewal pathways may be involved.  
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Figure 81. Comparison of Self-renewal in Normal and Cancer Cells.  
A) Normal prostate epithelial cells following the traditional cellular hierarchy 
and differentiation model. Only stem cells can self-renewal to form daughter 
stem cells or differentiate to form early transit amplifying (E-TA) cells and late 
transit amplifying cells (L-TA).  Transit amplifying cells have a limited 
proliferative potential and become terminally differentiated. B) Both prostate 
cancer stem cells and E-TA cells maintain a self-renewal capacity to form 
daughter cells identical to the parent cells with an infinite proliferative 
potential. Further differentiation to L-TA results in the loss of self-renewal 
capacity, and the cells undergoes proliferation and terminal differentiation. 
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Extensive proliferation is viewed as a hallmark of SCs in both normal and 
cancer tissues. The clonogenic assay measures short term proliferative 
potential, whilst serial cloning enables the study of clonal proliferation over 
many generations. In this study prostate epithelial cells became senescent 
after approximately one month of culture in vitro. In contrast putative stem 
cells in the DU145 prostate cancer cell line were able to undergo at least 200 
cell divisions any without loss of self-renewal capacity and were deemed 
immortal. Somatic stem cells must be able to maintain and regenerate the 
organ for life, therefore must have a high proliferative capacity (Ichim and 
Wells, 2006). However, in many tissues ageing is accompanied by a 
progressive decline in stem cell function, resulting in reduced proliferative 
and regeneration ability (Jones and Rando, 2011). The prostate epithelial 
cells in this study were obtained from elderly patient samples which may 
demonstrate reduced stem cell function and lower proliferative capacity. 
Culture in vitro may also affect their proliferative capacity by driving 
differentiation. In many studies CSC are viewed as immortal as tested by 
their ability to serially regenerate tumours over many months (Dalerba et al., 
2007). CSCs clearly have a high proliferative capacity, but cancer cell lines 
may not be representative of primary cancer cells in vitro, increasing the 
differences observed between SCs and CSCs.  
It is clear that both SCs and non-SCs can form colonies, as observed by their 
proliferative heterogeneity. However, it is not known whether all stem cells 
are able to form colonies. The cancer cell lines in this study were assayed in 
several different conditions, but little improvement in CFE was observed. This 
suggests that the number of SCs or the ability of SCs to form colonies is 
intrinsically regulated by cell population. Unlike cancer cell lines, primary 
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prostate epithelial cells are not ‘acclimatised’ to in vitro cell culture and it is 
unlikely that all stem cells form colonies under these conditions. Cells may be 
damaged during the tissue digestion process or act differently once removed 
from the regulation of the stem cell niche. Some stem cells are also 
quiescent and may not proliferate in response to low density in vitro cell 
culture.  
7.2.1 Quiescence and the Stem Cell Niche 
The colony forming assay may not account for the number of quiescent stem 
cells in a population. In slowly regenerating tissue, such as the prostate and 
brain, stem cells are usually located in a niche where proliferation and 
differentiation is controlled by intrinsic regulatory mechanisms and extrinsic 
signals from the microenvironment (Moore and Lemischka, 2006, Li and 
Bhatia, 2011). These stem cells are often quiescent and proliferate either 
slowly or in response to damage (Tsujimura et al., 2002). Stem cells in the 
normal prostate are believed to be maintained in a quiescent state by 
transforming growth factor beta (TGF-β) (Salm et al., 2005) and Wnt 
signalling (Li and Bhatia, 2011) from the niche.  
When the stem cell is removed from its natural niche by digestion and tissue 
culture it is unknown how differently it behaves. Cells may not proliferate in 
response to in vitro culture conditions, therefore underestimating the number 
of stem cells in the prostate epithelium in this study. This phenomenon has 
previously been demonstrated in neurospheres in which quiescent stem 
cells, expressing minichromosome maintenance 2 which labels cells at the 
initiation of DNA replication, fail to form spheres whereas activated stem cells 
do (Pastrana et al., 2009),.  
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Quiescent stem cells have also been observed in cancers and quiescence is 
predicted to be one of the mechanisms by which CSCs are resistant to 
chemotherapy (Reya et al., 2001, Dick, 2008).  In this study, cancer cells had 
been growing in vitro for many generations and therefore were adapted to 
their microenvironment. Ki67 staining showed that most cells in DU145 
colonies were actively proliferating, although all colonies contained at least a 
few cells which were in G0 phase. This suggests that some cells within the 
cell line may be quiescent and therefore the cell–cell signalling may provide a 
substitue niche for these cells. The cancer cell micro-environment may also 
play a role and control cell plasticity (Tang, 2012). The basic micro-
environment of the tissue culture dish may not provide the normal controls 
and influences observed within a tumour in situ, leading to altered clonal 
behaviour. 
The different CFE of cancer cell lines, both in this study and previous work 
suggests that there a large variation in the number of CSCs in different 
cancers. Previously, increased clonogenicity has been linked to more 
aggressive disease (Bapat et al., 2005). Characterisation of self-renewal, 
proliferation and tumour formation potential of colonies formed by each cell 
type is essential to avoid inaccurate interpretation and underestimation of the 
number of cells with stem cell traits. Characterised cancer colonies which are 
known to contain cells with stem cell traits can be utilised to allow rapid 
evaluation of new therapeutics and the study of gene mutations and 
signalling pathways involved in tumour initiation and progression.  
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7.2.2 Targeting Self-Renewal 
The increased capacity for self-renewal observed in prostate cancer colonies 
suggests that factors controlling self-renewal pathways may be targets for 
therapy. Signalling pathways such as Wnt/β- catenin (Reya and Clevers, 
2005), Notch (Sikandar et al., 2010), Hedgehog (Hh) and Bmi1 (Liu et al., 
2006b) have been implicated in the control of self-renewal of CSCs. These 
pathways are also involved in self-renewal in embryonic and somatic stem 
cells. Inhibition of these pathways using small molecules and monoclonal 
antibodies has resulted in a reduction in self-renewal and CSC capacity  
(Takebe et al., 2011) (Rudin et al., 2009, Yauch et al., 2009) (Wu et al., 
2010). Wnt is also thought to be linked to CD44 variant isoforms which act 
downstream of Wnt signalling (Zeilstra et al., 2013) and may be related to the 
increased CD44 expression observed in type 1 DU145 colonies.  
Bmi1 is a 37 kDa polycomb group protein (PcG)  which  plays a role in stem 
cell renewal and maintenance, which when deficient leads to compromised 
adult stem cell function. There is increasing evidence that polycomb group 
(PcG) proteins play a crucial role in cancer development and recurrence. 
Bmi1 is associated with a number of human malignancies including prostate 
cancer (Lukacs et al., 2010) which suggests that it plays a role in CSC 
maintenance (Cao et al., 2011), which is supported by the increase in Bmi1 
expression observed in both cancer and normal prostate type 1 colonies. 
Loss-of-function of Bmi1 induced by RNA interference (RNAi) in both normal 
and malignant human cells has shown that Bmi1 is crucial for the short-term 
survival of cancer cells but not of normal cells and abolishes chemo 
resistance in prostate cancer cells (Liu et al., 2006a), but had no effect on the 
proliferation of LNCaP or DU145 cells (Crea et al., 2011).  
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There may be significant cross talk and intersection between these pathways 
and, therefore their relationship requires further exploration and combination 
of pathway inhibitors maybe required. Colony morphology may allow the 
study of these interactions on self-renewal. A significant reduction in the self-
renewal capacity of CSCs would result in a reduction in the number of 
holoclones and meroclones and diminish their long term proliferative 
capacity.  
7.2.3 Cell Surface Marker Expression 
During recent years, efforts to identify and enrich for stem cell populations 
have concentrated on cell surface marker selection. In this study, colonies 
were stained with antibodies against the cell surface antigens CD44 and 
α2β1 integrin. Expression was heterogeneous within both normal and cancer 
colonies in terms of positive cell numbers and brightness of staining. 
Although these markers tended to be more highly expressed in stem cell 
colonies their expression does not in itself confirm stem cell identity.  
In previous studies CD44 and α2β1intergin alone and in combination with 
CD133 have been used to enrich populations of both normal and neoplastic 
SCs. Other markers which have been used to identify SCs in normal and 
neoplastic prostate are CD133 (Richardson et al., 2004), Epcam, CD49f 
(Guo et al., 2012), CD166 (Jiao et al., 2012). However CD133 has been 
shown to be a poor marker for clonogenicity and sphere formation, in 
contrast to CD49f (Yamamoto et al., 2012). There is unlikely to be one single 
marker that is specific for either normal or cancer stem cells, and many 
markers select both normal and cancer SCs, meaning new markers are 
required. In this study, phage display did not successfully identify new targets 
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to cell surface antigens. This lack of potential targets was possibly due to 
changes in marker expression during culture of primary cells in vitro.  
It is largely unknown whether CSC-marker expression is static or 
continuously shifting during differentiation or as an environmental response 
(Keysar and Jimeno, 2010, Roesch et al., 2010). There is evidence to 
suggest that the populations responsible for driving tumour progression are 
actually in a transient phase of altered cell cycling, gene expression, and 
drug sensitivity, likely because of alteration in chromatin structure resulting in 
changes in gene expression (Keysar and Jimeno, 2010). Cellular activities, 
such as the efflux of Hoechst dye or aldehyde dehydrogenase activity are 
also likely to be affected by cell cycle state. These markers can also be 
altered by exposure to anticancer therapeutics suggesting their role in 
protecting the SCs from toxicity (Keysar and Jimeno, 2010).  
Cancer cells lack some of the normal genetic and environmental controls that 
are present in healthy tissues and therefore may have greater plasticity 
(Tang, 2012). It has been suggested that non-CSCs can dedifferentiate into 
CSCs which have a more stem-like phenotype (Chaffer et al., 2011, Gupta et 
al., 2011), which  has been demonstrated, to some extent, by inter-
conversion of ABCG2+ and ABGG2- prostate and breast cancer cells 
(Patrawala et al., 2005) and CD44+ and CD44- prostate cancer cells 
(Patrawala et al., 2006). In these studies cells the negative cell fractions were 
able to generate numbers of positive cells in similar  proportions to those 
observed in the original cell line. However, this is not conclusive evidence as 
there may be overlap between marker expression of CSCs and non-CSCs 
and inadequate enrichment of unselected populations.  
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7.3 Further Research 
7.3.1 Clonal Origin 
The ability to track colony formation using time lapse photography confirmed 
the single cell origin of cancer colonies. However it is still unclear whether all 
cells are dividing equally throughout the colony or whether some cells are 
cycling more rapidly than others. Ki67 staining showed that all colonies 
contained a mixture of cycling and resting cells. This does not give any 
indication of the history of proliferation in each cell or cell cycling times. Some 
cells may be rapidly cycling whilst others are slower. There are several 
methods which could be used to study this. Bromodeoxyuridine (BrdU) is a 
synthetic nucleoside that is an analogue of thymidine which can be 
incorporated into the DNA of dividing cells, by substitution with thymidine, 
during S phase (Hardonk and Harms, 1990). Pulsing colonies with BrdU at 
different time points would allow detection of actively diving and resting cells 
over a longer period than Ki67 staining. Alternatively cells can be tracked by 
simultaneous transduction of cells with three lentiviral gene ontology (LeGO) 
vectors encoding red, green or blue fluorescent proteins (Weber et al., 2012). 
The unique and random combination of colours expressed by each cell 
enables tracking of their progeny by fluorescent microscopy. In this way the 
cell cycle time and proliferative heterogeneity within the colonies could be 
traced.  
Long term culture of cancer cells, which are genetically unstable, may result 
in  an increase in dominant clones, a type of in vitro clonal evolution 
(Duesberg et al., 1998). This instability has been shown in vivo in many 
tissues including prostate. In human samples, cancer progression is 
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concordant with PTEN gene deletions and TMPRSS2:ERG fusion 
breakpoints which confirm clonal origin (Sowalsky et al., 2013). The 
accumulation of genetic variations may give the cancer cells enhanced 
proliferative and stem cell capacity. However, in this study, no increase in 
CFE or the number of stem cells was observed over 17 serial clonings, 
suggesting clonal evolution is not taking place. Comparison of the whole cell 
genome of low and high passage cells to compare mutations  would confirm 
that genetic mutations are not responsible for the loss of function in type 2 
and 3 colonies. Studying any mutations which predominately give rise to 
highly proliferative colonies may give further insight into the mechanisms 
behind clonogenicity.  
7.3.2 Microarray 
This study clearly suggests that type 1 and 2 colonies DU145 are derived 
from and contain CSCs, but the mechanisms that control the CFE and 
maiantain a constant number of stem cells are unknown. Gene expression 
array would compare levels of genes in type 1, 2 and 3 colonies. Gene sets 
overexpressed in type 1 colonies could provide insight into the pathways 
involved in CSC maintenance, including self-renewal. Previously, analysis of 
gene expression of PC-3 holocones has shown an increase in FAM65B 
expression, which is a transcriptional target of FOXO1 that regulates RhoA 
activity (Rougerie et al., 2013), compared to the original monolayer (Zhang 
and Waxman, 2010). However, many of the gene sets studied were actually 
down-regulated in PC-3 holoclones compared to the whole cell population. 
The differences observed CFE between cancer cell lines may mean that 
different genes are involved, therefore analysis of several different cell lines 
may be required to study differences in gene expression in-depth.  
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7.3.3 Gene Silencing 
In this study phage display failed to identify a target to proliferative prostate 
cells. More knowledge about the genetic mechanisms behind CSC 
progression is required to understand cancer progression and identify new 
targets. Expression of CD44, α2β1 integrin, Bmi1 and Oct4 were increased in 
type 1 DU145 colonies and also observed in lower numbers in type 2 
colonies. To further study their effects on prostate CSCs, each of these 
genes could be knocked down using RNAi. If Bmi1 and Oct4 are involved in 
the increased self-renewal capacity of CSCs, knocking down these genes 
should significantly decrease the number of type 1 and 2 colonies observed. 
Alternatively, RNAi libraries could be used to test the loss of function of 
genes from either the entire genome or specific gene sets involved in specific 
cellular processes (Hannon and Rossi, 2004, Boutros and Ahringer, 2008). 
Genes that significantly affect clonogenicity can then be further studied to 
explore their role in CSC self-renewal and differentiation.  
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7.4 Conclusions 
This study explored the relationship between clonogenicity, colony 
morphology and stem cells within both normal and cancerous prostate cells. 
In normal prostate two types of colonies are formed which corresponded to 
stem and transit amplifying colonies. Cancer cells contain a larger proportion 
of cells with self-renewal capacity and therefore both type 1 and 2 colonies 
contain cells with stem cell traits. This is contrary to previous studies which 
have shown that only cancer holoclones contain stem cells. The mechanisms 
which control self-renewal and colony formation in prostate cancer cells are 
still unknown. Further investigation into these mechanisms may identify 
pathways which can be targeted therapeutically. Targeting of self-renewal 
would prevent the maintenance of the CSC pool and would lead to cancer 
regression.   
272 
 
8 Appendix 
 
Appendix 1. Naïve PhD-7 Library sequences 
 
 
Clone Peptide Amino Acid 
Sequence 
1 CGGACGAATATTGTGCTGGAT RTNIVLD 
2 TCTACTTTTCCGAGGAATTGGG STFPRNW 
3 TTTACTAGTTCTACGGTGCCT FTSSTVP 
4 CTGAAGCTGCCGCCTAAGTTG LKLPPKL 
5 GTGACTCCTCTGGTGCGGCTG VTPLVRL 
6 GCTAATCCTGCGCCTCCGAAT ANPAPPN 
7 CAGGTTACTCCGTCGGCTGGT QVTPSAG 
8 AGTGATCTTGGTAGTAATGAG SDLGSNE 
9 TCTGCGCAGAAGGCTCATTCT SAQKAHS 
10 GTTTCTAATGCTGAGCAGGAG VSNAEQE 
11 TCGCCGAAGTCGCATACTATT SPKSHTI 
12 ACGTCGTCTCCTTCTACTACG TSSPSTT 
13 GCTCCGGTTAGTAATATTCGT APVSNIR 
14 CAGCTTGGTGCGGCTGCGTCG QLGAAAS 
15 TCTCCGACTCTGCCGGTGACG SPTLPVT 
16 ACGACTTCTCATTTTAGTAAG TTSHFSK 
17 TTGATTCCTAATTCTAAGTCT LIPNSKS 
18 TTTTCGGCGCCGCTTCCGTAT FSAPLPY 
19 AATCTGAAGCATACTCCTCCG NLKHTPP 
20 GTGCCTACTAAGCATATGCTT VPTKHML 
21 GTTCATTTTCAGTTTCATATG VHFQFHM 
22 ACTGTTCCTTTGCCTATGATT TVPLPMI 
23 CAGTGGTCTCATCGTGAGCGG QWSHRER 
24 TCTCCTATGCTTCATACGTTG SPMLHTL 
25 GATGATTATACGCTTCATCTT DDYTLHL 
26 AGTCCTCGTTTGTGGCCTCTG SPRLWPL 
27 CAGCCGGCTAATCAGACTCTG QPANQTL 
28 AATCCGCGTGCTCCGCTGGCT NPRAPLA 
29 CTGCCTCATTCTGCGCGGCCT LPHSARP 
30 CAGCCTTTTTATTAGAATGCG QPFY*NA 
31 AGTACGTCTTCTCTTGCGCCT STSSLAP 
32 AAGCTTAGTGCCGAGTGTGCCT KLSAECA 
33 CAGATTACTTCGGATTATTCT QITSDYS 
34 TCTGATACGGTGTAGATTGAT SDTVLID 
35 CATGATAATACTCTTCCGACT HDNTLPT 
36 AGTCTGCCGATTGCGGCTGTG SLPIAAV 
37 ACGCCTCCGCCGGCTCATATG TPPPAHM 
38 TCGCCTACTATGACTACTCCG SPTMTTP 
39 GCTTCGCCTAGGGCTCCGATG ASPRAPM 
40 ACGCCTCATTTTCTTAATCCT TPHFLNP 
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Appendix 2. Sequences of third round phage clones 
Clone 
Number 
Peptides Amino acids 
1 TATCTTACGATGCCGACGCCT YLTMPTP 
2 GATAGGATGTCTGTTCGTACT DRMSVRT 
3 CATCCTACTGGGGCTGTTCTT HPTGAVL 
4 GTTTTGAAGCCTCCGAAGCAT VLKPPKH 
5 GGGAAGTGGAGTGTGTATGGT GKWSVYG 
6 GGTTCTATGCCTCGTACTCCT GSMPRTP 
7 AATAATCATCGTCCGATTTAT NNHRPIY 
8 CATCAGGCTTCTTATAAGCCG HQASYKP 
9 ACGAAGTTTGGGCGGCATCCG TKFGRHP 
10 ACGCCGTTTATGGCGTATCAT TPFMAYH 
11 TCTTATTTGAATCGGGCTCTG SYLNRAL 
12 TTTTGGCGTCCTCCGATGTTT FWRPPMF 
13 CATGTGCCTGCGACTGCGCGG HVPATAR 
14 TCTAATTTGAGGACGCATCCT SNLRTHP 
15 TCGCTGCTGTCTCTTCATTCG SLLSLHS 
16 ACGGCGCTTTCTGCTCGGACT TALSART 
17 CATACTGCGCCTAATTTTGCT HTAPNFA 
18 GCGTCTGTTCATTTGCCTCCT ASVHLPP 
19 ACTCATGTGATGCAGACTCTT THVMQTL 
20 TTTCCTTCGACGATTACTCCG FPSTITP 
21 GTTCAGACTTATGCTCGTGTT VQTYARV 
22 TATCTTACGATGCCGACGCCT YLTMPTP 
23 GATAGGATGTCTGTTCGTACT DRMSVRT 
24 CATCCTACTGGGGCTGTTCTT HPTGAVL 
25 GAGCTGCAGCCTATGCTGCAG ELQPMLQ 
26 AGTGCGCTTTATCGGCATTCT SALYRHS 
27 ACTACGCCGCCGTGGCGTACT TTPPWRT 
28 GAGGGTCCGCCTCTTTCGCGT EGPPLSR 
29 CAGCCTTGGCCGACGAGTATT QPWPTSI 
30 GCTCCGCCTACGTCTGGTACG APPTSGT 
31 TCTTTGTCGCTTATTCAGACG SLSLIQT 
32 GCGCATCATCCTGCGGTGAAG AHHPAVK 
33 CAGAATTCGCAGCTGAGTCGT QNSQLSR 
34 GAGCTGCAGCCTATGCTGCAG ELQPMLQ 
35 AGTGCGCTTTATCGGCATTCT SALYRHS 
36 ACTACGCCGCCGTGGCGTACT TTPPWRT 
37 TCTGCGCCGTCGTCTAAGAAT SAPSSKN 
38 TCGAGTCCTCTTACTCCTCCG SSPLTPP 
39 GAGCTTTGGCGGCCTACTCGG ELWRPTR 
40 ACTGATACTGAGTCTAAGCGG TDTESKR 
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Appendix 3.Sequences of Clones from the Fourth round panning of 
experiment 1.  Sequences which are repeated are displayed in bold  
Clone 
Number 
Peptide Sequence Amino acid 
Sequence 
1 GCGTGTGCTAGTAATAAGTCG ACASNKS 
2 CATGCTATTTATCCGCGTCAT HAIYPRH 
3 TATGCTGGTCCTTATCAGCAT YAGPYQH 
4 TCTATTCTGCCGTATCCTTAT SILPYPY 
5 GCTTTTCCGGTTTCTCATAAT AFPVSHN 
6 AAGTGGCCGTTGTCGCATCCT KWPLSHP 
7 GTTGCGCTGTCGGCGCCTTAT VALSAPY 
8 GGGAAGCCTATGCCTCCGATG GKPMPPM 
9 GCTCTTTATAAGAATACTTCT ALYKNTS 
10 TCTACGTTTACTAAGTCTCCT STFTKSP 
11 CATCCGATGTCGATTCGGGTT HPMSIRV 
12 TTTGCGACTCATTTTGCGCCG FATHFAP 
13 TCGGTGGAGTCGGCGTGGAGG SVESAWR 
14 TCTTATTTGAATCGGGCTCTG SYLNRAL 
15 AGTCCGACGCAGCCTAAGTCG SPTQPKS 
16 GCGCTGAATTCTCTGACGAA ALNSLT 
17 GCTTTTCCGGTTTCTCATAAT AFPVSHN 
18 AGTTCTACGAAGCTTTCGTTG SSTKLSL 
19 GTGAGGCCTCATACTTCTTCG VRPHTSS 
20 ACTTCTGAGCCGCCTACGAAG TSEPPTK 
21 TGGCCGCAGAAGGCTCAGCCT WPQKAQP 
22 AAGCTTCCTGGGTGGTCGGGG KLPGWSG 
23 AAGCATTATCATTCTATTAAT KHYHSIN 
24 GCGCTGATTCCGAAGCCTAGG ALIPKPR 
25 GCTTCTTATTCGGGGACTGCG ASYSGTA 
26 TCTATTCTGCCGTATCCTTAT SILPYPY 
27 GATTCGCATACTCCGCAGAGG DSHTPQR 
28 ATGTCTCTTCAGCAGGAGCAT MSLQQEH 
29 GTGATTCGTATGCCGACTCCG VIRMPTP 
30 TTTCATCAGCATACGTCTAAG FHQHTSK 
31 GCGAATACTCTGCGTTCTCCG ANTLRSP 
32 CAGTTTCTGTCTATTAATATG QFLSINM 
33 GGGATTCGGCATACTAATCCT GIRHTNP 
34 CAGCCTTGGCCGACGAGTATT QPWPTSI 
35 TATCTTACGATGCCGACGCCT YLTMPTP 
36 ACGCGGGCTGGTCTGGATTTT TRAGLDF 
37 ACGGATTCGCTTCGGCTGCTG TDSLRLL 
38 TCGTCTCTTCCTCTGCGGAAG SSLPLRK 
39 TCGACGGCGTCTTATACTCGT STASYTR 
40 TCTATTCTGCCGTATCCTTAT SILPYPY 
41 TCTATTCTGCCGTATCCTTAT SILPYPY 
42 GCGAATACTCTGCGTTCTCCG ANTLRSP 
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43 GCGCTTTGGGGGCCGACGAGT ALWGPTS 
44 TATAGGGCTCCTTGGCCGCCT YRAPWPP 
45 TCTGCGCCGTCGTCTAAGAAT SAPSSKN 
46 TGGCCTACGCTGCAGTGGGCG WPTLQWA 
47 GGGGAGACTCGTGCGCCGCTT GETRAPL 
48 GCGAAGATTGATGCTCGTACTG AKIDART 
49 TCTGCGCCGTCGTCTAAGAAT SAPSSKN 
50 CTTCCTAGTGTGGATCGTCCT LPSVDRP 
51 CATGCTATTTATCCGCGTCAT HAIYPRH 
52 GGTGTTCAGATTATGGGGCGT GVQIMGR 
53 ACGGCGCCTACGTCTCCGTCT TAPTSPS 
54 TGGCAGACTTCTCCGCCTTTT WQTSPPF 
55 ACGCCTATTACGCAGCTGCTG TPITQLL 
56 GCTCTGCATTCTGCTCGTGTG ALHSARV 
57 CATGCTATTTATCCGCGTCAT HAIYPRH 
58 TCGTCTCTTCCTCTGCGGAAG SSLPLRK 
59 TCGTATGTTAGTCATCATTCT SYVSHHS 
60 ACGATTCCTTCTCGGGTTCTT TIPSRVL 
61 AAGCTTCCTGGGTGGTCGGGG KLPGWSG 
62 CAGCCGCTGTCTAATGCTTCT QPLSNAS 
63 CTGAATAATAATCTGCCGTCT LNNNLPS 
64 CTACCTTCATATCATGTGCCT LPSYHVP 
65 CATGCTATTTATCCGCGTCAT HAIYPRH 
66 AGTAATCAGTGGTATGCTTCG SNQWYAS 
67 CATGCTATTTATCCGCGTCAT HAIYPRH 
68 ACGTTGACTACGCTGACGAAT TLTTLTN 
69 AGTCTTCCTACTCTGACTCTG SLPTLTL 
70 CATTGGCCTGTTAGGTCTCTT HWPVRSL 
71 TTTGCTCCTGTTAGTCATACT FAPVSHT 
72 TGGAATCCGAATCTTCCTACT WNPNLPT 
73 AGTACGTTTACGCATCCGAGG STFTHPR 
74 GTTCAGACTTATGCTCGTGTT VQTYARV 
75 AAGCTTCCTGGGTGGTCGGGG KLPGWSG 
76 TGGGCTTTGGATAGGGGTGCG WALDRGA 
77 AGTGCGCTTTATCGGCATTCT SALYRHS 
78 GGGGTGAAGGCTCTGTCGACT GVKALST 
79 TCGACGGCGTCTTATACTCGT STASYTR 
80 TCTCATTATCCTAATTATGGG SHYPNYG 
81 TGGCCTACGCTGCAGTGGGCG WPTLQWA 
82 TCGACGTCTGGGCGGCTTCCT STSGRLP 
83 ACGATTAAGTCTCCTCTGCAT TIKSPLH 
84 TCGACGGCGTCTTATACTCGT STASYTR 
85 GCTAATACTACTCCGAGGCAT ANTTPRH 
86 GGGGAGACTCGTGCGCCGCTT GETRAPL 
87 AGTACGTTTACGCATCCGAGG STFTHPR 
88 TCGGAGCGGGCGTCGTCGCCT SERASSP 
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89 ACTGTGACGTCTCGGTTGCCG TVTSRLP 
90 ACGCGGGCGATTTCTCAGCCT TRAISQP 
91 CATAGTCGTCTTGTGTTTCCG HSRLVFP 
92 GGGGGGTTTAATGGGCCTTTT GGFNGPF 
93 GCGACTCCGCTTTGGCTTAAG ATPLWLK 
94 GCTACTTTTACTCATTATAAG ATFTHYK 
95 GCTATGTCGTCTCGTTCGCTT AMSSRSL 
96 CTACCTTCATATCATGTGCCT LPSYHVP 
97 ACGCCGTTTATGGCGTATCAT TPFMAYH 
98 GTGTCGTTTACTCCGTCGTTT VSFTPSF 
99 GCTATTACTAGGTCGCCTGCG AITRSPA 
100 ACTCATCTTCCGTGGCAGACG THLPWQT 
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